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ABSTRACT 
The use of representative in vitro models has been favoured for the study of biologic and 
phannacologic responses of the equine superScial digital flexor tendon (SDFT). The 
objectives of this study were to determine the effects of exogenous sodium hyduronate 
(NaHA) and polydtkted glywsaminoglycan (PSGAG) on erdrace1lula.r matrix (ECM) 
synthesis and cell proiiferation by explants of the equine SDFT, and to compare the effects 
of NaHA and PSGAG at equivalent concentrations. Explants of the tensile SDFT were 
&ed in RPMI 1640/100/0 DEW100 pglml ascorbate in sealed bottles on rollers (14 rpm) 
at 3 6 . 5 s .  S°C. After a pre-treatment culture period of 1 8 days, cultures were randomized 
into treatment groups, and the drug being tested added to the medium. Cultures were treated 
for 6 days prior to pulsechase radiolabeling with "S-sulfate, L-[2,3,4,5-3H] proline and 
rneth~I-C'~-thymidine to determine rates of glycosaminoglycans (GAGs) synthesis, protein 
synthesis and c d  proliferation respectively. The explants and aliquots of medium were 
hydrolysed in 6 M HCL, scintillation counted, and explant and medium counts summed in 
order to d e t h e  molar incorporation rates pa mg dry weight of tissue. Protein in aliquots 
of the medium was precipitated and hydrolysed. The rates of collagen and nonwlhgen 
protein synthesis were determined fiom the derivatized amino acids by RP-HPLC. 
H@uoM~~ synthesis was determined by radiometric assay in one experiment. 
NaHA was evaluated at concentrations of 0 to 2000 pgM. The rates of proline 
incorporation into protein, collagen synthesis and GAGs synthesis were increased in a dose- 
dependent manner. Neither noncollagen protein synthesis nor cell proliferation were 
si@ady affected by NaHA PSGAG was added to the medium at concentrations of 0 to 
5000 pghl .  The rates of proline incorporation into protein, collagen and noncollagen 
protein synthesis, and GAGS synthesis were sigdicantly increased in the presence at 
concentrations high= than 100 pglmi. The degree of response to PSGAG is strongly dose- 
related, with optimal c o n d o m  for increased synthesis occurring at 1000 to 2000 pghl 
PSGAG. The &eds ofNaHA were compared to those of PSGAG, both at 1000 pg/m. The 
. . 
exogenous aQnrnstration of PSGAG results in a wider range and greater degree of cellular 
responses than NaKA. Exogenous PSGAG resulted in increased collagen, noncoIIagen 
protein, and sulf5te-d GAG synthesis, increased cell proIiferation, and decreased hyaIuronate 
synthesis. However, exogenously administered NaHA only increased wIlagen and sulfated 
GAG synthesis and the degree of response was significantly less than the response to 
PSGAG. This data provides empirical evidence that substantiates and identifies a cellular 
basis for the beneficial effects of NaHA and PSGAG on equine tendon repair. The results 
suggest that PSGAG may be a more potent drug for the stimulation or modulation of cell 
proliferation and ECM in the injured equine SDFT. 
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CHA,PTER ONE 
1.0 GENERAL INTRODUCTION 
The tendons and ligaments of the distal equine limbs are dynamic structures capable 
of withstanding high loads and strains @enoix 1996). They provide support to the fetlock, 
prevent carpal hyperextension, and transmit the energy of impact and fid weight bearing 
during propulsion and Limb lift off. Injuries affecting equine tendons and ligaments result in 
sigdcant mortality, morbidity and financial loss in the performance horse industries (Wilson 
et al1996; Wilson and Robinson 1996). The superficial digital flexor tendon (SDFT) of the 
forelimb is the most commonly injured tendon and although lacerations are common, the 
most f i quedy  reported lesions are related to acute exacerbation of degenerative tendinitis 
(Foland et d 1991; Belknap et al1993; Wdson et a[ 1996). Recent estimates of the rate of 
occurrence of SDFT i n .  range fkom 10 to 30% of horses in training or racing in Europe 
and North America depending upon breed and achity, with 4.3 to 1 1.3% of racing fatalities 
a t t r i e d  to tendon rupture or damage ( R o d e  et al1985; Anonymous 199 1; McKee and 
Clarke 1993; Goodship et al1994; Peloso et al1994; Estberg et a2 1996). Of 1036 equine 
racing injuries resulting in death in the United Kingdom, horses competing in the steeple- 
chase had the greatest occupational risk of death following tendon rupture or damage 
(1 1.3%), followed by hurdles (9.4%), National Himt flat racers (9.1 %) and flat racers (4.3 %) 
(McKee and Clarke 1993). In studies of injuries at American racetracks, the incidence of 
tendon injury in Thoroughbreds was greater than in Standardbreds or Quarter horses (Wison 
etall9%). In addition to the high rate of occurrence the prognosis for complete recoveIy 
to the previous level of performance is often poor, horses that return to high performance 
activity following injury and reparative scar formation are more likely to become lame with 
moderate wo* and re-injury is common (Rooney and Genovese 1981; Silver et al1983; 
Mohammed et d 199 1; Mohsunmed et al1992; Marr et d 1993; Peloso et d1994; W h n  
et al1996; Wilson and Robinson 1996). 
Mough  there have been many histologic studies investigating the cellular nature of 
equine tendon lesions, relatively f bv  studies have investigated the biologically active faaon 
involved in tendon repair and their possible manipulation in promoting restoration of the 
physical integrity and tensile strength of the original tendon structure (Stromberg 197 1 ; 
Webbon 1977; Williams et a2 1980). Recent in vibo studies have started to address this 
deficit in current knowledge and answer questions pertaining to the biological and 
biochemical aspects of tendon physiology and healing (Riley ei a2 1996; Dahlgren et QZ 1997; 
Murphy and Nmon 1997). 
There has been considerable controversy in the literature over the relative importance 
of the intra-tendinous (intrinsic) tissue versus the peri-tendinous (extrinsic) tissues to the 
blood supply and cellular contriiutions to tendon healing, particularly for centrally located 
'core' lesions in which there is little or no disruption of the epitendon or paratenon. 
However, recent studies in many species, including the horse, support the development of 
treatment methods aimed at enhancement of intrinsic contributions to tendon healing 
(Graham et ai 198 1; Manske et al1984; Lunborg and Rank 1987; Mass and Tuel 1991; 
Kraus-Hansen et al 1992, Riley et a1 1996; Murphy and Nucon 1997). Fibroblast growth 
factor, platelet derived growth factor and insulin-like growth factor-I have been 
demonstrated to have potent stimulatory effects on protein synthesis, proteoglycan synthesis, 
and cell proKeration in avian, equine, rat and rabbit tendon dtures  (Gauger et a2 1985; 
Stein 1985, Abrahamsson et a2 199 la&; Murphy and Nxon 1997). The results of these 
studies suggest that exogenous growth factors and other biologically active molecules may 
be of importance in iahinsic tendon healing, and usefid for the treatment of tendons in vivo. 
Pharmacological agents haw been used arperimentally in man and animals during the 
repair phase of tendon healing but have failed to consistently reduce adhesion formation, 
promote more rapid tendon healing or reduce scar formation in clinical cases of tendon 
disease (Gaughan et al 1991). The adrrmustra . . tion of exogenous polysulphated 
glycosaminoglycans, hyalwonate and beta-aminopropionitrile fiunarate have recently been 
investigated in vivo in cliraid trials and studies (Churchill 1985; Gaughan et all99 1; Foland 
et uZ 1992; Gift et al 1992; Redding et al 1992; Marr et al 1993; Gaughan et ai 1995; 
Genovese et d 1996; Reef et ~21996). The results of these trials have demonstrated some 
support for the use of these drugs but the studies have generally had poor statistical power, 
variable andor equivocal results, or have used a model for tendon injury which has 
questionable relevance or suitability for determination of lesion responses to phannaceutid 
agents. Responses to the drugs in the studies were largely determined by indirect assessment 
methods such as ultrasoaography or return to performance activity, and the studies did not 
provide infoxmation on the cellular or molecular responses of tendon tissue to these drugs 
(Marr et al1993; Gaughan et aZ1995; Genovese et a2 1996; Reef et a2 1996). 
In order to achieve an understanding of the biological or biochemical responses of 
tendon at the cellular and m o l d a r  level to cytokines and drugs, representative in M'tro 
tissue culture models have been highly valued as tools for studying the repair phase of tendon 
healing (Graham et ol 1981; Gelberman et al 1984; Manske et aZ 1984; Mass and Tuel 
1991). 
The objectives of the present study were to investigate the intrinsic synthetic 
metabolic responses of the equine SDFT to commercial preparations of polysulphated 
gtYco~ogIycans and hyduronate using a modification of a previously developed in vitro 
submerged ~cplant t h e  culture model ofthe equine forelimb SDFT (Riley et a2 1996). This 
approach has been supported in recent literature as a suitable technique for investigating the 
effects of pharmaceutical agents and growth facton on the equine SDFT (Riley et d 1996; 
Dahlgren et d 1997; Murphy and Nixon 1997). 
2.0 LITERATURE REVIEW 
2.1 Normal Tendon Development 
There has been little definitive work investigating the developmental changes that 
occur @caUy in the equine SDFT, but considerable insight into tendon development has 
been obtained ffom studies other tendons, and tendons and ligaments in other species 
(Otomo 1973). During limb bud formation in the rat embxyo, histologic changes occur which 
are characterized by changes in cell morphology and density with respect to the extracellular 
matrix (ECM). roitially, undifferentiated mesenchymal cells coalesce in the regions adjacent 
to the primordial digit (Him and Cormack 1979). As the mesenchymal skeleton differentiates 
into cadage, dense bundles of fibroblasts differentiate into numerous longitudinally arranged 
tendon cells with plump granular nuclei, between which are eosinophilic collagen fibres 
(Otomo 1973; Webbon 1978; Ham and Cormack 1979). As development progresses in the 
newborn animal there is a decrease in celhdar density and a concomitant increase in the fibril 
component and collagen concentration of the ECM (Webbon 1977; Webbon 1978; Vailas 
et d 1985). Shortly after birth the epitendon has a histologic appearance that is distinct fkom 
the tendon tissue which it surrounds (Otomo 1973). In young horses the tendon cells are 
numerous with plump slightly elongated nuclei which tend to become further elongated in 
older horses. Over the age of 5 years, acellular areas develop in the metacarpal regions 
(Webbon 1978). Chondroid metaplash also tends to be seen most frequently in older horses 
(Smith and Webbon 19%). 
Accompanying these cellular changes are changes in the quantity and quality of the 
ex&ac&h a composite of two main classes of molecules: (1) polysaccharide chains 
referred to as glywsaminoglycans (GAGS), which (with the exception of hyaluronate) are 
covalently Wed to protein in the form of proteoglycans (PGs), and (2) fibrous prot& 
which are either structural (eg collagen and elastin) or adhesive (eg. fibronectin and laminin) 
in nature. Ofthe matrix fibrous proteins, the most ubiquitous and widely studied type is 
collagen (Bailey and Light 1989). The rate of synthesis and therefore the relative amounts 
of collagen present increase change embryonic development, as do the physical 
characteristics and distriiution of the collagen fibrils (Diegelmann and Peterkofsky 1972; 
Parry and Craig 1988; Birk and Zycband 1994). The fetal or immature connective tissues 
initially have wide@ spread bundles of small, relatively constant diameter fibrils, oriented in 
a random manner (Parry and Craig 1988). In precocial animals the distniution of collagen 
fibd diameters broadens considerably before birth, padelling the requirements for the 
resistance of tensile force in the limb. In most species the mean fibril diameter increases 
substantially, and assumes a unimodaI or bimodal (as is the case for the adult horse) 
distribution at maturity (Parry et a2 1978; Craig and Parry 1988; Birk and Zycband 1994). 
After mafuration, mean fibril diameter decreases with advancing age, a change that has been 
reported to be more distinct in the horse than in other species (Parry et al 1978). More 
defbitive work examining fibril diameter in the equine SDFT has recently demonstrated that 
mean fibril diameter doubles within the first 5 years of life compared to fetal diameters, 
plateaus in the five to ten year old age group, and tends to decline in older horses (Patterson- 
Kane et al1997a). These workers concluded that the rapid rate at which this occun in the 
SDFT of athletic horses may be a pathological response induced by training for performance 
activity (Patterson-Kane et al1997b). Further research is required to verifi this hypothesis. 
Investigations into developmental aspects of the PGs or GAG components of the 
tendon ECM have been limited. In general, all fetal comective tissues are rich in hyaluronate 
(HA), a ubiquitous GAG which plays an essential role in cell proLiferation, migration and 
diffetentiafion (MdMion and Ferguson 1996). Examination of its role in other fetal tissues 
has determined that its action regulated mady via the CD44 and RHAMM transmernbrane 
molecules, the principal cell surface receptors for HA (Knudson 1 993 ; Sherman et al l  994; 
McCallion and Ferguson 1996). Hyaluronate is also able to inhibit cell differentiation and 
bind growth factorsJ thus influencing cell growth and differentiation by changing the local 
concentrations of these factors (Kujawa et al 1986; Ruoslahti and Yamaguchi 1991). 
Therefore HA appears to play an especially important role the highly cellular phase of 
connective tissue development (including tendon formation). Relationships between fetal 
hyauronate levels and angiogenesis, collagen synthesis and fibril development have also been 
identified (McCallion and Ferguson 1996). Degradation products of HA may stimulate fetal 
angiogenesis and increase type I collagen synthesis which is though to provide a substrate 
for endothelid cell migration in the fetus (Kumar ei d1992). High concentrations of HA and 
PGs in early fetal development of the chick, rabbit, rat and bovine tendons are associated 
with thin fibrils which increase in diameter only after these concentrations drop to low levels 
(Scott 1980; Scott and Hughes 1986; S ~ t t  1988; Scott 1990). 
Although interaction between PGs and collagen have been documented in fetal and 
adult tissues, there are few studies which have examined changes in the concentration and 
types of PGs during fetal development (McCallion and Ferguson 1996). It has been 
determined that as tendon matures, and large collagen fibrils form, the PGs molecules that 
link as many as four collagen fibrils in the fetal and neonatal tendon may be trapped in the 
coalesciog fibriUar mass (Scott 1990). CowerseIyy PGs may also inhibit fibril formation. For 
example, the small dermatan sulfate @S) containing PG has been demonstrated to inhibit 
fibril formation of types I and II collagen in bovine tendon in viiro (Vogel et a1 1984). 
Differences in the PGs content of fetal and adult tendon have been demonstrated in the rat 
and bovine. In the rat, chondroitin sulfate (CS) and HA were demonstrated as the major 
GAGS in foetal tendon, whereas DS became the predominant GAG within several weeks 
after birth (Scott et al 198 1). In fetal bovine tendon, smaller PGs have been found to 
predominate, whereas the large PGs found in the compressive regions (reflecting a change 
in function) of adult tendons were not found (Vogel and Evanko 1985; Vogel and Heinegard 
1987). Recedy Smith and Webbon (1996) reported a change in the distribution of keratan 
d a t e  (KS) in the flexor tendons when foals were compared to adult horses. There was 
lllinimal staining for KS at all  levels of the foal flexor tendons (although there was increased 
intensity in the metacarpophaangeal regions). Staining for KS became more marked in the 
metacarpophalangeal and phalangeal regions with increasing age, but was low in the 
metacarpal region (Smith and Webbon 1996). Although differences have been detected 
between fetal and adult tendons which are believed to reflect functional requirements, their 
importance to the development of the tendon has not been clearly elucidated, and W e r  
study of the role of PGs is required (Vogel and Heinegard 1987; Jones and Bee 1990). 
2.2 Histologic Structure 
There have been few studies investigating the histologic and ultrastructural nature 
of normal equine tendons (Webbon 1978). The structural properties of mammaiian tendons 
are wmplq  with unique morphological characteristics ~~ et al1992). Longitudinal 
sections of the SDFT reveal distinct patterns of longitudinal parallel collagen fibres in 
bundles between which are elongated tendon cells which are often anranged in rows 
(Norberg et ol 1967; Stromberg 1971). The basic tendon unit is called the fibril which 
consists of an ordered arrangement of microfibrils. These have transverse bands with a 
characteristic periodicity of approximately 70 MI which disappear when tension is applied 
to the fibrils, and reappear on relaxation (Evans and Barbenel 1975). Aggregations of the 
fibrils form collagen a re s  which occur in a planar waveform or 'crimp' pattern that appears 
as dark and light transverse banding under polarized light ( W i  et a2 1992; Patterson 
Kane et al1997a). Aggregations of these extracelldar protein threads (collagen fibres) and 
associafed tendon cells with their processes, fom primary tendon bundles (subfasicular units) 
which have a diameter up to 300 pm. The primary bundles are arranged into larger 
s6condary units (fascicles) with a diameter of 600 prn in an open helical pattern which form 
into more comp1ex tertiary bundles (Webbon 1973; Evaos and Barbenel 1975). The tertiary 
bundles are bordered on either side by a thin layer of endotendon (Stromberg 1971). 
Transverse sections of tendon reveal that the endotendon regions between the tendon 
bundles usually contain an artery accompanied by two veins (Stromberg 1971). 
2.3 Nutrient Pathways 
There has been considerable controversy regarding the role of perhion versus 
diffusion for the supply of nutrients and oxygen, and the removal of metabolic and gaseous 
wastes fiom the equine SDFT in health and disease (Smith and Webbon 1996). Although 
tendon h e  has been demonstrated to be more tolerant of hypoxic conditions in vitro than 
other tissues, hypoxia has been implicated in the development of tendinitis or degenerative 
tendinopathy (Jozsa et al 1982; Webster and Burry 1982; Birch 1993). Ligation of the 
kitratendinow blood supply of the mid-metacarpal region of the equine SDFT has produced 
lesions consistent with those documented in cases of naaually occurring tendinitis but further 
study with sham controls is required to validate this protocol as a model for tendon injury 
(Kraus-Hansen et ai 1992). These results concurred with an earlier study in the rabbit in 
which an intact blood supply was determined to be essential to tendon remodelling (Landi 
et a2 1980b). Therefore the vascular and microvascular anatomy of the equine SDFT has 
been considered to be of particular importance with respect to the aetiology and 
pathogenesis of tendon disease (Stromberg and Tuftesson 1969; Webbon 1973; Kraus- 
Hansen et a2 1 992). 
In the tensile portion of the SDFT, the intratendinous blood supply is composed of 
two major pardel vessels which course distally in the medial and lateral borders with an 
extensive interlacing network of perpendicularly arranged intratendinous arterioles with 
accompanying small venules and finer longitudinally arranged vessels which course between 
the collagen bundles (Norkg et aL 1 967; Stromberg 1 969; Stromberg 1 97 1 ; Kraus-Hansen 
et al1992). Several reports have indicated that the intratendinous blood supply is poorer in 
the mid-metacarpal segment of the SDFT, giving rise to an anatomical 'watershed zone' into 
which nutrients must diffuse, and which many authors believe may predispose this area to 
Mscular injury and the development of tendinitis (Stromberg and Tuftesson 1969; Webbon 
1973; Kraus-Hansen et ai 1992). Stromberg (1971) concluded that metabolic stimulation, 
including exercise, oniy slightly enhanced intratendinous capillary flow in horses. In rabbits 
exercise resulted in increased blood flows of approximately 140% above resting values 
(Lmdi et d 1983). Following temporary occlusion of the peripheral circulation of the distal 
equine forlimb (using a tourniquet applied immediately above the carpus), maximal blood 
flows of only 60.292% above resting values were achieved (Strornberg 1971). It has been 
suggested but not substantiated, that stretching the d o n  during physical activity may result 
in increased diffusion out of the tendon, instead of an increased flow to accormnodate 
metabolic demand (Birch 1993). 
In human flexor tendons, diffusion is considered to be an important pathway for 
supplying the tissue with nutiients particularly in regions where the tendon is surrounded by 
a synovial sheath (Manske and Lesker 1987). In avian studies in which the flexor tendon 
blood supply was severed, tritiated proline uptake was comparabie to that of tendon with an 
intact blood supply (Mmdce et al1978a). Other studies have found that when intra synovial 
rabbit tendon segments have their blood supply interrupted or are placed into a synovial 
environment they remain viable, indicating that they may be nourished by the synoviai fluid 
environment (Lunborg and Rank 1987; Manske and Lesker 1987; Weber 1987). In the 
equine SDFT, those regions surrounded by s y n o d  fluid are limited to the digital sheath and 
the carpal sheath. Studies have not been published to date which have demonstrated the 
c o n t n i o n  of diffusion in these areas to nutrition of either the SDFT or deep digital flexor 
tendon (DDFT), and these regions are not commonly affected by tendon injury. However, 
explants of the equine SDFT of up to 5 mm thickness x 4 mm diameter have been cultured 
& vi~ro? without widence of degeneration in the centre of the explants, or loss of the ability 
to synthesize molecules of the ECM, confirming the plausibility of cMEsion as a possible 
nutrient pathway in the tensile equine SDFT (Riley et d 1996). 
C ~ e n t l y ~  both diffusion and perfuson are supported as routes for the nutrition of 
the flexor tendons in man, monkeys, dogs, rabbits and chickens, particularly for intra synovial 
tendons @ h s k e  et aZ 1978a; Maaske et al1978b; Mankse and Lesker 1982). However, 
studies comparing the two routes have conduded that diffusion is the more important of the 
pathways (Uaoske and Lesker 1987; Weber 1987). It has been speculated that diffusion may 
play an important role in the nutrition of equine tendons, but similar studies comparing 
perfhion versus diftkion have not been performed in the horse (Smith and Webbon 1996). 
2.4 The CeiluIar Components of Tendons 
2.4.1 Cell Morphology and Function 
For over 60 years it has been recognized that each subpopulation of fibroblast-like 
cells has unique properties related to the tissue of origin of those cells (Parker 1933). The 
morphological appearance of the tenocyte population appears to be variable, yet little has 
been done to characterize the properties of different cell populations within equine tendon 
(l3anes et al1988). 
Equine tenocytes have been arbitrarily classified on the basis of histologic 
characteristics alone into three morphologically distinct subpopulations: type I (cells with 
thin spindle-shaped nuclei), type II (linearly arranged groups of cells with more rounded, 
cigar shaped nuclei) and type III (dage-l ike cells with round nuclei and visible nucleoli) 
cells (Webbon 1978; Webster and Burry 1982; Riederer-Henderson 1983; Goodship and 
Birch 1996; Smith and Webbon 1996; Riley and Bailey unpublished data). The relative 
proportions of these celI types and thkr overall density in the ECM varies according to the 
tendon of origin, the segmental location of the cells (ie. zones subjected to predominantly 
tensile forces compared to zones subjected to primarity compressive forces), and the age, sex 
and type of the hone from which the tendon is obtained (Holmes 1971; Otomo 1973; 
Webbon 1 978; GeIbennan et a l l  984; Smith and Webbon 1 996; Bailey et aZ 1 996; Bailey et 
al unpublished data). Within the matrix of the SDFT, type I tenocytes are small 
(approximately 1 8 x 6 pm), have dark ovoid nuclei and scant amounts of pale staining 
cytoplasm (haematoxylin and eosin), and are responsible for synthesis, organization and 
ma&enance of adjacent ECM components (HoImes 1971; Wtlliams et a1 1980; Dome and 
Birk 199 1). In the endotendon regions there is a mixture of fusiform fibroblasts (jmcluding 
type 11 tenocytes) with plump nuclei and endothelial cells. The tendons of younger horses 
have greater numbers of type II cells between the collagen fibres and greater cell density 
generally, whereas in older horses the type I cells are more common and cell density lower, 
especially in the core regions (Webbon 1978; Goodship and Birch 1996; Riley and Bailey 
unpublished data). In regions subjected to compression such as the metacarpophalangd 
zone, there are more type Ill cells. In the tendons of older horses, or horses that have 
previously SuSbined an injury, aggregations of type III cells surrounded by cartilage-like 
matrix and/or calcified matrix may be observed (Webbon 1978). The cellular density of the 
equine SDFT has generally been shown to be greater than that of the DDFT, and the 
morphological characteristics of the tenocytes suggest that they are more metabolically 
active (Bailey et a2 1992). 
In studies using the chicken as a model of synovial sheathed tendon healing, 
techniques for the separation of tendon cell subpopulations and for the identification of those 
cells which are producing collagen in healing flexor tendons have been described (Riederer- 
Hendenon et al1983; Banes et ~ 1 1 9 8 8 ;  Gamer et all989) .  Morphological, adherence and 
growth curve ~harz~eristics were determined which indicated that the swface and internal 
cells of avian flexor tendons are comprised of at least two different cell populations panes 
et al 1988). A surface population (synovial cells) derived fiom the chick epitendon was 
differentiated f?om internal tendon fibroblasts by location in the tendon, decreased 
susceptibility to trypsin, slower growth rate, and distinct morphology. The surfhce cell 
population consisted of large, round cells with f l e d  plasma membranes and two classes 
of cytoplasmic inclusions. Conversely the internal fibroblast population appeared to be a 
more homogenous group based on morphological characteristics (Banes et a2 1 98 8). I .  one 
study the cells of the outex surfhce population (synovid cells) of sheathed tendons produced 
collagen types I and III, whereas the inner cells produced only type I (Riederer-Henderson 
et al1983). Skin fibroblasts are capable of synthesizing both collagen types I and III (Gay 
et al1976). The tenocytes have been shown to differ from other fibroblast-like cell types in 
their sedhdy  to reduced oxygen tension as well as their in vitro responses to tissue culture 
(Webster and Burry 1982; Riederer-Henderson 1983). 
The separation and investigation of cellular subpopulations within the equine SDFT 
has been hampered by the resistance of the tissue to chemical or enzymatic breakdown, the 
risk of damghg cells when mechanical techniques are used, and the low cellular density of 
mature tendon tissue. Collagenase digestion has been utilized to release intact tenocytes, but 
this technique released only 0.3% of the total number of cells, mostly fiom the cut surface 
of the tendon (Birch 1993). Birch (1993) isolated tenocytes from the peripheral and central 
zones to evahnte and compare their anaerobic and aerobic metabolic activity. Cells fiom the 
central and peripheral zones were found to have similar morphology and enzyme profiles. 
With the exception of pathologic studies, there have been few other published reports 
i n v e s t i e  the morphological or functional characteristics of subpopulations of tenocytes 
in the equine SDFT (Webbon 1978; Goodship and Birch 1996). 
It has long been known that c e U  density is a key determinant of the rate of cell 
proliferation and collagen synthesis by fibroblasts in vitro (Freshney 1987; Schwarz 1991). 
However, investigation into intercellular signalling mechanisms between tenocytes is in its 
infancy. Cells fkom primary cultures of avian tendon are able to detect changes in cell density 
over -1 mm distance via a 'cell density signal', and intercellular signalling and therefore 
proc~ilagen synthesis, can be disrupted by mechanically agitating the cultures (Schwartz 
1991). More recently gap junctions were demonstrated in rat tail tendon and canine patellar 
and digital tendons in situ by transmission electron microscopy and immunoflourescent 
labeling (CieIli ei al1996). It is believed that these junctions may be part of an intercellular 
communication network enabling the tenocytes to respond to their mechanical environment. 
The author is unaware of any publications which have investigated intercellular signalling in 
the equine tendons or their constituent cells. 
2.4.2 Energy Metabolism of Tenoctges 
Basic bodedge pertaining to the ultrastructural composition and enzyme activities 
of normal tenocytes may be usefid in the understanding of the pathogenesis of tendon 
disease. Currently there is a limited understanding of such processes in the tenocyte during 
development and ageing, or in response to injury or exercise (Landi 1987). As previously 
stated, it is the tenocytes which are responsible for maintaining the tendon through the 
synthesis (and possibly catabolism), aggregation and organization of the ECM (Dome and 
Birk 1991). Since both synthesis and transport of the ECM proteins are energy dependent 
their investigation is of value for understanding the development and capacity for repair of 
the tendon (Birch 1993). In the equine SDFT is has been theorized that type II and type III 
cells are the more metabolically active of the tendon cells, although rnorphologic changes in 
the type I cells occur when explants are maintained in vibo for up to 30 days (Smith and 
Webbon 1996; Riley et al unpublished data). The majority of what is known of tenocyte 
metabolism has been obtained in the rabbit, while the equine SDFT has only recently been 
investigated @ndi et a2 1980 a,b,c; Floridi et d 198 1; Landi 1987; Birch 1993). 
Birch et a2 (1 993) investigated lactate dehydrogenase (LDH), citrate synthetase 
(CtS), maleate dehydrogenase (MDH) and glutamate dehydrogenase (GDH) activities of 
freshly isolated cells of the equine SDFT in vitro. LDH was used to assess anaerobic 
metabolism of glucose (glywlysis), and the latter three enzymes to identify the presence of 
mitochondria and the cellular potential for mitochondria1 respiration (the &ate or Krebs 
cycle). Finally glucose utilization through gIywIysis and the Krebs's cycle was assessed 
direaly and it was found that tenocytes had an oxidative capacity comparable to that of other 
mammalian ceIl types (based on CtS, MDH and GDH levels of activity), were able to utilize 
glucose, and also had d c i e n t  LDH activity to withstand short periods of low oxygen 
tension using anaerobic glycolysis (Birch 1993). However, in contrast to a previous study 
by Webster and Bury (1982), the latter finding did not suggest a greater anaerobic capacity 
for these cells than other cell types. In subsequent studies, both LDH and MDH activities 
were found to increase with longer in vitro culture periods, and the oxidative metabolism of 
glucose declined (Birch 1993). Furthermore, the cells depend upon anaerobic metabolism 
for the maintenance of intracellular ATP (energy) levels at least to some degree. 
2.5 CeII Surlace Receptors for the Extracellular Mitrix 
Contrary to earlier belief, the tendon is a dynamic structure capable of metabolic 
achky inchding cell proliferation, differentiation, migration and regulation of the synthesis 
and catabolism of the constituent molecules of the ECM (Fackelman 1973). Both the cells 
and the ECM may interact with and influence each other. Changes in the composition and 
mcture ofthe ECM must be c o ~ o u s l y  transmitted to and interpreted by the target cells 
and tissues (Raghow 1994; Goodship and Birch 1996). Conversely, cell orientation (ie. the 
linear arrangement of tenoqtes parallel to the collagen fibres and lines of tensile force) and 
the mechanical forces to which they are subjected influence the synthesis, assembly and 
orientation of ECM (Norberg et dl967; Stromberg 197 1; Goodship et a2 1980). Evidence 
of the activation of ion channels in response to mechanical stimuli such as stretch and 
compression which alter cell shape has been found (Guharay and Sachs 1984; Giori et al 
1993). However, the initiation and regulation of these and other processes are poorly 
understood and there in little information on transmembrane receptors and the transmission 
of signals fiom the extracellular matrix and other tenocytes to the cell cytoplasm (Labat- 
Robert et a2 1990; CiareUi ef ~~21996). 
2.5.1 The Integrins 
The cellular response to the ECM is mediated by two major classes of surface 
receptors: (1) a family of over 20 heterodimeric cell adhesion receptors called the integrins, 
and (2) a family of unique cell surface associated PGs (Goetink 199 1; Jackson et a1 199 1; 
Wight et al1992; Hynes 1992; Juliano and Haskill 1993). The integrins are the principal 
transmembrane receptor proteins and are composed of two glycoprotein subunits which 
mediate cell surfke interactions with other cells (?in some instances) and link the ECM to the 
cells' cortical cytoskeletons. They are expressed by almost all normal cells but most cells 
express more than one type of integrin on their surfhce, with the unique cell and ligand 
specificity of each of these receptor proteins generated by greater than 20 various 
heterodimeric combinations of the 14 hown a and nine chain subunits (Raghow 1994; 
Yamada et ~21996). Additional variations in the specificity of the integrins are created f?om 
extensive alternative splicing of the precursor mRNA molecules of the constituent a and P 
chains (Raghow 1994; Yamada et a2 1996). Some integrins bind only one ECM molecule 
such as fibronectin or laminin Others, includmg a fibroblast integrin which binds fibronectin, 
binin and collageq recognize more than one ECM molecule type (Raghow 1994; Alberts 
et al1989). Some ECM proteins may be recognized by multiple integrins, and the sequences 
or domains that are recognized within these molecules may vary for different integrins, or 
for Merent cell types. 
The integrins differ fiom other cell Surface receptors such as those that bind 
hormones, growth factors and other small signalling molecules because they bind with 
relatively low aff?nity and are present in concentrations that are 10-1 00 fold greater on the 
cell surface. This arrangement permits the cell to bind weakly to large numbers of matrix 
molecules, so that they may move readily without losing contact with the ECM. Differences 
in the integrins and their ligand-binding specificity are expressed by different cell types and 
reflect their ability to migrate within and interact with the ECM (Yarnada ei al l996) .  
The D, chains form heterodimers with at least nine different a chains and are found 
on most vertebrate cells. Examples indude the a , f3, and a, D, integrins which bind native 
collagen, a, 4 which is a fibronectin receptor and a, 4 which is a lamiain receptor, all of 
which are found on most co~nective tissue cell types (Fd et al1993; Gailit and Clark 1994; 
Yamada et d 1996). The 4 integrins are responsible for mediating cell-cell interactions and 
are expressed only by white blood cells. The O, integrins are found on a variety of cells 
including platelets, permitting their interaction with fibrinogen, and endothelial cells (a 3, 
integrin), ficilitating angiogenesis (Gailit and Clark 1994; Alberts ei al 1989). 
The integrins are the principal transmembrane receptor proteins which mediate 
interactions that link the ECM to the cell cytoskeleton. This iri facilitated by the extracellular 
and intracellular domains of the integrin molecules. Activation of an integrin may result in 
reorientation of the e x t m e h h  receptor domain, following which the linking of this domain 
to its ECM rigand results in binding of the cytoplasmic tail of the beta chain to talin and a- 
actinin This initiates the formation of a complex of intracellular assembly proteins that link 
the integri. to the actin filaments of the cytoskeleton, resulting in focal contact between the 
ECM and the cortex of the cell (Juliano and Haskill 1993). Thus the ECM can influence the 
organization of the cell's cytoplasm (eg. the tenocytes are aligned in the same direction as 
the collagen fibres), and conversely the intracellular actin fibrils can influence the orientation 
of secreted fibronectin molecules (Alberts et al1989). The adhesive activity of each cellular 
integrin is regulated by &anging either the conformation of the extracellular domain or their 
intraceliular attachment to actin filaments. The exact mechanism of these regulatory 
processes are hewn (Alberts et al 1989). Nevertheiess, the interrelationship of the 
cytoskeleton and ECM molecules permits the propagation of forces &om cell to cell, and the 
orientation of larger structures (eg-tendons), with the integrins mediating these processes. 
In addition to their structural role as m e m b r a n e  linkers, the integrins are also capable 
of activafing intracellular sisnalling cascades, thereby permitting ECM molecules to influence 
the behaviour of cells in culture, their shape , their polarity, movement, metabolism, 
development and differentiated hctions (Alberts et al l  989). 
2.5.2 The Cell Surface Associated ProteogIycans 
Proteoglycans are glycoproteins to which one or more polysaccharide chains are 
attached. Although the majority of the well characterized PGs occur in the ECM, there are 
some forms which remain and function intrace1Iularly (eg-serglycin), and still others which 
are integral components the cell plasma membrane (Jackson et a2 1991; Wight et a2 1992). 
Of the latter category, the best characterized is syndecans which has a transmembrane 
protein core (- mw 32,000) with intracellular and extracellular domains (Alberts e t al l  989). 
The intrace1lula.r domain interacts with the actin cytoskeleton and the extracellular domain 
has a variable number (one to three) of heparin sulfate (HS)  and CS GAG sidechains, giving 
it an anionic charge density suitable for binding a variety of charged molecules (Wlght et al 
1992). Syndecans is f w d  in fibroblasts and many other cell types, and has a similar role to 
the integrins in binding collagen, fibronectin and other matrix proteins (Alberts et d 1989). 
Syndecans also acts as a co-receptor by binding fibroblast growth factor (FGF) to its HS 
sidechains, and then presenting it to the appropriate FGF receptor proteins on the same cell. 
Other transmembrane PGs such as betagiycan (which also occurs on a soluble form in the 
matrix that is not associated with the plasma membrane) bind transforming growth factor 
beta (TGF-D) and presents it to the TGF-l3 receptors (Alberts et a2 1989). However in the 
case of betaglycan, TGF-J3 b*& directly to the core protein, unlike the non-specific binding 
to the GAG chains seen with other growth factors (Boyd et al1990). Hence betaglycan is 
believed to regulate the clearance or storage of TGF-D, releasing it when the matrix is 
damaged. 
2.6 The Extracellular Matrix of Connective Tissues 
Once thought to be an inert do l l d ing  hctioning only to stabilize the physical 
structure of tissues, the ECM of the connective tissues is believed to play a crucial role in 
tissue development, function and repair (Alberts et ~11989). The tendons have a very high 
ratio of ECM to cells, and the relative scarcity of cells within the adult equine SDFT 
compared to its muscular origin, implies that turnover of this component of the normal 
tendon occurs at a slow rate (Chvapil 1996; Bailey et ai unpublished data). Tendon tissue 
is strucaually diverse in its composition, with variations in matrix components corresponding 
to the various tensile and compressive forces to which it is likely to be subjected (Okuda et 
al. 1987; Jones and Bee 1990; Abrahamsson 199 1; Bailey et d 1992; Riley et al 1995; 
Bailey et aZ 1996; Crevier et a2 1996). AU connective tissue matrix consists of at least four 
major types of macromolecules: collagen; elastin; PGs (and nonsulphated GAGS); and 
connective tissue glycoproteins (Birch 1 993). The tendon is a stress-resisting system in 
which the fibrillar collagen component resists pulling (tensile) forces and the inter fibrillar 
PGs and HA gel resist compressive forces (Scott 1990). The fibrous proteins of the ECM 
constitute two major subclasses: the structural proteins, of which collagens and elastin are 
the major molecules present, and the adhesive proteins like fibronectin and laminin that are 
associated with the migration and attachment of cells, and are important in wound healing 
(Abrahamsson 1991; Yamada and Clark 19%). The PGs contribute to water content and the 
resiliency of the tissue, and are thought to be important in regulation of collagen fibril 
formation and other ECM and ce1lular interactions (Parry et al 1982; Vogel et al. 1984; 
Swtt 1990). In the equine SDFT, the water content has been determined to be 65-68% by 
weight, compared to 55% for the rabbit, 5457% for the dog and 70% in the human digital 
tendon (Okuda et a2 1987; Abrahamsson 1991; Birch 1993; Bailey et aZ 1996). 
2.6.1 Collagen Structure and Synthesis 
Collagen constitutes a major portion of total body protein, with the concentration in 
the normal adult equine SDFT reported at 64-80% of the dry weight, with marked horse to 
horse variation ( W i h m  et al1980; Birch 1993; Riley et al1995; Bailey et all996 ). It has 
been suggested that the tendon is a dynamic structures in which the cells may renew all its 
collagen every six months (Fackelman 1973). There are no published reports of research 
substantiating this claim in the horse but it is clear that high rates of collagen synthesis and 
catabolism do occur during healing after tendon injury (Chvapil 1996; Clark 1996). 
Collagen rnoldes  are the basic unit for the tendon collagen fibre and the essential 
moiety for the resistance of tensile force. Each molecule consists of three polypeptide a- 
chains, wrapped around each other in a right handed superhelix with a pitch of about 39 
residues (89 A -units) Qhhn 1987; N k  and Harhess 1988). Each subunit polypeptide a- 
cbain is formed into a left handed helix with 3.27 amino acid residues per -1 10" turn, resulting 
in a 2.9 1 A displacement between consecutive amino acids, and a 8.7 k distance between 
each third glycine wimni and Harkness 1988; Parry 1988). This separation prevents 
intrachain bonds fiom forming, leaving sites open for interchain hydrogen bonds (one to two 
bonds per amino acid triplet) to form and stabilize the triple chain supercoil wmni and 
Harkness 1988). There are at least 20 different a-chains which have been identified as 
subunits of at least 15 different collagen molecules, although new members of the collagen 
f b i l y  are still bemg identified and used as markers for merent connective tissues (table 2.1) 
(Kiihn 1987; Jones and Bee 1990; Abrahamsson 1991). 
The three a chains which form the triple helb of the rod-like collagen molecule each 
contain a substantial proportion of amino acid sequences in a repeating triplet of glycine 
(Giy) and two other amino acids (Giy-X-Y), where X and Y may be any amino acid, but are 
most frequently proline (Pro) in the X position, and hydroxyproline (Hyp) in the Y position 
(Parry 1988; Bailey and Light 1989; van der Rest and Garrone 199 1). For type I collagen, 
two of the three a chains are identical (a,@)) and the third a, is homologous but chemically 
distinct (table 2.1) (Kuh 1987). The triplet region of both chains extends for a length of 
apprordmately 1000 residues, temhkd at either end by short sequences called telopeptides 
@my 1988). The irnino acids Pro and Hyp are particularly important for the stability of the 
hw the order of stability for imino acid containing tripeptides being: Gly-Pro-Hyp (most 
rigid) > Gly-Pro-Y and > Gly-X-Hyp (least rigid) (Kuhn 1987). Therefore the rigidity and 
f l m i  of the molecule can be modified by varying amounts of Pro and Hyp incorporated 
into the collagen molecule. 
Table 2.1: Characteristics of major and minor collagens in tendon tissue 
- -- - 
Type Chains Molecular structure Supermolecular Location 
tertiary structure 
IV' ale, ol,O 390 nm C globular 
domain 
vt a~Cc?,%Cv)~ 3 00 nm N globular 
%(V) domain 
3 [ a 1 ~ ]  globular with 75 nm 
tail & 3x60 nrn arms 
3 [ a , r n l  
67 nm banded fibres 
small 67 nrn banded 
fibrils 
nonfibrillar sheet-like 
tetramer network 
small fibrils 
nonfibdar complex; 
fibril associated 
nonfibrillar complex, 
fibril associated 
UnkIlown 
matrix 
matrix & 
endotendon 
basement 
membranes 
basement 
membranes 
unknown 
unknown 
unknown 
= major, ' = minor constituent; Quhn 1987; Anriel and Kleiner 1988; Dublet et d 1989; 
Dublet and van der Rest 1991; Jones and Bee 1990; van der Rest and Garrone 199 1) 
Hydroxyproline is important in the f o d o n  of the interchain hydrogen bonds which 
stabilize the collagen molecule. Hydroxylysine is unique to collagen and is associated with 
intermolecular covalent cross-links within the telopeptides (with the exception of the C- 
terminal end of the a, chain) (Parry 1988). A deficiency in Hyp results in reduced tensile 
strength of the tendon (Abrahamsson 199 1). The intermolecular hydrogen bonds stabilizing 
the triple helix extend fiom the NH of a glycine residue to the back-bone C=O of the X 
residue in the adjacent chain, &Mizing each molecule with approximately 1000 such bonds 
per collagen molecule (Birch 1993). The hydroxylation of Pro and lyshe occurs after 
incorporation into the respective amino acid into the peptide chain, and is catalysed by 
enzymes that require free oxygen, ferrous iron, alpha ketoglutarate and ascorbate (Kuhn 
1987; Abrahamsson 199 1). The enzymes that catalyse these reactions, proline Chydroxylase 
and lysyl hydroxylase, fid.itate the oxidation of residues in position Y of the tripeptide unit 
Gly-X-Y (&dm 1987). There is also a prolyl-3-hydroxyfase which oxidizes Pro residues in 
the X position (Abrahamsson 1991). DiflFerences occur between ditferent collagen types in 
the concentrations of Hyp, Pro and other amino acids present in the X and Y positions, an 
thus, the overall m o l e a h  and tertiary aggregate structure of their helices (table 2.2). Proline 
ranges from approximately 13% of all amino acids by weight for type I collagen to 17.4% 
for type IIl collagen (Bailey and Light 1989). In the rabbit and the cow, Hyp has been 
estimated to constitute 78- 1 1 8 mg/g of tendon thy weight, with variability reported due to 
age and tendon location (Manske and Lesker 1984; Koob and Vogel 1987a). Although very 
small amounts are present in elastin and acetylcholine, Hyp is almost unique to collagen and 
is not amenable to metabolic recycling by the cell. 
Tabk 2.2: Amino acid cumposition of the achains of the major collagens in tendon tissue? 
Type I Type III Type IV Type V 
Amino acid 
Gly cine 
Proline 
Hydroxyproline 
Alanine 
Glutmine 
Arginine 
hparagine 
Serine 
Lysine 
Valine 
Leucine 
Threonine 
P heny lalanine 
Isoleucine 
Methionhe 
Hydroqdysine 
Histidine 
Tyrosine 
Cysteine 
'based on values reported by Bailey and Light (1989); %umbers represent approximate 
number of residues per a-chain molecule. 
The predominant structural coUagen types I, II, IIl and V are present in many tissues, 
but it is the variation in occurrence and distribution of the minor collagen types which assist 
in distinguishing connective tissues previously considered as identical (Gordon et a1 1987; 
Arniel and Kleiner 1988; Jones and Bee 1990; Goodship et al1994). Types I, It, III, V and 
XI form tertiary aggregates of quarter staggered fibrils, whereas types XII ,  X W  and the 
GAG-linked type M (which assembles around type II fibrils in hyaline cartilage) are fibril 
associated with intempted triple helices (the FACIT collagens) (van der Rest and Garrone 
1991; Raghow 1994). Collagen types IVY VIII and X form into sheets of lattice-like sheets 
of tetramers ('spiders'), type VI forms beaded filaments of serially linked tetramers, and type 
WI aggregates into h e r s  which act as anchoring fibrils. Collagen type I is the primary 
fibrous structural protein of adult equine tendon (-95% of all collagen), irrespective of 
intrinsic morphoIogicd or age variation (Wiarns et al 1980; Silver et a2 1983; Parry 1988; 
Jones and Bee 1990; Goodship et ~11994; Smith and Webbon 1996). 
The second most predominant collagen in tendon, type III (- 5%), surrounds type 
I fibres regardless of fibril diameter, and is linked covalently in tendon to type I collagen by 
lyshe derived cross-links (Keene et aZ 1987). It is also found in the endotendon regions and 
in tendon sheaths and has d e r  fibril diameters than type I (Dunce et a1 1977; Birch 1993; 
S d  and Webbon 19%). Increased type III collagen production occurs in association with 
tendon healing, and has been identified in conjunction with increased cellularity in equine 
tendon scars of the intratendinous regions of the SDFT (Silver et a2 1983; Watkins et al 
1985a; Watldns et al1985b). It also occurs in high concentrations in the immature tendons 
of the fetal and neonatal horse ('Williams el al 1980). Collagen types N and V are 
peridulat collagens that have been detected in association with basement membranes and 
the fine reticulate network of endotendinous sheaths and embryonic tendons of the chick 
(Duance et a1 1977). Type IV usually occurs in alI basement membranes together with the 
glycoproteins laminin, nidogen, entactin, and HS-PG, and tends to form aggregates in the 
form of sheets rather than the quarter staggered fibrils that occur with types I, II, III, V and 
XI collagen (Glanville 1987; van der Rest and Garrone 1991). Collagen type V has been 
reported peripherally adjacent to the endothelial cells of capillaries and functions as a 
connector between basement membranes and stroma (Watkins et a2 1985a; Fessler and 
Fessler 1987). It may also be closely associated with type I collagen during fibre formation 
(FessIer and Fessler 1987). The presence of both types m and V collagen molecuIes have 
been shown to have a direct effect on the fibril diameter of other fibrillar collagens (Adachi 
et al 1989). Collagen types IV and V have been identified in the pericellular regions of 
healing equine SDFT following the creation of a surgical lesion (Watkins et a2 1985a; 
Watkins et a2 1985b). Although these types were detected at weeks two, four, eight and 
twelve following injury, they were not detected at week 24, and their occurrence and 
distriiution in n o d  equine tendon has not been reported. A novel coLlagen type W has 
also been i d d e d  in chick embryo tendons (Sugrue et a2 1987). Type W collagen has not 
yet been i d d e d  in equine tendon, but recently two proteins have been isolated fiom fetal 
SDFT (np 52 with molecular weight 52 kD and np 54 with molecular weight 54 kD) and 
another from the fetlock region of the adult SDFT ( fp 55 with molecular weight 55 kD) 
(Jones and Bee 1990). The fp  55 was found to be wllagenase resistant and was thought to 
have homology with other collagen types but details of its precise nature have not been 
published. The equine SDFT may contain other unidentified unique minor collagens and 
M e r  investigation may identify these (Jones and Bee 1990). 
Collagen Synthesis d MolemZar Aggregation 
The large genes (of which 10-30% of each codes for the protein) responsible for 
synthesis of the fibrillar collagens have similar intronlexon structures and are well conserved 
across the species (Boedtker et aZ 1983). The firillar collagens are synthesized initially as 
pre-procollagen molecules with iarge amino- (N-) and carboxy- (C-) terminal globular 
domains which m not deposited in the finaI fibrillar structure (figure 2.1). The triple helical 
domain, including the non-triple-helical segments at either end, contains all the structural 
data for the constmction of a cross-linked fibril in the extracellular space (Kiihn 1987). 
23R, 130R ,17R, 1020R 23R a 244R 
I I t i t I 
N-propeptide main triple helix C-propeptide 
P m  N- C- 
propept. telopept teloptpt 
Figure 2.1. Representation of the prepro a,(III) chain of collagen (Kuhn 1987). The 
cleavage sites of the amino and carboxyl procollagen peptidase are indicated by the arrows. 
R = amino acid residues. 
Newly synthesized pre-procollagen polypeptide chains contain a short hydrophobic 
signal peptide of 23 amino acids located at the N-terminal which ~ ~ t e s  the penetration 
of the achaios through the rough endoplarmic reticulum after which the peptide is cleaved 
off ( K t h  1987). 
The hydroxylation of Pro and lysine residues is crucial to collagen biosynthesis and 
occurs in the endoplasmic reticulum. Hydroxylysine may then become glycosylated by the 
addition of galactose, catalysed by hydroxylysine galactosyl tranderase, or by the addition 
of galactose and then glucose via the catalytic enzyme galactosyl hydroxylysine glucosyl 
tramfierase (Khdcko and Myllyla 1979). The level of glycosylation is low for collagen types 
I and III with only 051% of hydroxylysine residues transformed. The carbohydrate residues 
a@ect the amount of assdated water and therefore fibril spacing. The C-terminal propeptide 
has eight cysteine residues, a proportion of which are associated with interchain disulphide 
bonds catalysed by disulphide isomerase. This aligns the polypeptide chains in order and 
initiates triple helix (tropocollagen) formation (Fessler et all98 1). 
The energy dependent secretion of newly fonned prowllagen by exocytosis is 
followed by the cleavage of the amino- and carboxy-terminal residues by specific peptidases 
just before or during fibdogenesis. The presence of the N- and C- propeptides prevents 
intracellular fibril formation (Kiihn 1987). They are important for the post transiational 
modZcation of collagen, and possibly for feedback regulation of coIlagen synthesis (Fessler 
et a2 1981; Wiestner et d 1979). 
The molecular packing of collagen molecules is an important determioant of the 
mechatlicaI strength of the tendon Once the propeptides are cleaved the collagen molecules 
have the capacity to self assemble into microfibrils under the influence of local tenoblasts 
(Birk and Zycband 1994). The plasma membrane of these cells is complex and 
c o m p a r t m ~  the extracellular space to create defined regions in which collagen fibril, 
bundle and macroaggregate formation can occur. All these phases of structural development 
of the collagen ma& occur in close association with the tenoblasts @irk and Zycband 
1994). The microfibrils are packed into a tetragonal lattice with a lattice period of 3.8 nm 
leading to the collagen fibril (Baer et (11 1974). X-ray difhction techniques and electron 
microscopic examination of collagen fibrils in tendon have determined that a periodicity 
exists of about 67 nm (D) (Parry 1988). However, the length of the collagen molecule 
including the telopeptides (-300 am or 4.4 D) is not an integral multiple of the D-period, 
implying that individual molecular structure has alternating regions of dense molecular 
packing (overlap regions of 0.47 D) and less dense molecular packing (gap regions of 0.53 
D). Statistical evaluation of the amino acid sequences of a,@, %(I), and al@n) polypeptides 
indicated that the 234-amino-acid-residue-long unit was the most prominent repeat and is 
equivalent to 67 nrn (D) observed on electron micrographs ( K h  1987; Parry 1988). It is 
formed predominantly by polar charged and hydrophobic residues and divides the a chains 
into four homologous parts: D 1, D2, D3, and D4 (Hohann et a2 1978; Hulmes and Miller 
1979). Tbree dimensional calculations of the interaction between collagen I and III 
molecules, indicates that the highest polar and highest hydrophobic contact occurs when the 
individual molecules are shated against each other by a distance of 234 amino acid residues 
(Hofhw et a2 1978). The interaction of neighbouring molecules allows the formation of 
ordered clusters of ions and hydrophobic side chains giving greater stability than possible 
with only single residue interactions (Parry 1988). This appears to be important for axial 
stab&y of the fibrils. The lateral array of the fibril is also important, but it is not as strongly 
determined by the amino acid sequence as is the axial stagger of the molecules. 
Fibd  Growth and Development 
The morphology of collagen fibrils has been examined with the electron microscope 
through stages of development rang@ from the early fetus through to maturity and this has 
been described in section 2.1. InmaUy collagen appears as widely dispersed bundles of limited 
size containing small constant diameter fibrils. Over time, the lateral dimensions of the 
bundles increase without an increase in the diameter of its constituent fibrils. Hence the 
number of fibrils increases and it is assumed, but not confirmed, that fibril length increases 
(Kiihn 1987). During the next stage of development, fibrils in neighbouring bundles often 
have different mean diameters. The fibril diameter distribution widens and each bundle is 
composed of populations of fibrils of discrete sizes. This occurs prenatally in precocial 
animals and postnatally in altricial animals. Finally, collagen fibril diameter distribution 
becomes unimodal or bimodal in tendon as the animal matures (Parry 1988). There is little 
data on fibril length due to the difficulty associated with preparing, mounting and examining 
entire fibrils. However, based on trammission electron micrographic studies, a mechanism 
for lengthening and lateral enlargement of fibrils has been proposed @irk and Zycband 
1996). Microfibrils first enter the extracellular space in deep narrow channels or 
invaginations in the plasma membrane of the tenoblasts (close to the Golgi region) which 
open to the extracellular space. As the microfibrils move out of these invaginations and enter 
the adraceilular space proper, it has been proposed that new microfibrils enter the vacated 
space and are fbsed onto the microfibril produced earlier, enabling lengthening in the case 
of linear fusion, and increase in diameter of a larger fibril in the case of lateral fusion @irk 
and Zycband 1996). Mean fibril lengths of 125pm and 1700pm have been reported for 5- 
day-old and 4-momh-old rats respectively, but are not reported for the horse (Parry 1988). 
Mature equine SDFT has been reported to have a bimodal distribution of fibril 
diameters with the mean diameters of the two peaks equal to 3 5 and 2 15 nm (Parry 1978). 
Following injury to the SDFT small fibrils predominate for 14 months or more (Silver et al 
1983). Recent work in the horse has established and compared some of the fibril 
characteristics of the equine SDFT and DDm, and examined the effects of exercise on fibril 
diameter (Bailey ei aZ1992; Birch 1993; Patterson-Kane et al1997b). A comparison of mean 
fibril diameter and fibril  butio ion found no significant differences between peripheral and 
cemral zones of the SIIFT. However, the mean diameter of the fibrils in the SDFT (median 
48 nm, range 9-364 nm) was significantly lower than that of the DDFT (median 123 nm, 
range 18458 nm) (Bailey et aI 1992). N i q  percent of fibrils in the DDFT had diameters 
greater than 1 50 nm whereas only 55% of those in the SDFT were greater than 1 50 run in 
diameter. It has been suggested that these differences may reflect the different fimctiom 
performed by the two tendons and differences in their level of developmental maturity (Birch 
1993). When a group of 18-month-old Thoroughbred horses given a controlled exercise 
program for 18 months, fibril diameters were decreased compared to unexercised controls 
in the central mid-metacarpal regions of the SDFT (Patterson-Kane ei al1997b). 
There are specific regions along the triple helix which are important for the 
stabilization of the collagen fibril by cross-linking for resistance of fibril degradation by 
collagenase, and for the interaction of collagen with cells and other matrix molecules (Kuhn 
1987). The intramolecular and intermolecular cross-links contribute greatly to the high 
mechanical strength of collagen fibres (aud elastin fibres), and the tendon as a whole (Eyre 
et a2 1984). The three major types of cross-links are disulphide bridges, lysyl oxidase 
mediated cross-links and those r d t i n g  fiom the non-enzymatic glycosylation of lysine and 
hydroxylysine residues (Bailey and Light 1989). 
Disufphide bridges occur only in collagen molecules with cysteine residues (eg. type 
UI collagen). In type III collagen the cysteine residue in the final tiplet before the C-terminal 
domain of the triple helix is the site of cross-link formation (Birch 1993). These bridges do 
not contribute sigmficantly to the mechanical strength of the collagen fibres. 
Lysyl oxidase mediated cross-links are the major covalent cross-links in type I 
collagen and essential determinants of the tensle strength, and resistance to chemical or 
enymatic breakdown of collagen @ h e r  and Last 1986; Amiel and Kleiner 1988; Smith and 
Webbon 1996). These enzyme mediated reactions involve mainly lysine and hydroxylysine 
which have secondary amioe groups on terminal projections extending lateral fiom the a- 
chains and are available for cross-linking (Amiel and Kleiner 1988). Inhibitors of lysyl 
oxidase such as B-cyanoalanine and its decarboxylated product f3-amino pro prionitriie, and 
D-penicillamine result in decreased cross-linking and lathyrism (Amiel and Kleiner 1988; 
Chvapil 19%; Davis 1996). Cross-linking sites are characterized by low Pro and Hyp content 
and the presence of the sequence Hyl-Gly-His-Arg, which is an important attachment site for 
the enzyme lysyl oxidase Wuhn 1987). 
A third group of nonenzymatically derived glycosylated lysine and hydroxylysine 
residues occurs in collagen (Eyre et al1984). These residues are thought to be sugar derived 
cross-links, but the biochemical pathways are poorly understood, and their importance as 
cross-links in tendon is not known (Birch 1993). Others have suggested that these residues 
are not cross-links, but molecules which complicate the 'cross-lir~king profile' which are 
elevated in concentration with age and diabetes mefitus (Eyre et al1984) . 
2.6.2 Elastin 
Elastin is a inert, amorphous protein of approximately 750 amino acid residues 
capable of high degrees of reversi'ble extension. It is a highly hydrophobic protein which has 
a high concentraton of Gly and Pro residues (like collagen), but unlike collagen, it has little 
Hyp (4 .5%)  or hydroxylysine, and is not glycosylated (Bailey and Light 1989). Although 
it is a major constituent of blood vessels and some Ligaments (ftom 5% in most ligaments to 
70% of the nuchal ligament of ruminants), it occurs in low concen&tions in the equine 
SDFT, predominantly in the blood vessel walls of the endotendon (Bailey and Light 1989; 
Smith and Webbon 1996). Following exocytosis, the elastin molecules conglomerate into 
fibres which then become cross-linked to one another to fonn fibres and sheet-like networks. 
Turnover rate is very low and the molecules are extremely resistant to degradation due, in 
p e  to extensive crossldchg which occurs during its maturation (Eyre et a2 1984). Unlike 
collagen, the elastic fibre is formed &om two components. In the mature elastic fibre the 
major component is elastin, but during development, a 10 to 12 mn diameter micro&riUar 
protein is detected at the periphey of the amorphous elastin and becomes progressively 
envdoped in elastin (Bailey and Light 1989). The enveloped microfibril appears to function 
as a template during elastic fibre development only, constitutes only a small percentage of 
the mature fibre, and does not contribute to the mechanical qualities of the mature fibre. 
2.6.3 Proteoglycans and the Glycosnminogtycans of the Extracellular  mat^ 
The proteoglycans constitute a group of cornpiex rnacromoIecules containing one or 
more sulfated GAG side chains covdently linked to a cure protein either through: (1) 0- 
glycosidic linkage between D-xylose and the hydroxyl group of serine (unique to 
proteoglycan) , (2) an N-giycosamine linkage between wacetylgl~wsamine and the amide 
group of asparagine residues, or (3) an 0-glycosidic bkage between Nacetyfgalactosamine 
and the hydroxyl groups of serine or threoaine (Rod& 1980; Scott 1988; Raghow 1994). 
It is the presence of the one or more polyanionic GAG side chains (due to sulfate and 
cahoxylate residues) which serves to differentiate the PGs fiom other glycoproteins (Roden 
1980). The PGs may ouw intraceUuIariy in secretory vesicles (eg. the serglycin P a ) ,  at cell 
surfaces where they cross the plasma membrane an act as cell receptors and w-receptors 
(see section 2.4.2), and in soluble form as part of the structure and signalling apparatus of 
the ECM (Jackson el al l99 1; W~ght et al 1992; Gallo and Bemfield 1996). The major 
function of PGs is to GAG chains which impart strongly hydrophilic properties on the 
PGs, increasing the ability of matrix to bind water, particularly where tissue is required to 
resist compression (Vogel and Heinegard 1985). Therefore the regulation of transport and 
expression of the protein core of the PGs in tum determines the availability and type of GAG 
chains (Gallo and Bedeld 1996). In addition to this function, the PGs are recognized as 
regulators of cell behaviour via their interactions with growth factors (eg. the core proteins 
of biglycan and decorin bind directly to TGF-D and therefore regulate its activity and 
storage), and regulators of the synthesis of PGs and collagen, and the macromolecular 
assembly of fibrils (lhndley and Lowther 1977; Boyd et a2 1990; Gallo and Bemfield 1996; 
Gu and Wada 1996). In addition, there are qxdic  peptide sequences withif. the core protein 
which bind other proteins such as link protein, or the metalloproteinases which are capable 
of degrading complexes of PGs. There is marked heterogeneity in the proteoglycan f d y  
of molecules, because structure may vary depending upon the differential expression of genes 
encoding their core protein, and the number, type and length of the GAG chains attached 
during the post translational modifications of the core proteins (Goetinck 199 1). The protein 
cores vary markdy  in size (ranging in molecular weight fiom 10,000 to 600,000), and it has 
been suggested that the PGs be categorized on the basis of molecular weight (small, large 
or very large) or on the basis of their predominant GAG side chains (Scott 1988; Gallo and 
Bernfield 1996; Smith and Webbon 1996). To date, very few of the core proteins of PGs 
have been isolated and their structure characterized (Jackson et al1991).The small leucine- 
rich PGs such as biglycaq decorin and fibromodulin are globular proteins with one or two 
GAG sidechahs. The large PGs have one or more globular regions and a bear polypeptide 
extension to which five to ten sulfated GAG chains are attached. Very large PGs (of which 
aggrecan the major PGs of cartilage, is the most widely studied) have up to three globular 
regions attached to a long polypeptide chain to which as many as 100 glycan chains are 
attached and can form large aggregates with hyaluronic acid (table 2.3) (Scott 1988). 
The synthesis of the proteoglycan core protein on membrane-bound ribosomes is 
followed by threading into the lumen of the rough endoplasmic reticulum (McQuiUan et a2 
1986). The biosynthesis and addition of the many complex carbohydrate chains and sulfated 
GAG side chains onto the core proteins which possess the specific amino acid sequence, 
Serine-Glycine dipeptide, occurs mostly in the Goigi apparatus (McQlllllan et a1 1986; 
Yanagishita 1993). This is initiated by a special link tetrasaccharide which first attaches to 
a serine residue on the core, acting as a primer for the serial addition of sugar residues by 
hexose-specific glycosyl t r a n s f i  and sulfotransfeases. Suhtion of the GAGS occun 
after the sugar residue has been incorporated into the growing chain. The sulfotransferases 
transfer W t e  groups fkom 3'-phosphoadenosyl-S'phosphodate to the GAG chain at 
sp&c sites (Champ and Harvey 1994). Following extrusion into the extracellular space 
the binding of the PGs (up to 100) molecules to hyaluronate and Link protein results in the 
formation of aggregates which, with the water they bind, form the bulk of the non-collagen 
portion of the ECM. 
Table 2.3: The major types of proteuglycans identified in the extracellular matrix of 
connective tissues. 
Proteogfycan Major GAG Major cellular Reported functions 
constituents distribution 
Aggrecan IU CS, KS; many Chondrocytes binds water in cartilage, 
chains resists deformation 
Versican HA CS; 12-15 chains Fibroblasts binds water in fibrous 
tissue 
Perlecan 
DS; 1 chain Fibroblasts fibdogenesis control 
binds TGF-O, fibronectin 
DS; 2 chains Fibroblasts binds TGF-13 
KS binds TGF-f3 
KS binds TGF-f3 
HS; 1 -3 chains Fibroblasts,endothelia, organizes basement 
epithelia membrane, binds bFGF 
IUfryaiuronate and link protein assOciated; BMbasement membrane associated; Lleucine rich. 
(Jackson et al l  99 1 ; Kresse et al1993; Gallo and Bernfield 1 996). 
The degradation of PGs occurs both intracellularly and extracellularly. W~thin the 
extmc&k space the pratein core is subject to a number of proteinases which act at specific 
sites resulting in its degradation. These metalloproteinases wiil be discussed in a following 
section The degradation of the GAGS, on the other hand, occurs intracehlarly following 
phagocytosis. The phagosome fuses with a lysosome and a number of hydrolytic enzymes 
cleaves the polysaccharides first into oligosaccharides, then sequentially by s p d c  
uronidases, suhtases and transferases into simple hexoses (Gallo and Berfield 1996). 
The &ed GAGs are polysaccharide chains (usually unbranched) of varying length 
that are composed of repeating disaccharide units, one of which is always a hexosamine (N- 
acetytglucosambe or N-acetylgdactosamine) and the other either a uronic acid (glucuronic 
acid or iduronic acid) or galactose (Abrahamsson 199 1). The acetylation of the amino sugars 
e h h t e s  their positive charge, and the carboxyl groups of the uronic acids and the d a t e  
groups of the hexosamines impart a highly negative charge to the chains (Champe and 
Harvey 1994). The sulfated GAGs tend to be extended in solution, binding water and 
repelling each other so that when compressed, water is expelled, giving the tissue resilience. 
The f d y  of sulfated GAGs include demtan sulfate @-glucaronic or Giduronic acid + 
N-acetylgalactosamine4sulphate = DS), chondroitin d a t e  (D-glucuronic + N- 
acetylgalactosamine sulfated either in the four or six position = CS), keratin sufite @- 
galactose + N-acetyglucosamine-6-dphate = KS), heparin sulfate or heparin (N- 
acetylgluwsamine-6-sulphate + L-iduronic acid or D-glucaronic acid = HS or H 
respectively), and hyduronic acid @-glucuronic acid + N-acetylglucosamine = HA). The 
GAGs possess the a b ' i  to bind covalently to a wide variety of molecules including protease 
inh'b'rtoxs (eg. antithrombin II), plasma lipoproteins, growth factors (eg. FGF), adhesive and 
structural proteins of the ECM (Jackson et al 1991). Chondroitin sulfate and DS are 
galactosaminoglycans. These GAGS have considerable variation in the extent of sulfation 
resuhg in significant heterogeneity (Gallo and Berfidd 19%). Produced by many cell types, 
CS is the most abundant GAG in d s ,  and is the predominant GAG of tendon, 
cartilage, ligaments and the aorta (Birch 1993; Champe and Harvey 1994; Bailey et al 
unpublished data). It commonly occurs in large aggregates of CS-PGs ( aggrecan in 
cartilage, and d c a n  in tendon or ligaments) which are linked to hyaluronate and stabilized 
by their associated link proteins. In the ECM the role of the CS rich PGs is considered to be 
largely structural, giving the tissue resilience to mechanical forces, particularly those which 
are compressive in nature. It is also an important constituent of the intraceIlular and 
transmembrane PGs (Gallo and Berfield 1996). 
Dennatan sulffte has many similarities to CS and is found in skin, blood vessels and 
heart valves, as well as tendons (Champe and Harvey 1994; Bailey et al unpublished data). 
It is not an impoxtaut constituent of the intracellular and transmembrane PGs nor the large 
PG aggregates (Gallo and Berfield 1996). However, its occurrence in the leucine rich and 
fibroblast associafed small PGs (eg decorin and biglycan) suggests that DS may be important 
with respect to the cell and ECM regulatory roles played by these PGs. The presence of 
iduronic acid confers on DS an ability to self aggregate. 
Keratan sllfate does not contain an uronic acid, but both its constituent galactose and 
N-acetylglucosamine may be sulfated at the six position. It occurs in aggregating PGs, 
usually in domains between the link protein binding sequence an the CS chains. KS is also 
a constituent of the small PGs fibromodulin (fibroblasts) and perlecan (basement membranes) 
which, like decorin and biglycan, may participate in cell and matrix regulation (Gallo and 
Berfield 1996). The physiological role of KS has not been well defined to date. 
Heparin is an intraceUdu GAG with anticoagulant properties. Its extracellular form, 
HS, is the most complex of the ECM sulfkted GAGS with N-sulphate, iduronic acid and 0- 
dfkted regions (high charge density regions) of -12 to 30 dissccharides that are separated 
by alteroatiag regions of low sulfation (low charge density regions)(Ga.Uo and Berfield 1996). 
It is common in the basement membranes, and is a widespread component of cell SUCfaces. 
The major role of these GAGS is protein and peptide binding (eg. antithrombin III binding). 
In addition HS has  bee^ reported to interact with collagen types I, 11, IV and V, fibronectin, 
laminin, thrombospondin, vitronectin , growth factor binding proteins, cell-adhesion 
molecules and cytokines (Gallo and Befield 1996). Basic FGF selectively binds to penta- 
or heptasaccbaride HS sequences to &om a complex with the cell receptor for FGF, 
mediatiog the mitogenic response of the Cea Heparan sulErte is also an important component 
of the ECM of the basement membrane, where it is present in two PGs forms, one of which 
is perlecan (Tiipl 1993; Salmivirta et a2 1996). I .  this location the protein core binds to 
nidogen, and via the HS-GAGS to type N collagen, fibronectin and laminin. 
Proteogiym and Giyco~~mtinoglyccat~ in Tendons 
The PGs constitute less than 1% of adult bovine tendon dry weight, 1-5% in the adult 
dog, and 2% in the rabbit (Vogel and Heinegard 1985; Okuda et al. 1987; Daniel and Mills 
1988). Because of the heterogeneity of the protein core of the PGs family much of the 
comective tissue work investigating their ocumence has focussed on evaluation of different 
GAGS, using these as indicators of the species of the PGs present in tendon. The quantity 
and distribution of PGs in tendon differs between those regions subjected only to tensional 
forces and those where combinations of tensional, frictional and/or compressive forces are 
sustained (Koob and Vogel1987b; Okuda et d 1987; Birch 1993). In the bovine deep flexor 
tendon the predominant PGs is decorin, which has been shown to differ in structure from that 
found in either bone or cartilage (Vogel and Fisher 1986; Evanko and Vogel 1993). 
However in regions of the tendon subjected to compression or fiction, fibrocartilage was 
identified in which aggrecan and biglycan were elevated compared to the tensile regions 
(Kmb and Vogel1987b; Okuda et QZ 1987). In the horse decorin, biglycan and fibromodulin 
have been identified in the digital tendons, as have levels of CS compatible with the presence 
of aggrecan in the metacarpophalangeal regions of the tendons, but a definitive publication 
of this work is not yet available (Smith and Webboa 1996). 
In the tensional (mid-metacarpal) region of the equine SDFT total sulfated 
chondroitin sulfate equivalent GAG content is not significantly different between the core 
and the periphery of the tendon (Birch 1993). In older horses (mean age 14.3 years) the 
DDFT has a significantly higher total GAG content than the SDFTs (Birch 1993). However, 
in a group of unexercised 18-month-old Quarter horses total GAG content was higher in the 
SDFT, particularly d e n  the proximal metacarpal regions of the two tendons were compared 
(Bailey et al qubIished data). When individual sulfated GAGS were evaluated, differences 
in the relative proportions of both DS and KS were found between the DDFT and SDFT in 
one study, and in CS, DS and KS in young unexercised horses (table 2.4). The differences 
in re& between the two studies may the reflect the influences of age, breed and/or exercise 
history on the ECM composition of the horses evaluated in the two studies, factors which 
have been determined to be of importance by other workers (Vogel and Heinegard 1985; 
Vogel and Evanko 1987; Daniel and Mills 1988; Vogel and Thonar 1988; Evanko and Vogel 
1993; Patterson-Kane et al1997a&b). Comparisons between the ECM of the tensional and 
compressive regions of the equine SDFT and DDFT have not been published. However 
segmental variations in the ECM of the tensile (metacarpal) regions of the SDFT and DDFT, 
were investigated and higher GAG concentrations approaching the metacarpophalanged 
compression zone in the DDFT, and lower GAG concentrations in the mid-tensile zone of 
the SDFT were found (Bailey et a1 1996). Similar comparisons have been made in rabbit, 
dog and cow (Vogel and Heinegard 1985; Koob and Vogel 1987b; Okuda et d 1987; Vogel 
and Evanko 1987; Daniel and Mills 1988; Abrahamsson 199 1; Abrahamsson ei a2 1994). 
Table 2.4. Propodom of sulfated glycosaminoglycans in equine digital flexor tendons. 
Proportion of totd GAGS Proportion of total GAGS 
Glycosamino&can in equine tendons (YO) HB in equine tendons (%) JB 
SDFT DDFT SDFT DDFT 
Chondroitin sulfate 68.5 64.8 46-44 43.12 
SDFT = superficial digital flexor tendon. DDFT = deep digital flexor tendon ' Significant 
Merencesbetween SDFI'& DDFT @ c 0.02'; p < O.lS; p < 0.01 ?; p < 0.001 3; n =  6 for 
both studies; HB = Birch 1993; IB = Bailey et a2 unpublished data. 
In the bovine tendon the total amount of GAGS per unit wet weight of tissue is 
sipificanth, greater (three fold) in the pressure bearing region of the tendon compared to the 
p r o d  fibrous region (Vogel and Heinegard 1985). The quantitative and qualitative 
distr i iom of PGs in developing bovine tendon are related to the type and distribution of 
forces to which the tendon is subjected (Evanko and Vogel1993). 
2.6.4 Hyaluronate 
Hyahuo~lirte (syn. hyaluronic acid; hyaluronan) consists of repeating units of up to 
several thousand non-sdfkted disaccharide units (N-acetylglucosamine + D-glucuronic acid) 
joined by 1,4 Ptycosidic bonds. It is the only GAG not o rdhdy linked to a core protein, and 
its chains (up to 10' Da in size) are not modified or sulfated (Champe and Harvey 1994; 
Gallo and Bernfieid 1996). It differs ffom the other GAGS in its synthesis in that it is 
produced by an enzyme complex assoCiated with the plasma membrane of the cells, through 
which the growing poiysaccharide chain is extruded into the ECM (Prehm 1984; Ghosh et 
d 1992). This results in very large molecules capable of occupying large volumes and 
binding many cations. The mechanism for controlling HA synthesis is not &fly understood, 
but it has been detamined that HA receptors on the cell surface are preferentially stimulated 
by high molecular weight HA and may be inhibited by low molecular weight HA (Ghosh et 
al1992). Hyaluro~liife is not cataboW locally but is circulated via the lymph and degraded 
by the reticuloendothelid cells, mostly of the liver (Gallo and Bemfield 1996). 
Hyaluronate occurs exclusively in the extracellular space (in the ECM and body 
fluids) and acts as a boundary lubricant and shock absorber of synovial-lined structures, in 
solution behaviog in a viscous manner at low shear rates and as an elastic body at high shear 
rates (Ghosh et a2 1992; Gallo and BernfieId 1996; Howard and McIlwraith 1996). It fills 
the vitreous humor of the eye, but occurs at the highest concentrations in the pericellular 
region of fibroblasts and other cells of mesenchymal origin (Gallo and Bernfield 1996). In 
the ECM the large HA chains are highly hydrated, and fold in such a manner that pores or 
spaces are created which can admit ions and other small molecules. Control of the 
concentrafions and diffUsion rates into and out of the HA complex may s e c t  the activity of 
these ions and snall molecules. In addition, HA may assist in cell aggregation by binding to 
them via cell sllrface receptors (Knudson 1993). Several proteins, including the core proteins 
of the PGs and the link proteins, are able to recognize and bind Hq resulting in the 
formaiion of large PGs aggregates in the E m  The structural importance of HA in the ECM 
lies in its ability to covalently bind Iarge numbers of PGs molecules in the formtion of large 
PG aggregates such as in aggrecan In many instances, many PGs monomers are bound to 
a single hyaluronate molecule in the extracellular space, thereby coalescing into giant PGs 
aggregates (Abrahamsson 1991). The anionic HA molecule (due to the carboxylic acid 
residues present in glucuronic acid) is also capable of weak reversible bonding to the 
positively charged amino acids (lysine, hydroxylysine and arginine) of collagen. However this 
tendency appears to much lower than that of the sulfonic acid residues of the sulfated GAGS 
(Munni and Harkness 1988). The importance of HA in fetal tendon development, where it 
regulates cell proliferation, migration and differentiation via transmembrane cell surface 
receptors, has been discussed in section 1.0 mudson 1993; Sherman et al1994; McCallion 
and Ferguson 1996). 
2.6.5 Link proteins 
The link proteins (LP) are a d family of three closely related glywproteins which 
were first discovered in cartilage, and later in other connective tissues (Neame and Parry 
1993; Binette et a2 1994). Recently three LPs (mw = 41,000,43,000 and 46,000) have been 
isolated fiom adult equine cartilage and the complimentary DNA sequenced @udhia and 
Plan 1995). They have separate binding domains which facilitate their linkage to PGs and 
to HA which in tum s t a b ' i  the PGs aggregates (aggrezam and versicans) and protects the 
HA binding domain ofPGs fiom proteolytic enzymes (Neame and Parry 1993). No other 
function has been determined for LP. In the absence of LP, PGs aggregates tend to be 
d e r  and less stable. The binding domain on LP for HA has similarities with those of the 
CD44 and TSG-6 cellular HA receptors. In addition to binding sites, two specific sites for 
cleavage of LP by stromeolysin, collagenase, gelatinase and matdysin (the 
metalloproteinases) have been identified (Nguyen et al 1993). Although LP's have not been 
specifically identified in equine SDFT's, they are likely to be present in these tissues. 
2.6.6 Proteoglycan - Collagen Interactions 
The formation and aggregation of collagen into more complex structures and the 
ageing of these aggregates has been reported to be affected by interactions with both the 
protein core and the GAG sidechains of PG molecules (Vogel et a2 1984; Scott 1985; Scott 
and Haigh 1985; Brown and Vogei 1989; Scott 1990). The PGs and their relationships with 
collagen types I, II, IlI and VI appear to be complex and their investigation diflidt (Kresse 
et al 1993). The interactions between the two groups of molecules are both direct and 
ind ire  the indirect effects being facilitated by the interaction between PGs bound growth 
fmors, and the cells within the ECM which respond by increasing or decreasing collagen 
synthesis. The interactions of the smaller PGs , although not filly characterized, are better 
understood than those of the larger PGs because of their simpler structure. Decorin (PG-II 
or PG-S2), with its single DS chain, decorates the surface of type I and II collagen fibrils 
both in vitro and in vivo (Hehegird et al 1988; Kresse 1993). In soft connective tissue 
decorin occurs regularfy and is orthogonally arranged at the bands of type I collagen where 
it binds to the fibril by its protein core (not the GAG side chains). When decorin is bound 
to the surfkce of collagen fibrils in tendon tissue, the lateral assembly of individual triple 
helices into the forming fibril is delayed, and the find fibril diameter is reduced in vim 
(Vogel et al1984). This action has been shown to be due to the protein core, and does not 
occur in response to DS-GAGs alone, or when large PGs are used (Kresse ef al1993). This 
Iatter &ding is not true of all PGs interactions. In the corneal stroma the self association of 
decorin DS-GAGS (which are of constant length) on opposite collagen fibrils is thought to 
maintain a constant interfibrillar space and thus contribute to uniformity of corneal structure. 
In fibroblast cultures is has also been demonstrated that decorin is essential for bridging 
collagen fibrils and therefore transmitting forces generated by fibroblasts from one cell to 
another @hsse et a2 1993). The bct ion of biglycan (PGI or PG-S 1) is not hown, but it 
interacts with other ECM constituents under suitable conditions in vilro Wesse e l  a2 1993). 
Fibromoddhq which is a KS linked PGs also has inht'bitory effects on collagen fibril 
formation while lumican, which fkcilitates the development and maintenance of corned 
transparency, is also a KS bearing PG (Kresse et a1 1993). The differences in their activities 
are therefore not due to the KS moiety alone, but a r d t  of interaction with the protein core 
(possibly via their signal peptides), or the protein-KS combination (Scott 1988; Kresse 
1993). Fibromodulin, has recently been found to influence collagen fibrillogenesis in vitro, 
with marked retardation of collagen types I and II (Hedbom and Heinegard 1989). It has 
considerabIe homology with the small interstitial proteoglycan decorin (Oldberg et a1 1989). 
Other studies have focussed on the response of collagen to the different GAG 
moieties alone and have revealed complex responses particularly to CS and DS. 
Investigations in rat tendon using both cupromeronic blue dye with electron microscopy and 
biochemical techniques have confirmed that the GAG moieties of the PGs interact 
electrostatically in a reversible manner with type I collagen This a&iity is dependent upon 
molecular shape and linear cbarge density, and provides up to 25% of the stabilization forces 
in tendon collagen (Mi and Harkness 1988; Scott 1990). Glywsaminoglycans were not 
actively incorporated into type I or II collagen fibrils. However CS and DS linked PGs may 
be incorporated into type I fibrils if present during fibrilogenesis (Scott 1988). It has also 
been reported that CS and DS accelerate fibre formation during the nucleation phase, but 
when CS, HS or PGs are added after the nucleation phase, the growth phase of fibrilogenesis 
is delayed, limiting fibril diameter (Ni and Harhess 1988; Parry and Craig 1 988). It has 
also been suggested that DS may inhibit the calcification of fibrils (Scott and Haigh 198 5). 
The basal laminae are continuous thin sheets of ECM that surround many cells, 
including connective tissue cells. One of the most documented collagen-PG interactions is 
that between type N collagen, HS, laminin and entactin, the latter two m o l ~ e s  being 
basement membrane glycoproteins (Alberts et d 1987; Timpl 1993). The HS-GAGS are 
associafed with two Merent protein cores, one of which is called perlecan It appears that 
the glycuprotein nidogen binds to the cure protein of perlecan, whereas the HS component 
of perfecan mediates PG interactions with laminin, fibronectin and the central region of the 
type LV collagen triple helix (Timpl 1993). Studies of collateral ligaments have also 
suggested interactions between type VI collagen and CS (Bray et a l l99  1). 
2.6.7 Other Glycoproteins 
There are several other structural or connective tissue proteins that contribute to the 
d u l a r  matrix of tendon These incbde fibronecth, laminin, tenascb, thrombospondh, 
von-Wdebrand factor, nidogen and fibrillin (Birch 1993). 
Fibronectin an adhesive glycoprotein which is distn'buted throughout most connective 
tissues, has a high affinity for denatured collagens and is reported to serve as a mediator 
between the collagen matrix and the interior of tenocytes, facilitating cell adhesion and 
migration (Potts and Campbell 1994). It exists in a soluble form in blood plasma and is 
involved in clotting and womd healing, in an insoluble form in the ECM, and as a component 
of basement membranes where it interacts with cell surfaces (Aiberts ef a2 1987; Raghow 
1994). The molecule is a 540 kDa dimer of two similar polypeptide chains, with peptide 
domains for binding fibrin, cell Surfaces, collagen, heparin, CS and its integrin receptor a$, 
(the latter being essential for appropriate assembly) (Potts and Campbell 1994). 
Laminin is a constituent of basement membranes, and therefore is in contact with 
cells of mesenchymd and epithelial origin. It consists of three very long polypeptide chains 
arranged in a cross-like shape (Alberts et a1 1987). Like fibronectin, it has binding domains 
for type N collagen, HS and cells, but the responses of cells to these may be either 
stirnulatory or inhibitory (Raghow 1994). Its activities include promotion of cell 
proliferation, attachment and chemotaxis, inhibition or stimulation of angiogenesis, and 
induction of wllagenase IV and tyrosine hydroqbe enzymes. Both the entire molecule and 
its subhgments have demonstrated biological activity. 
Carft-hge Oiigomeric Motrir Protein 
R d y  cartilage oligomeric matrix protein (COMP) has been demonstrated to be 
present in adult, but not neonatal, bovine and equine digital flexor tendons (Smith and 
Webbon 1996). It is present at high levels all regions of the equine flexor tendons (-3% dry 
weight), and occurs in higher concentrations in the SDFT (especially in the mid-metacarpal 
region) tban the DDFT. The precise function of COMP is not known, but there is evidence 
that it may bind to other molecules, and may have a role as a transfer protein, similar to 
ceruloplasmin (Stanescu et a2 1994). Other workers have suggested that based on its 
distribution in tendon and its variation with age, COMP is a structural protein synthesized 
in response to loading (Smith and Webbon 1996). It has been proposed as a marker for 
determining the response of equine tendons to exercise and disease. 
2.6.8 Regulation of Matrix Synthesis and Catabolism 
The complexity of the -1luIar matrix suggests regulatory mechanisms which are 
mdtXarious in nature. Just as a comprehensive understanding of the structure of the ECM 
of tendons is not yet available, the regulation of matrix synthesis and catabolism of 
connective tissues is poorly understood (McIIwraith 1996). Given the complexity of cell 
signalling (autocrine, paracrine and systemic) within the animal, and intermolecular 
interactions within the ECM, it is unlikely to be M y  understood in the near fbture. 
Essentially, regulatory responses are initiated by receptor activation on the cell d a c e  (by 
cytokines, mechanical or electrical stimuli, or other sigoalling molecules), triggering either 
a biochemical and/or a mechanical response in the case of the cells of the tendons, ligaments 
and other connective tissues. Different aspects of matrix synthesis and regulation as they 
relate to cell-cell, cell-matr'nt and matrix molecule-ECM interactions have been introduced 
m previous sections of this dissertation, and these all contribute to an understanding of the 
processes and molecules involved in regulation of the ECM. 
The role of cell-cytokine contriiutions to this process of tendon homeostasis is 
poorly understood, as is the regulation of homeostasis of normal tendon tissue. In cartilage 
inteleukin 1 (IL-I), interleukin 6 @A), inte1eukin 8 (IL-8), tumor necrosis factor (TNF), 
insulin-like growth factor (IGF) and transforming growth factor beta (TGF-B) have been 
demonstrated as necessary for interceUular communication and the regulation of synthetic 
and catabolic pathways (Plan 1 996). Although there is little infomation available on the 
effects of cytokines on tendon tissue, it is expected that some of the responses observed in 
m t h g e  will be discovered in other connective tissues. Recently IGF-I was shown to have 
an anabolic &'i on collagen metabolism in the equine SDFT (Murphy and Nion  1997). 
The elEcts of ageing and exercise on Merent aspects of the tendon matrix development and 
maturation have also been introduced in previous sections, and appear to have signtficant 
bearing on the biochemical composition and molecular structure of the ECM (Koob and 
Vogel1987b; Patterson-Kane 1997a&b). 
Several enzymes have been identifled in cartiIage and tendon tissue which are 
responsible for the extracellular catabolism of the connective tissue ECM during disease, 
where they are essential for repair and tissue remodelling, and during normal homeostasis 
(Gailit and Clark 1994; Mdhvraith 19%). They include the metalloproteinases and the tissue 
inhribitors of metalloproteiaases (TIMPS), as well as serine, cysteine and aspartic proteinases. 
The metalloproteinases (MMPs)  are a group of proteolytic enzymes characterized 
by their requirement for Zn2' at their active site (McIlwraith 1996). They are present 
errtraceIlularty at high concentratom during the inflammatory and early reparative phases of 
wound healing, deaeasiag as the wound remodels and matures (Gailit and Clark 1994). All 
MMPs are secreted fiom fibroblasts, synovial cells, osteobiasts, chondrocytes, endothelid 
cells, macrophages, and keratinocytes in an inactive zymogen form which is activated by 
other MMPs, or serine proteases such as plasmin, trypsin or neurophil elastase (Mignatti el 
d 1996). The mechanism of their activation during n o d  tissue homeostasis is not 
understoodOOd Each of the MMPs act on one or more specific molecular substrates at specific 
sites. Link protein for example has two domains at which different MMPs cleave the protein 
(Nguyen et a2 1993). Stromeolysiu 2 and gelatinase A cut LP at both these sites (creating 
three fhpents) ;  cohgenase, gelatinase B and stromeolysin 1 cut at one site; matrilysin cuts 
at the other site. Many of the protein cores of the PGs and the individual collagen molecules 
also have specific sites at which the MMPs act. The best characterized MMPs are the 
collagenases. Interstitial or tissue collagenase (MMP-I) is specific for collagen and cleaves 
all three chains of the molecule at one specific site between a glycine and isoleucine residue 
of the a,@) chain of collagen types I,II and III (Mcllwraith 1996). It also cleaves collagen 
types WI, Vm and X, but not basement membranes or types IX and XI. The other major 
MMPs thought to be important in cormdve tissue ECM are stromeolysin 1 and 2 (MMP-3 
and MMP- 10). Table 2.6 summarizes the substrate activity of the MMPs. 
The MMPs are regulated largely by a family of tissue derived inhibitors of the 
rnetalloptoeinases ('ITUPS), three of which have been identified and labeled as TIMP (or 
TIMP-I), TIMP-2 and TIMP-3 (Mignatti et al 1996). The TIMPs bind covalently and 
irreversibly to inhibit the catalytic activity of MMPs but not other proteases, and have also 
been reported to have growth promoting activity for many cell types (Hayakawa et al1992). 
TIMP- I is a glywprotein which inhibits all numudim MMPs (but not collagenase of 
bacterial origin) and acts only on the active enzymes and not the zyrnogens (except for the 
92 kDa progelatinase). Due to the presence of six disulfide bonds and their molecular 
configuration, the TIMPs are highly resistant to extremes of pH and temperature. The 
activity of TIMP-2 is directed mostly at the 72k Da gelatinase, and although similar in 
structure to TIMP-1, it is not glycosylated. The activity of the recently discovered TIMP-3 
is not h o w  but this MMP inhibitor is localized predominantly within the ECM (Mignatti 
et al1996). 
Table 2.5: Metalloproteinases associated with tissue remodelling. 
MetaUoproteinase Substrates 
- 
Tissue collagenase 
MMP-1' CollagentypesI,II,E&W&~LP 
Gelatinases Denatured type II, gelatin, elastin, entactin 
A (72 kDa) MMP-2' Collagen types X & XI, LP, 
B (92 ma) MMP-9' Collagen types N & V, LP 
Stromeolysins 
(I )  MMP-3! Procollagens, collagen types IX & XI, elastin, LP, 
Bronectin, decorin, aggrecan, activates procollagenase 
(2) MMP-lo' Fibronectin, LP, activates procollagenase 
Neutrophil collagenase 
MMP-8' Proteoglycans, gelatins, fibronectin 
Macrophage metalloelastase Elastin, collagen type IV 
MatriIy sin Collagen type IV, elastin, laminin, entactin, elastin, LP 
LP = link protein; ' gelatins = denatured collagens; 'inhibited by TIMP-1 and TIMP-2; 
tinhibited by TIMP-I. (Gailit and Clark 1994; Mcflwraith 1996; Mignatti et al1996) 
The serine proteinases are the other enzyme group that plays a major role in 
physi010gical and pathological tissue remodelling (Mipatti et aZ 1996). The enzymes in this 
group include phmin, tissue plasmhogen activator (PA), urokinase (*A), neutrophil 
elastase, cathepsin G and plasma kallikrein. The PAS convert the rymogen plasrninogen to 
plasmin which, in turn has a broad substrate activity which includes fibronectin, laminin, 
gelatins and the core protein of PGs (Mignatti et a1 1996). In addition to its catabolic 
activity, plasmin mediates the release of basic FGF fkom cell &aces and the ECM. Plasmin 
is also an activator of the MMPs, but is inhlibited by the serum protein %-antiplasmin. Their 
activity is regulated by PA inhiiitors (PAM, PA?-2 and PAI-3) and protease nsdns, which 
can bind and inactivate the activators (Mcnwraith 1996). InterIeukin-l has been 
demonstrated to stimulate the production of tPA but not uPA Elastase and cathepsin G are 
produced by neutrophils and are potent degraders of PG, and inhiibitors of PG synthesis. 
Both are inhibited by a,-proteinase inhibitor (a,-PI). 
Wepsins B, L and H are Iysosomal proteinases, with cathepsin having the broadest 
pH range for activity (McIIwraith 1996). Cathepsins B and L cleave the end terminal 
peptides of collagen that contain the intermolecular and intramolecular cross-links. In 
addition, cathepsin B cleaves the HA binding domain on PGs, and degrades and hgments 
the GAG attachment region. Cathepsin L causes more extensive degradation than B, but 
both cleave all three LPs at multiple sites. As with the MMPs, the cathepsins have active and 
inactive forms. They may also be stimulated by &I and tumor necrosis factora ('IN?<), 
but are inhibited by molecules called cystatins. These are secreted by the same cells which 
secrete the cathepsins - synoviocytes and chondrocytes, and imbalances between the two 
may result in orthopedic disease. The other member of this group of proteinases are the 
&pains which are CaB dependent enzymes in the ten cytosol capable of degrading monomer 
and aggregated PGs. Their corresponding inhibitors are the cdpastatins. 
Cathepsin D requires an aspartate residue in its structure to facilitate its catabolic 
action during intlammdon and rapid ECM breakdown (Mdwraith 1996). It is secreted into 
the extracellular space by macrophages and connective tissue cells where it degrades PGs 
by cleaving the HA binding domain on PGs adjacent to the sulfated GAG attachment region 
2.6.9 Segmental Variation in the Equine Digital Flexor Tendons 
Until ready, there were very few published works which had exarnined the degree 
of histologic or biochemical variation due to age or location along the length of the equine 
digital flexor tendons (Otomo 1973; Webbon 1978). Early histologic comparisons have been 
made within the normal SDFT between the tendon at the musculotendinous junction and 
within the carpal she& the metacarpal (extrasynovial) region, the tendon within the digital 
sheath, and the insertion of the tendon into the first and second phalanges (Webbon 1978). 
The surf2ic.e of the musculotendinous junction and within the carpal sheath is covered by a 
layer of densely staining nuclei, with the p r o d  fibres forming an intermeshing network 
which become longitudinally oriented more distally. The tendon of the metacarpal region is 
surrounded by loosely arranged tissue or the paratenon, and has wavy, eosinophilic fibres 
with reduced cellularity compared to the intrasynovial region. The cells are arranged in 
longitudinal columns. Chondroid metaplasia occurs occasionally in the metacarpal region 
(particularly in older horses) and in some regions the cells are manged irregularIy7 resulting 
in 'acellular' areas. Tendon within the digital sheath does not have the low cell density 
observed in the metacarpal region and there is a well developed vascular zone below the 
synovial layer. In the region of periosteal insertion more chondroid cells are observed. 
Recently cell density was determined in a sequential manner by morphometric 
techniques along Merent zones of the tensile equine SDFT and compared to the DDFT 
@dey et a1 unpublished data). The cell density of the endotendon was counted separatelj: 
and although there was a tendency for a higher density in the SDFT, differences among the 
zones in either tendon were not significant- The cell density of the remaining matrix was 
significantly higher in the middle of the SDFT, and increased significantly from proximal to 
distal in the DDFT. The mean cell density of the SDFT was approximately double that of the 
DDFT. Although all the horses were 18-month- old Quarter hones raised on the same farm, 
there were sigdicant ditferences among the horses for the parameters measured. 
Regional differences in cellular proliferation and matrix synthesis have been identified 
in many other species, reflecting differences in the mechanical requirements of dBkrent 
tendons and different zones each tendon (table 2.5) (Kain et al 198 8; Abrahamsson et a2 
1994). In a paranel study to the histologic study by Bailey et al, biochemical parameters were 
determined and compared in a similar manner (Riley ef a2 1995; Bailey et al1996). In the 
DDFT, uronic acid (UA) concentrations (an indicator of CS, DS, HS and HA but not KS) 
were significantly higher for the distal zones as the compression region of the tendon was 
approached. In the SDFT the UA concerrtration was significantly lower in the middle zones, 
a finding compatible with the findings in other species (Vogel and Heinegard 1985; Okuda 
et a.21987; Daniel and Milk 1988; Vogel and Thorn 1988; Abrahamsson et a2 1994). When 
CS, DS and KS wncentmtions were individually determined there was a si@cantly higher 
concentration of CS in the SDFT than in the DDR, a tendency for higher DS concentrations 
in the SDFT than in the DDFT (p < 0. I), but a significantly higher KS concentration in the 
DDFI' than the SDFT (Bailey et a2 1996). A segmental comparison along the tensile SDFT 
did not indicate significant merences in CS, DS or KS concentrations. However in the 
DDFT, CS levels were sigdicamly higher in the distal zone (those approaching the 
metaklrpophalangeal joint), but DS and KS levels were signdicantly higher in the p r o d  
zones. In addition to these kdings, collagen concentration did not vary segmentally in either 
tendon or between the SDFT and DDFT. Recently, these differences in total GAG content 
in the SDFT have recently been parallelled by a study which demonstrated segmental 
differences in the mechanical properties of the tendon (Crevier et a2 1996). 
Table 2.6. Proportion of individual glyc~saminoglycaos in digital flexor tendons. 
Specie Region Predominant Predominant Other GAG 
Proteo@ycan GAG chain chains 
Rabbit Compression high MW CS KS 
Tension low MW DS 
Canine Compression Not reported CS DS 
Tension Not reported DS HA 
Bovine Compression high MW CS KS 
Tension low MW DS CS 
CS = chondroitin whte; DS = dermatan d a t e ;  KS = keratan sulfate; HA = hyaluronate 
;(VogeI and Heinegard 1985; Okuda et a2 1987; Daniel and Mills 1988; Vogel and Thonar 
1988; Abrahamsson et all 994) 
2.7 Tendon Healing 
2.7.1 Extrinsic Versus Intrinsic HeaIing 
The healing of the SDFT has been claimed to occur either by the migration of cells 
and vasculature fkom surrounding peritendinous tissues (extrinsic healing) or by outward 
growth fiom the cut or damaged ends of the tendon (intrinsic healing). There is considerable 
controversy in the literature over the relative importance of cornbutions fiom intratendinous 
and peritendhots blood supply and cellular proliferation to tendon healing. However, there 
is considerable evidence for both contributions to healing and, depending upon the type of 
injury that occurs and whether or not the injury is intrasynovial or extrasynovial, it has been 
suggested that a combination of intrinsic and extinsic &ors is necessary for optimal healing 
(Graham et a2 1984; Lundborg and Rank 1987; Kain et al 1988; Abrahamsson 1991; 
Abrahamsson et ul1994; Pool 1996). 
The concept of extrinsic healing has been used as one of the rationales for surgical 
tendon splitting in chronic cases of equine SDFT tendinitis (Asheim and Knudsen 1967). The 
formation of adhesions between the injured tendon and surrounding tissues, and the relative 
h y p d h h t y  of tendons have also been interpreted as evidence of sctrinsic contri'butioris 
to healing (Pot- 1%2; Peacock 1984). In laceratons of the equine flexor tendons healing 
is dominated by actrinsic responses in the early stages of repair, and intrinsic healing is 
mhhd  due to disruption of the intratendinous vasculature and cells and ECM at the wound 
margins. In cases where contamination is m h h d ,  it is recommended that the tendon ends 
be reapposed, and that suture techniques which minimize damage to the intratendinous 
v a s x k w  are used - both aimed at supporting intratendinous healing and minimidng scar 
formation (Bertone et al1990; Easley et al1990; Jarm et a2 199 1; Mahshadi and Amis 199 1 ; 
Jarm et ul l992a; Jam et all W2b; Watkins l992b; Montgomery et a2 1994). Lacerations 
involving the tendon sheath, those involving other comective tissue support structures, and 
those that have a prolonged interval between injury and treatment carry a poorer prognosis 
(Wagner and Shires 1986; Spurlock 1989). Where the tendon sheath is involved both 
pathways for nutrition -perfision and f i s i o q  are disrupted. It has been suggested that 
diffusion is an important nutritive pathway in these areas, and may account for the poorer 
prognosis (Smith and Webbon 1996). In man, where intrasynovial tendon injury and surgery 
is commos extrinsic healing is considered particularly undesirable when it leads to the 
formation of adhesions. Therefore considerable effort has been put into the care11 
reconstruction of the injured tendon, pharmacological control of adhesions, and early 
mobilizaton of the tendon to minimize adhesions and optimize intrinsic healing (Bora 1987; 
Gelbennan and Manske 1987; Kutz 1987; Lundborg and Rank 1987; Michon 1987). 
There is also strong support for stimulating and optimizing the intrinsic healing 
capacity of the flexor tendons (Lundborg and Rank 1987; Schepel 1987; Abrahamsson 199 1 ; 
Abrabamsson et al1994). CeIls from the epitendon and endotendon proliferate to repair the 
tendon defect (Lundborg and Rank 1987; Riley et al1996). Studies in the rabbit found that 
tendon segments introduced into synovial compartments sunrived without developing 
adhesions (Furlow 1976; Maowell and Snyder 1977). 
In studies of equine SDFT tendinitis, Webbon (1973) found evidence of cellular 
proliferation in both the endotendon and peritendinous regions of the injured equine SDlT 
(suggesting intrinsic and extrinsic contributions to healing) in v i v a  In acute lesions, 
examined a few days after onset of c h i d  signs, there is pyknosis and death of tenocytes in 
the core region, haemo-e, disruption and disintegration of collagen fibres as well as 
oedema (Norberg et a2 1967; Stromberg 1971). This may be accompanied by extensive 
subcutaneous and peritendinous haemorrhage (Webbon 1977). W W  7-21 days of acute 
injury, the infiltration of mesenchymal cells is increased, with a graduaI increase in the 
number of vessels growing into the lesion eom the periphery (Stromberg 1971). Whether 
the origin of these vessels was peritendinous or endotendinous was not clear. However, 
intrinsic fktors have been most commonly implicated including vascular changes within the 
middle metacarpal region of the SDFT, and changes in the core temperature of the tendon 
(Asheim 1964; Stromberg and Tufiesson 1969; Stromberg 197 1; Wilson and Goodship 
1991). The support for extrhsic healing in these lesions when they are not extensive enough 
to involve the epitendon is scant, and ultrasonographic studies have not demonstrated 
changes in echogenicity which would be consistent with extrinsically based remodelling 
(Genevese et al19%). Both in vifro and in vivo studies in the hone and other species have 
c o h e d  the intrinsic capacity of flexor tendons for repair, and support the development 
of treatment methods aimed at enhancement of intrinsic tendon healing (Gelberman et al 
1984; Manske et al1984; Manske et al1985; Mass and Tuel 1990; Mass and Tuel 199 1; 
Kraus-Wansen et al1992). Several recent publications have reported research focussed on 
the manipulation of the intrinsic healing capacity of the equine SDFT (Dahlgren e? al1996; 
Dahlgren el al1997; Riley ef d1996; Murphy and Niion 1997). 
2.7.2 Tendon Healing In Yvo 
With supportive treatment and time, the injured tendon heals with a scar but usually 
remains enlarged and slightly sensitive to firm palpation. Experimental resuIts and clinical 
experience suggest that healing of partial tendon ruptures may take eight to twelve months 
before the structure approaches normal function (Wiams et d 1984; Nixon l99Ob). The 
sequence of events following tendon injury is similar to that which occurs in other tissues: 
idarmmion (fhid and ceMar emdate); repair (fibroplasia); and remodelling (organization 
and maturation) (Peacock 1984; Williams et al1984). 
1) Mamation (days 1-5). Serosanguineous fluid and cells accumulate resulting in 
oedema of the peritendinow tissues and tendon stumps. Fibrin, platelets and red blood cells 
bridge the site with a clot. Small numbers of irregularly shaped fibroblasts may be seen after 
two days, with a nmhmil rate of prolifkmtion attained by day 7 (Chvapil 1996; Davis 1996). 
2) Repair (days 6-28). This phase consists of clot organization, cellular proliferation 
and matrix symhesis. Fibroblast-like d l s  (possily type II tenocytes) &om the epitendon and 
endotendon proliferate and migrate into the site along the network of fibrin Necrotic cells 
as well as damaged and undamaged ECM in the locale of the injury are phagocytosed by 
macrophages and denatured both intracellularly and extracellularly by MMPs serine 
proteases and other degradative enzymes. Coincident with the migrating fibroblasts 
(tenoblasts) there is an increase in the amount of fibronectin in the wound bed (Williams et 
al1984). This is present throughout the new matrix, in the walls of new capillaries and in 
areas ofunresohed haemorrhage and cellular debris and it preferentially binds denatured or 
partially denatured collagens. As fibroplasia occurs, endothelid buds penetrate into the 
injured region by degrading the fibrin network and arterioles are found in the tendon 
periphery after ten days (Abrahamsson 1991). Type III collagen synthesis predominates, and 
is distributed in a loose reticulum throughout the matrix one week after injury (Williams ef 
d 1984). Type I collagen is also present but is predominantly pericellular, as are types IV 
and V (Watkins 1985a). The rates of synthesis of PG and GAG increase in tandem with 
collagen synthesis but taper off more rapidly than collagen by day 28 (Chvapil 1996). 
3) Remodelling (day 17-several years). This phase consists of organization and 
maturation of the granulation tissue filling the wound bed. The collagen is altered fkom a 
mostly random pattern of deposition for the first weeks, to a more oriented deposition after 
day 28 (Chvapil 1996). The proliferating epitendon tissue forms a bulbous callus 
(Abrahamsson 1991). The fibroblasts become longitudinally oriented and the thicker type I 
collagen fibres increase in density and number compared to type III fibres (Wiiiams et al 
1980; Wfiams et al 1984). Elastin fibres are also present and the amount of fibronectin 
decreases with time. The scar gradually matures but is more cellular and less uniform in 
composition than normal tendon with type Ef collagen persisting for months or even years 
(Williams et d1984). The persistence oftype III collagen affects formation of collagen type 
I fibrils and lowers mean fibril diameter thereby decreasing the ultimate tensile strength of 
the tendon. Inherent in the maturation process is an increase in cross-linking which 
commences between two to three weeks post injury and peaks at three to four weeks 
(Chvapil 1996; Davis 1996). During this time the tensile strength of the scar increases 
markedly with a more gradual increase after six to eight weeks. 
During tendon healing in vivo, collagen synthesis slowly increases over six weeks 
whereas non-coUagen proteins and total protein synthesis peak and plateau at approximately 
day ten @am et al1988; Abrabamsson 1991). Total collagen content and the percentage of 
collagen synthesized as a propomon of total protein produced decreases. In the healing 
equine SDFT 300/0 of all coUagen synthesized is type III, compared to 10% in the rabbit and 
dog (Gelberman et 021984, Wfiams et d 1984). 
2.7.3 The Study of Tendon Healing in Via 
Embryonic and adult tendon tissues have been cultured fiom the chicken, man, rabbit, 
horse, dog and monkey (Siber et al1983; GeIbennan et al1984; Mass and Tuel 1990; Mass 
and Tuel 1 99 1; Abrahamsson 199 1 ; Riley et al 1996). Serum or plasma is necessary to 
stimulate cell proliferation and migration during in vitro tendon healing (Gelberman et al 
1984; Manske et al1984). Fibroblast growth factor (FGF) and platelet derived growth factor 
(PDGF) stimulate tendon fibroblast proliferation in explant cultures of rat tail tendon with 
or without the supplementation of media with serum (Stein 1985). Studies using explant 
cultures of rabbit flexor tendons indicate that insulin-like growth factor-I (IGF-I) has a 
potent anabolic effect on protein synthesis and cell proliferation in senun-he and 
supplemented media (Abrahamsson et a2 199 1 a,b). The results of these studies suggest that 
serum or tissue derived growth and mitogenic facon may be of importance in tendon 
healing and may be udid  for treatment of injured tendons in viva 
During the initial two weeks of tendon culture, epitendon cells proliferate and 
encapsulate the cultured segments (GeIbennan et a2 1984). Collagen is synthesized by 
epitendon cells within the first week of culture, and by the endotendon after two weeks of 
incubation. DNA and hydroxyproline synthesis also increase in vitro (Abrahamsson 199 1). 
Equine SDFT explants have endcaps of new tissue and an irregular contour within two to 
four weeks (Riley et a2 1996; Murphy and Nocon 1997). Cell proiiferation, differentiation, 
migration and collagen synthesis occur in all the species Listed above, but at merent rates 
(Gelberman et a2 1984). 
Short and long tem cell and explant culture techniques have been reported for the 
equine SDFI' (Sifver et d 1983; Dahlgren et al1996; Dahlgren et a2 1997; Riley ei a2 1996; 
Murphy and Nnron 1997). Tendon healing in W o  has many similarities with healing in vivo, 
with the exception that it proceeds at a slower rate and without systemic regulation 
(GeIberman et aI1984; Manske er al1984). Explant cultures facilitate the study of tendon 
healing as well as collagen-cell and collagen-proteoglycan interactions. It does not permit 
study of the effect of systemic homeostatic mechanisns on tendon repair, and limits the study 
of cekcell interactions, other than those among the tenocytes themselves. 
2.8 Pharmacological Agents and Tendon HeaIing 
2.8.1 General Principles for the Management of Tendon Injury 
There are many conditions affecting the equine SDFT and its associated structures 
but lacerations and degenerative tendinitis are the most common lesions reported and the 
discussion of phannacologicd treatment of tendons will be limited to their possible use for 
these conditions. Although both conditions follow a course of injury, inflammation, repair 
and maturation of the scar, the timing of these events differs for the two types of injury. 
There have been many therapeutic regimes applied in an attempt to inhence the 
duration of the inflammatory, debridement, reparative and maturation phases of tendon 
healing and to improve the quality of the resultant scar tissue. However, the results of 
treatment of SDFT tendinitis are frequently unsatisfactory due to a high rate of reinjury 
fonowing return to athletic aaivity (Norberg et d1%7; Watkins 1 99Za). Tendon lacerations 
have also been reported to have guarded prognosis (Foland et a2 1991). The aim of initial 
treatment fillowing aarte injury is to reduce and minimize idammation and prevent further 
injuryinjlny Therapy for the acute inflammatory phase of injury usually consists of cold therapy, 
complete re* topical anti-idammatory application (in the case of tendinitis), antiphlogistic 
wraps, non-steroidal anti-inflammatory drugs (NSAIDS) and firm pressure bandages 
(Webbon 1973; Nmon 1990a). In severe cases, immobilization in a cast for 1-2 weeks or 
splinted support has been suggested (Rapp et al1991; Rapp et aI1992). 
Once the acute inflammation has subsided (usually 3-5 days), physical therapy 
following injury or surgery has been identified as an important part of the rehabilitation 
program for the patient. The program used may affect scar formation, remodelling, and 
adhesion formation (Gelberman et d 1983). Passive mobilization and massage of the tendon 
may commence within a few days after injury and has been demonstrated to increase collagen 
synthesis and inhibit the activity of collagenase (Amiel and Kleiner 1988; Gaughan et a2 
1991; Rapp et al 1992; Kubota et uI 1996; Nabeshima et al 1996). Rest alone for up to 
twelve months has been recommended but many clinicians favour stall rest with a graduated 
program of cuntroUed passive or mild exercise for one to twelve months depending upon the 
degree and response of the injury (Niion 1990a; Rapp et al1991; Watkins 1992a; Gillis et 
al 1996). Passive exercise may take the form of swimming in a suitable facility (Niion 
19%). Following ultrasonographic confirmation of satisfactory tendon healing, horses may 
be jogged and gradually returned to training (Watkins 1992a; Gillis et al1996). 
The use of pharmacological agents, both experimentally and clinically3 for the 
treatment of SDFT tendinitis has failed to reduce adhesion formation, promote more rapid 
tendon healing or reduce scar formation in either man or animals (Gaughan et al 1991). 
Agents which have been used include cortiwsteroids, antihistamines, lathyrogeq 0- 
amin~propionitrile~ orgotein, exogenous collagen, dimethyl sulpholdde, hyaluronidase, 
sodium hyaluronate (NaHA) and polysulfated glycosaminoglycans (PSGAG). Recent 
attention has been focussed on the use of NaHA (LegendQ or Hyonate?, PSGAG 
(~dequan? and Baminopropionitrile (Mion and Gaughan 1989; Schmidt 1989; Goodship 
et al1992; Marr et al1993; Chvapil1996; Dahlgren et aZ 1996; Davis 1996; Ordidge 1996). 
In contrast to human digital tendons where most research has been directed at 
pharmacological control of adhesions, most of the therapeutic regimes examined for equine 
tendon injury have focussed on treating innammation or modulating the rate and type of 
repair in the tendon (Bora 1987; Gaughan et a2 199 1; Marr et a2 1 993) . 
2.8.2 Anti-inflammatory Agents 
The use of corticosteroids for treatment of inflammatory conditions of the connective 
tissues has had a long and controversial history. This is in part due to the small amount of 
information available about the e f f i  of these drugs on the fibroblasts and the ECh4, and 
partly due to some poorly founded but highly publicised assumptions that first entered the 
equine literature in the late 1960's (O'Comor 1968; Trotter 1996b). Cortiwsteroids consist 
of tbree 6-carbon rings and a 5-carbon ring, with activity d e t d e d  by the presence of a 
hydro* group at the C-l 1 position (Trotter 1 996). Molecular substitutions at various sites 
has resulted in the production of synthetic corticosteroids with improved anti-inflammatory 
activity, decreased mineralocorticoid activity and altered solubility. Phosphate and succinate 
esters are water soluble and good for parented use, but the acetate and acetonide esters are 
more lipid soluble thus delaying their absorption following intra-articular administration, and 
prolonging their duration of action. Triamcinolone hexacetonide has the longest duration of 
action of corticosteroids currentiy used in the horse (Trotter 1996). To date the only 
corticosteroid that has been critically evaluated in the equine SDFT is methylprednisolone 
acetate (MPA) which is an intermediate to long-acting drug in the horse (Pool 1996; Trotter 
1996). There are also a few anecdotal reports of its use by clinicians in cases of tendinitis, 
tenosynovitis and desmitis of the fetlock annular ligament (Goodrich and White 1997). 
The reported range of activities of corticosteroids is diverse and will be only briefly 
summarized as they pertain to the degradation and synthesis of connective tissue ECM. 
Corticosteroids pass into the cell cytoplasm and bind with steroid specific receptors, resulting 
in a conformational change in the receptor complex (Trotter 1996). The complex then is able 
to reverslily bind to the nuclear chromatin associated with glucocorticoid responsive genes 
and to modulate the transcription of mRNA h m  these genes. The anti-innammatory effeas 
of corticosteroids are potent, influencing cellular (leukocyte movement) and humoral aspects 
of the process. These drugs inhibit leukocyte migration into the site of iuflammafion, increase 
bone marrow production of neutfophils and prolong the half-life of neutrophils; all of which 
contribute to neutrophilic leukocytosis. The reduction in macrophage accumulation at the 
site of injury may inhibit chemotaxis and adherence of neutrophils to the vascular 
endothelium, and later, of fibroblasts into the wound during the repair phase. The most 
notable humoral Sect  is that of inhibiting the synthesis of prostaglandin fiom arachidonic 
acid, thus minimirrjng the effects of the pro-inflammatory products of cyclooxygenase and 
lipooxygenase pathways (H~ggins and Lees 1984). 
In connective tissues triamcinolone has been shown to decrease the expression of 
collagenase and TIMP mRNA in synovial tissue fiom human rheumatoid arthritis patients 
(Firestein et al 1 99 1). However corticosteriods did not suppress stromeolysin synthesis by 
equine synod cells in virro (May et al1988). In equine synovial fluid PG concentration is 
elevated after either methylprednisolone or betamethasone administration and although 
stromeolysin induced cleavage of PG aggregates was suggested as the reason, this has not 
been substantiated as the mechanism of action (Trotter 1996). Corticosteroid suppress HA 
(but not suIfated GAG) synthesis in human skin fibroblast and canine synovial cultures. 
However, in vivo studies in the horse showed increased HA concentrations in the synovial 
fluid following intra-articular corticosteroid administration (Trotter 1996). The effect on 
cadage depends upon the type and dose of drug used as well as the species of aRimal and 
the design of the trial (for excellent review see Trotter 1996). 
In the only published equine SDFT studies to date, MPA was first injected by an 
intratendinous route along the tensile length of the normal SDFT and compared to carrier 
injected and saline controls (Pool 1996). Significant histopathologic findings were not 
present in the control groups between 3 to 14 days post-injection. However at day 3 in the 
MPA group there was Msarlar thrombosis and acute focal necrosis of the small blood vessel 
w a s  of the endotendon, epitenon and paratenon Adjacent to the crystalline deposits of 
M P 4  most tenocytes were dead. Two weeks after MPA injection there was a focal 
inflammatory process characterized by the presence of macrophages7 some containing 
engulfed crystals of MPA The daxnage to vessels, tenocytes and macrophages may be due 
to the physical form of the drug, rather than a pharmacological response. In a parallel study, 
tendons with SDFT tenditis that had been injected with corticosteroids were examined at 
autopsy (Pool 1996). Many of the microscopic abnormalities in these tendons did not differ 
si@cantly fkorn those found in untreated horses with tendinitis. However in several tendons 
treated with corticosteroids there were increased numbers of hyahbed and mineralized 
fibres and linear mineralized amorphous foci compared to untreated horses. Although 
hyahbd collagen fiequedy mineralizes in aged horses and in cases of untreated tendinitis 
the authors concluded that the crystals of MPA may create nidus for the initiation of 
dystrophic mineralization (Webbon 1978; Pool 1996; Smith and Webbon 1996). Local 
injection of an injured tendon with MPA may increase the amount of local darnage present, 
accelerate or potentiate dystrophic calcification and delay the reparative phase of tendon 
healing (Pool I 996). 
In man the use of corticosteroids (triamcinolone acetonide) has been recommended 
only for difficult cases for adhesion prevention following surgery in order to preserve the 
@ding fimction of intrasynovial tendons following tenolysis (Strickland 1987). Similar 
recommendations have been made for its use in the treatment of equine cases of 
tenosynovitis either alone or in combination with NaHA for the prevention of adhesion 
formation and reducing Mammatiion (Nixon and Gaughan 1989; Gaughan et a l l99  1 ; Nixon 
1996). The use of corticosteroids in severe cases of equine fetlock annular ligament desmitis 
was recently reported, and appreciable side effects were not observed clinically (Goodrich 
and White 1997). 
The non-steroidal anti-inflammatory drugs (NSAIDs) are agents which inhibit the 
conversion of arachidonate to prostaglandins and thromboxane my and Lees 1996). 
PhenyIbutazone and fl+ megulanrme are the NSAlDs most commonly used in the horse 
and are competitive antagonists of cyclooxygenase. In contrast with aspirin which 
irreversibly antagonizes by acetylation and deactivation of cyclooxygenase, their activity 
depends upon their continued presence in the tissues (May el d 1984). Although used in 
tendon injury for their general ability to reduce innammation and associated pain, the 
NSAIDs have side effects which include increased bleeding time due to decreased platelet 
aggregation (aspirin only), gastrointestinal ulceration, renal papillary necrosis and blood 
dyscrasias. The NSAIDs appear to stimulate synthesis of ECM moleculaes by cartilage in 
addition to their effects on the inflammatory cascade (Palmer and Bertone 1994; May and 
Lees 1996). Sodium salicylate and aspirin have been reported to inbibit proteoglycan 
synthesis, with a more pronounced effect with salicylate in osteoarthitic cartilage (May and 
Lees 1996). Phenylbutazone does not appear to affect equine articular cartilage anabolism 
(Cambridge and Lees unpublished data). It is possible, but not proven, that some NSAIDs 
may also exert some effects on matrix synthesis in normal and/or diseased tendons. 
2.8.3 Sodium Hyaluronate 
Commercial preparations of sodium hyaluronate are commonly used for the treatment 
of equine orthopaedic disease and like the naturally occurring HA of the ECM, consist of 
chains of disaccharide subunits (N-acetylglucosamine linked to D-glucuronic acid by 1-3 
glycosidic bonds) joined by 1-4 glycosidic bonds but vary in their biological source (see 
section 2.6.4). In normal equine horse synovial fluid the average molecular mass of HA was 
1.5 x 106daltons (range 0.5 to 3.0 x 106 daltons ) in one study, and 2.5 x 16 daltons (range 
2 to 3 x lo6 daltons) in another study (Tew 1984; Tulamo 1994). 
Table 2.7: Summary of major sodium hyduronate products available for equine use. 
-- -- 
Product NaHA Concentration Molecular Manufacturer 
(m%W Weight 
Hylartin@ 8.9 2652703 Kabi Pharmacia, AB, Sweden 
Hyvisd 9.2 2449000 Anika Research, Inc. 
EquronQ 5.2 766500 Solvay Animal Health, Inc. 
Map 5 0  9.5 757200 Vetrepharm Inc. 
Hyalovet@ 9.8 605500 Fort Dodge Laboratories, Inc 
Legendo i/a 10.3 361900 Bayer Corporation ' 
Legend43 ilv 10.9 321600 Bayer Corporation 
9.2 82240 Schering Plough Animal 
Health Corporation 
'Also called Hyonat&, Bayer Canada. (Ghosh et a2 1992; Uden and Lavoie 1997). 
The commercially available NaHA products for equine use in North America vary 
widely in protein concentration, intrinsic viscosity and molecular weight (Uden and Lavoie 
1997). In a comparative study, viscosity was found to increase with increased molecular 
weight, with the highest viscosities reported for HylartinQ and Hyvis&(table 2.7) (Uden and 
Lavoie 1997). 
The reported and potentid actions of exogenous NaHA are many, including effects 
on i&mmAon and on ECM catabolism and synthesis. Inflammatory cells are affected, with 
HMW-HA reported to prevent neutrophil migration by binding and disrupting 
chernoattiactant gradients necessary for cell locomotion, in a dose dependent manner (ie. a 
steric ei5ect) (Balazs 1985). Solutions of high viscosity or HMW-HA also inhibit the motility 
and phagocytic activity of macrophages in a dose dependent manner. Although steric 
hindrance was thought responsible for these inhibitory effects, it is now believed that they 
are mediated by the interaction of HA with CD44 receptors on the cells (Tamoto et aZ 1993). 
This finding is important since it infers that effective CD44 binding and activation requires 
a minimum chain length of Hq and that s d e r  chains may act to competitively block the 
cdular responses to HA (Knudson 1993). In vivo, HMW-HA Wibits prostaglandin (PGEJ 
levels in synovial fluid, further moderating the inflammatory response (Pund et a2 1989). 
The cell surtitces of synoviocytes bear HA receptors which are preferentially 
stindated by exogenous high molecular weight (HAW > 5 x 1VDa) HA to produce HMW- 
Hq and may be khiiited by low molecular weight (LMW) HA (Ghosh et a2 1992). The 
response of the synoviocytes was determined by the molecular weight and the concentration 
ofNaHA in the local environment (Smith and Ghosh 1987). Glucosamine incorporation into 
HA produced by primate fibroblasts in dture is increased by exogenous NaHA (100 pg/ml) 
@h 1985). The @kcts of NaHA are somewhat variable on ECM synthesis in vihq with 
&%ition of PG synthesis by chondrocyte cultures at concentrations < 1 NaHA pglml, but 
no inhibition d muscle, skin or synovial fibroblasts up to 10 pg/rnl (Ghosh et a2 1992). 
Articular in vivo studies in dogs, rabbits and horses found decreased PG and water loss &om 
cartilage, and lameness in response to treatment with HMW-HA and high doses of LMW- 
Hq the latter drug formulation having less persistent effects (Gingerich et a2 1 98 1 ; Ghosh 
ei al1992). A recent study investigated hyaluronate harasaccharide in chondrocyte cultures 
( a very LMW form of HA - HAJ and found that its presence inhibited PG synthesis by 
blocking the HA receptors and displacing endogenous HA (hudson 1993). The addition 
of exogenous HMW-HA did not inhibit PG and ECM formation unless & was also added 
to the cultures. 
Wormation on the effects of NaHA on soft connective tissues is scarce. It inhibits 
granulaton tissue formation in vivo, popossily by inhibiting the chernoattraction of fibroblasts 
by magophages (Rydell 1970; Rydell and Balazs 197 1). In rabbits with traumatized digital 
tendon sheaths, treatment with HMW-HA (mw 1-3 x 1 06) resulted in less comective tissue 
reaction, smoother subcutaneous scarring and fewer and less serious adhesions (Rydell and 
Balazs 197 1). In another study of the effea of NaHA (mw 1.5 x 1 06) in rabbits with partial 
tenotomy significant improvement in the histological appearance of the scar was not 
observed (Thomas et a1 1986). 
Most of the Sonnation that is available on the treatment of horses with NaHA has 
been obtained in studies of joint disease. Its mechanism of action in joints is unknown; the 
same is true of tendons because reported studies in the horse have been clinical trials in 
which few or no biochemical parameters have been measured (Churchill 1985; Nmon and 
Gaughan 1989; Spurlock et a2 19894b; b g h a n  et a2 199 1; Gift et uZ 1992). There are 
several published reports supporting the use ofNaHA for acute tendon injury, but only a few 
anecdotal reports of its effects with respect to return to performance activity (Churchill 
1985; Nmon and Gaugban 1989; Spurlock et al1989b; Gift et al1992). Small studies using 
NaHA in an equine model of flexor tendinitis have indicated that the drug may reduce 
adhesion formation in acute tenosynovitis but intratendinous healing was not improved as 
determined by histologic and morphometric evaluation at six weeks (Gaughan et a2 1991; 
Gift eta1 1992). However, during the six week period there was ultrasonographic evidence 
of a d e r  lesion size, suggesting an &kc% on the early inflammatory response to the injury 
(Gift et aZ 1992). In a recent study by the same workers, sequential weekly NaHA injections 
using the same model did not resuIt in significant diBierences in healing (Gaughan el a2 1995). 
Neither mechanical nor biochemical evaluation was performed in these studies. Other reports 
suggest that NaHA is more beneficial in chronic than acute tendon injury, but this hypothesis 
has not been critically evaluated (Schmidt 1993). Despite its current use by some 
practitioners for equine teadinitis, NaHA has not been clearly proven to be of benefit, and 
W e r  studies are required to determine its efficacy (Madison 1 995; Bertone 1 996). 
There are several reports of the use of intrasynovial NaHA in cases of tenosynovitis 
of the digital sheath, with or without concurrent tendinitis of the DDFT in the horse (Barr 
er al 1995; Nion 1996). Presumably this approach has been formulated on the basis of 
results in other species where adhesion formation has been reported to be reduced, and the 
limited results that are available for the horse (Rydell and Balazs 197 1 ; Hagberg and Gerdin 
1992; Gaughan et ai 1991; Gift et a1 1992; Gaughan et a1 1995). However, a criticaI 
evaluation confirming its efficacy in the horse has not been published. 
Natudy ocauring polysulfated glywsaminoglycans and their structural properties 
have been diswsed. Commercially, these substances have been available as pharmaceutical 
agents for over 30 years and are widely used for the treatment of arthritic conditions 
(Dettmer 1982). They consist of preparations of naturally occurring or synthetically 
m&ed GAGS, and include Mqeuan8 and ~rteparon~, pentosan polysulfate (Cartrophena) 
and glycosaminogiycan- peptide complex (Rumalon9 (Burkhardt and Ghosh 1987; Ghosh 
ef a1 lm). Recently, a number of oraliy administered PSGAGs (so cded 'nutriceutids') 
has become availabIe, of which one, Cosequinm, is currently being investigated to determine 
its bioavdability and efficacy (White et al 1994; Hanson et al 1997). However, only 
AdequanQ@SG~~) which consists predominantly of CS purified fiom bovine trachea, has 
been investigated to a significant degree for treatment of orthopedic disease in the horse and 
its bioavailability confinned for connective tissues (Andrews et al1985; Burba e l  al1993; 
Trotter 1 996b). 
AdequanQ is the veterinary formulation currently in use, with intramuscular (canine 
and equine) and intra-articular preparations (equine) available. ~rteparon* is its human and 
more extensively studied equivalent. The principal GAG present in PSGAG is CS, which is 
highly anionic due to an average of three to four sulfate esters per CS dissacharide.(Ghosh 
et a2 1992). It therefore has the capacity for covalently binding with collagen, PG and 
nonwllagen proteins, with a greater afhity for the latter two components of the connective 
tissue ECM (Andrews ef a1 1985). It has been determined that the drug has effects on 
-0% biosynthesis of ECM components, and ECM catabolism (Ghosh et al1992). 
AdequanQ has been shown to have some inhibitory effects on some infIammatory 
reactions, including complemerrt fbcmafion and activation (C3a and CSa), as well as reducing 
haemolytic complement activity (Ghosh et al 1992). In the horse, the inhibition of 
complement has been associated with a greater risk of sepsis following intra-articular 
medication with ~ d e q u a n ~ .  PSGAG also has an anticoagulative activity approximately one- 
sixth that of heparin in virro, but in vivo studies indicate that its potency is closer to two- 
thirds that of heparin (Ghosh et aI 1992). These effects are mediated through antithrombin 
DL PSGAG is also able to activate p d d k h s  and fibrinolysis in the presence of Hageman 
fixtor (factor WI) in vitro. Prostaglandin E, synthesis and the release of leukotriene B, are 
also Inin'bited by PSGAG. An antagonistic effect on interleukin-1 (L-1) has been suggested, 
based on findings of inhibited release of PG &om cartilage, presumably due to decreased 
stimulation of MMPs by IL l  (Jones and Sandstrom 1985). 
Hyahrronic acid synthesis by chondrocytes and synovial cells is markedly stimulated 
(up to 250%) by PSGAG at 100 Wmi, and at 200 pg/d the average molecular weight HA 
was higher and had a narrower range (Greiling 1982; Bwkhardt and Ghosh 1987). In 
s y n o d  membrane er vivo explant cultures HA synthesis was increased by DS, chondroitin- 
4sutfate and chondroitin-6-~e, after s p e c  injection of rabbits. The action of PSGAG 
appears to r e d  fiom binding to receptors on the synovial cell surface (Ghosh et a2 1 992). 
Increased a m o m  and molecular weights of PG are synthesized in a dose-dependent manner 
by c u b e d  human and rabbit articular chondrocytes in response to exogenous PSGAG, but 
not in chick embryo or rabbit meniscus fibroblast dtures (Burkhardt and Ghosh 1987; 
Ghosh et al 1992). In osteoathritic human cartilage LP and PG synthesis (both the core 
protein hction and the GAGS) was increased in vim, and the mechanism responsible is 
thought to be direct i n h i o n  of synthesis of the MMPs (Adam 1982). 
Collagen synthesis is markedly increased by PSGAG in cartilage fiom chick embryos 
and oaeoarthritic human cartilage, with the effect being more marked in the osteoarthritic 
carhlage. The mechanism responsible is thought to be inhibition of catabolic MMPs (Adam 
1982). In another study of culture chick stemal cartilage, doses of P S GAG below 20 pgh l  
did not increaseeaSe collagen synthesis, but higher doses increased collagen in the medium, and 
collagen synthesis decreased at concentrations > than 100 pg/d (von der Mark 1982). 
The effects of ~ d e q u a n ~  on catabolism ('chondroprotection') are widely known and 
are a key component of the marketing strategy used for sale of the product. It is a 
competitive inhibitor of neutrophil elastase and an inhibitor of cathepsin B, (Baici and Fehr 
1982; Tmavsky 1982). Io addition it is a strong inhibitor of Dglucuroniciase, l.3-gahctosidase, 
BN-aatylglucosaminidase, a-glucosidase, a-mannosidase, KS glycano hydro lase, 
chondroitin sulfotransferase, neutral protease, myeloperoxidase, cathepsin G, and human 
granulocyte elastase (Ghosh et al 1992). An in vivo lapine cadage model showed that 
sigoifi*mt suppression of MMPs and serine proteinase activity occurred after intra-articular 
administration of A.dequand (Howell et al1986). One in vie0 study investigating the effect 
of PSGAG on equine tenocytw has been published @ahlgren et al1996). Concentrations 
from 25 to 200 pghl did not affect PG synthesis or cell viability compared to controls. 
The use of glycosaminoglycans for intdesional, perilesional or systemic treatment 
of SDFT tendinitis is currently under investigation and although there is some support for 
its use, the available information is largely anecdotal (Redding et al 1992; Goodship et al 
1992; Ban ef a2 1995). One injection every four days for up to seven doses has been 
recommended, with major reduction in pain and swelling reported by the third injection. 
However, one study found no sigruficatlf differences between the percentage of 
Thoroughbred horses returning to work following a course of intratendinous or 
intramuscular glycosaminoglycans and those retuning to work following conservative 
management alone (Mam et al1993). M y  horses with lesions less than four weeks old were 
treated with glycosaminoglycans, and injury recurrence rates were 50% in treated horses 
versus 3 1% in conservatively managed horses (Marr et al 1993).A recent clinical survey 
found PSGAG to be 'efficacious' in 80% of cases of SDFT tendinitis when administered 
mtmmxddy e v q  four days after injury for seven treatments (Dow et al1996). However 
the cases were not standardized, the obsmers not blinded to the treatment, and there were 
no control horses. Clinical studies in human athletes with Achilles tendinitis have supported 
the use of intdesional glycosaminogtycafls based on the clinical outcome of cases (Sundqvist 
et al 1987). Although some clinicians are advocating its use in the horse for equine 
tendinitis, a clear scientific rationale for its use is lacking (Barr et a2 1995; Bertone 1996). 
To date there have not been any published controlled studies evaluating orally 
administered GAGS in horse. In an uncontrolled, non-blinded clinical trial, orally 
administered PSGAG was found to be 'efficacious' for treatment of traumatic arthritis in 
hones (Harwn et a2 1997). Controlled studies are underway to investigate the effect of 
Cosequh@ on synovial and serum levels of HA and GAGS (White et al unpublished data). 
Beta-aminoproprionitrile (OAPN) and D-penicillinamine @-PEN) are both agents 
which inbibit lysyl oxidase (lathyrogens), thus interfering with cross-linking and normal 
collagen ma t tdon  DAPN is the most widely studied and used of the two, and has recently 
entered the literature as a proposed treatment for equine SDFT tendinitis (Reefer a1 1996). 
Although it acts by specifically and irreversibly inhibiting lysyl oxidase, DAPN does not 
interfere with cross-hking once ftesh lysyl oxidase is synthesized (24 hours) and the effect 
of its enzyme inhihiion has worn ofS and does not affect collagen synthesis (Chvapil 1996; 
Davis 1996). D-PEN however, permanently blocks collagen cross-linkiog by cleaving off 
unreduced S c M  bases, chelating CuZ+ and inhibiting lysyl oxidase or by complexing 
aldehydes formed by oxidative deaminization of hydroxyallysine or allysine (Davis 1996). 
BAPN has been recommended for topical or local administration due to toxic side 
effkcts following systemic administration in other species (Chvapil 1996). BAPN is slowly 
absorbed through the skin, with -5% of the drug diffusing into the subcutaneous tissue 
within 24 hours. It is rapidly absorbed by scar tissue five times fgster than by normal 
connective tissue (Chvapil 1996). Following infusion of DAPN the gliding and flexion of a 
chicken foot model of tendon adhesion was improved and peri-articular stiffening and joint 
fibrosis was reduced in rabbits. The idision of OAPN has been advocated for the treatment 
of equine tendinitis. Chvapil(l9%) has suggested that several requirements need to be mitt: 
a) the drug requires fkequent re-administration or continuous delivery due to the 
rapid re-synthesis of lysyl oxidase within 24 hours of complete inhibition by DAPN; 
b) dose response effectiveness should be established; 
c) knowledge of when to administer the BAPN for optimal eff- is required. 
. . Therefore, admmstmtion in the horse should coincide with peak lysyl oxidase acyivity, - 
three to four weeks after onset of tendon injury. Recently over 200 horses with acute injury 
to the SDFI' were treated with intralesional DAPN (Reef et al1996). Only the sonographic 
findings were reported, but over a 4-month period the lesion had markedly improved in 
response to OAPN. However, the recommendations of Chvapil were not followed in this 
study, and there are no biochemical or biomechanical data to confirm its efficacy. D-PEN 
has not been investigated in the horse to date, but is maintained by some workers to be 
potentially more effective than DAPN (Chvapil 1996). 
2.8.6 Other Drugs 
Orgotein (Palosein", has been used in the past for the treatment of equine soft tissue 
injuries (Linton 1976). It was recommended for its superoxide dismutase activity, its low 
toxicity and its chemotactic effixts on polymorphonuclear leukocytes. In a case series of 
horses with tendinitis and other injuries, orgotein was found to be effective in resolution of 
acute clinical signs without side effects (Linton 1976). However the study was neither 
controlled nor blind, and long term follow-up of performance was not available. 
Proline analogs have been used to block the synthesis of hydroxyproline, but they 
inhl'bited colIagen secretion and proved too toxic for cIinical use (Bora 1987; Chvapil 1996) 
Colchicine interfkes with the secretion process, &'biting all protein secretion and producing 
undesirable effects (Chvapil 1996). 
3.0 EXPERIMENT 1: ESTABLISHMENT OF THE MTRO EXPLANT 
CULTURE MODEL OF THE E Q m  SDFT AND DEVELOPMENT OF 
ANALYTICAL PROTOCOLS 
3.1 Introduction 
The use of GAGS (HA and PSGAG) for intra-Iesional, peri-Iesiod or systemic 
treatment of SDFT tendidis has recently been investigated in clinical studies. Although there 
is some support for its use, the available information is largely anecdotal. Almost all the 
reported studies are of low power and are poorly controlled, andlor outcomes were 
determined by subjective non-blinded techniques (Schmidt 1989; Redding et al 1992; 
Goodship et al 1992; Marr et al1993; Barr et a1 1995). In osteoarthritis, the use of some 
drugs that were determined to be efficacious in clinical studies were later determined to be 
ineffective or harmfd when controlled or laboratory oriented studies were performed 
(Burkhardt and Ghosh 1987). The dBicuIties and high risk of confounding variables involved 
in clinical trials has prompted many researchers to use controlled animal or tissue culture 
models in order to permit more rigorous biochemical and histochemical techniques in the 
assessment of the response to potential therapeutic agents. 
The use of organ explant tissue culture for models of tendon repair has been widely 
supported in other species because the ECM constitutes a major portion of the tendon, and 
the presenation of cell-matrix interactions is considered to be important (Scott 1 990). There 
is a substantial amount of literature suggesting that sisnificant interactions do ocau between 
the macromoldes of the ECM, influencing the biochemical and structural nature of matrix, 
as well as the migration and attachment of cells within tendon (Parry et a2 1982; Gelberman 
et a2 1984; Manske et a2 1984; Vogel et al. 1984; Mass and Tuel 1990; Scott 1990; 
Abrahamsson et d 199 la; Abraharnsson et all991 b; Mass and Tuel 1991). 
Until recently there was only one published study in which the equine SDFT tissue 
was cultured but neither the culture techniques nor conditions were descnied (Silver et d 
1983). Tie cuiture models has been accepted as a valid and usefbl technique for the study 
of the equine SDFT (Birch 1993; Dahlgren et d 1996; Riley et a2 1996; Dahlgren et a2 1997; 
Murphy and Nixon 1997). In each of these reports different culture techniques, sera and 
media were used. Only one study attempted to identify the optimal combination in the 
development of their model (Riley et al1996). In recent publications workers have used fetal 
bovine serum in their cultures when evduating drugs and cytokines (Dahlgren et aI 1996; 
Murphy and Nivon 1997). There are marked differences between the composition and 
wncentrations of molecules in fetal sera compared to serum fiom adult animals. Fetal serum 
is collected fiom a wide variety of fetal ages and mixed to produce a product which is 
infrequently characterized by the manufacturer (Barnes and Sato 1980; Jayme 1990; 
Abrahamsson 1991). In addition, fetal serum in high concentration has an inhibitory effect 
on cell growth and synthesis in culture (Jayme 1990; Abrahamsson 1991; Tomesi et a2 
1993). Adult equine serum more closely approximates the biological fluid fiom which 
nutrients diffuse into the tendons of the adult horse in vivo and this is important for an in 
vitro model which aims to replicate aa aspect of an in vivo system in a controlled 
environment. The use of homologous serum for cultures of this type, particularly for 
comparative studies, has been recommended by many workers (Gelbermam et a2 1984; 
Manske et al1984; Minor et a[ 1986; Russell and Manske 1989). Many support using serum 
fYee media or adult mammalian serum for many tissue culture applications (Ham and 
McKeehan 1978; Hayashi ef al1978; Barnes and Sato 1980; Jayme 1990; Tornesi 1992). 
Based on previous work, a modification of the equine SDFT explant model was 
developed in this laboratory for use in the present investigation (Riley et al1996). Donor 
horse senun (Dm) and RPMI 1640 was utilized for the reasons outlined above, and for the 
improved reproducibility and reduced variability identified with this culture medium durkg 
previous studies (Riley et al1996). Changes in the preparation of the equine SDFT explants 
were made to standardize explant size, and establish baseline conditions for the proposed 
study. Although explants of the SDFT had been successfdly cultured previously, it was 
necessary to re-establish laboratory conditions and protocols in order to minimize the risk 
of obtaining inconclusive or uninterpretable r d t s  (Dahlgren e? al 1996). Thus, the 
following experiment was designed to establish protocols and methodology for the 
experiments investigating the eff'ects of different drugs on the equine SDFT. 
3.2 Objectives 
1) To establish the modified in vibo explant culture model of the equine SDFT to be used 
for pharmacologic studies. 
2) To validate the radiolabeling protocol proposed for use in the model. 
3) To measure the variance of radioisotope incorporation rates as indices of in vitro 
biosynthesis in this model which are necessary for the planning of k r e  studies. 
4) To evaluate the suitability of bromodeoqwidine (BrdU) labeling as a technique for 
quantifying the rate of cellular proliferation occurring in the equine SDFT model. 
5) To determine whether or not there is segmental variation in the rates of radioisotope 
incorporation rates in the model. 
6) To develop a reverse phase - high performance liquid chromatography (RP-HPLC) 
protocol for separating radiolabeled hydroqproline and probe, to determine the relative 
rates of collagen and non-collagen protein synthesis.. 
3.3 Materiais and Methods 
3.3.1 Experimental Animal 
One 14-month-old female Quarter horse, untrained and free tiom clinical evidence 
of tendon injury, was donated for medical reasons (Appendix I). 
33.2 Establishment of Equine SDFT Explnnt Organ Cultures 
The t d e ,  non-intrasynovial, metacarpophaIangeal portions of the forelimb SDFT's 
were harv&ed under aseptic conditions from the horse within 5 minutes of death, placed in 
a sterile stainless steel pan containing Ringer's lactate (with 2 pg/d amphotericin B, 100 
W/ml penicillin G sodium and 100 &mi gentamicin sulfate), and transferred to the tissue 
culture laboratory @ley 1994). The tendons were transversely divided with a scalpel into 
three sections: p r o d  (15 to 10 cm proximal to the digital sheath; distal to the carpal 
sheath), middle (10 to 5 an proximal to digital sheath) and distal (0 to 5 cm p r o d  to the 
digital sheath) thirds (ie-each portion approximately 5 cm long). Each pomon was sliced 
transversely into 5 mm slices and, explants cut using a 4 mm diameter circular biopsy punch. 
The explants h m  each slice were individually placed in 30 ml glass Wheaton culture bottles 
containing 4 ml of prepared medium (RPMI 1640 with 10% DHS and 50 pg /d  ascurbate), 
sealed, and sterile gas (50% OJ45%N#%COJ injected for 10 seconds at 15 psi (Tornesi 
1992; Riley 1994). Cultures were maintained on rollers (14 rpm) in a customized incubator 
at 36. 5+0S°C for the dwation of the experiment (24 days) and the media changed (50% 
replacement) every 72 h unless otherwise indicated (figure 3.1). 
3.3.3 Radiolabeling of Equine SDFI' Explant Organ Cultures 
C h e s  were radiolabeled on day 24. The serum containing medium was removed 
b m  each culture and replaced with 4 ml of serum and proline free modified RPMI 1640 and 
50 pg/ml sscorbate. Cultures were then radiolabeled with 3SS-sulfate (40 pCi/culture) and 
L-[2,3 ,4,S3HJ prohe (20 pCi/culture) in order to assay for sulfated glycosaminoglycan 
@rote&can) and protein (proline wnhhbg protein only) synthesis, respectively. Mer 24 
hours, the radioactive media was removed and fiozen at -20°C in stoppered vials for later 
analysis. The explants were then chase incubated with isotope fke serum Eee medium for 
24 hours at wbich time the chase medium and tissue were harvested and fiozen at -20°C for 
later analysis. 
Front view Side view 
Figure 3.1. Modified roller incubator ( R o u s ~  1990; Riley 1994). 
d = door, dc = drive chain; em = electric motor; r = roller; wb = Wheaton bottle 
3.3.4 Determination of Radioactive Isotope Incorpontion Rates 
Prepmution and Scintillation Counting of Tendon &~Ianfs 
Explants labeled with 3s~-sulfate and L-[2,3,4, 5 -3Hl-proline were fieeze dried and 
weighed. Each explant was hydrolyzed in a capped 1.5 ml microfbge tube in 1 ml of 6M HCl 
at 110°C for 24 hours (Bailey and Light 1989). The hydrolysates were vortexed gently and 
a 0.5 ml aliquot t r d e m e d  fiom each tube to a scintillation vial and evaporated to dryness 
by creating a gentle vortex in each vial with nitrogen gas in a hot water bath at 100°C. 
Samples were cleared with Solvable@, biodegradable scintillation cocktail added, and 
counted in a Beckman scintillation counter following the installation of quench curves for 
3sS-sulfate and ~[2 ,3 ,4 ,  5-3HJ-proline. 
A microwave hydrolysis protocol was also evaluated on uncultured samples of the 
SDFT in 1 ml of 6M HCl placed in either in capped 1.5 ml microfuge tubes or a 7 ml 
vials at 800 watts for times varying fiom 20 seconds to 2 minutes. The vacuum 
centrifuge was also evaluated as a technique for drying hydrolysates. 
The n m a h b g  M o n  of the hydrolysates was a d f b g e d  for 5 minutes at 3000 rpm 
to 1.5 ml microfbge tube with a 0.22 pm filter. The filtrates were fiozen at -20°C for later 
derivatization with dabsyl chloride (DABS-Cl) and 0-phtalaldehyde (OPA), and RP-HPLC. 
Preparation mad Scintillation Camtng of Labeled Mema 
~iospin@ chromatography coIumns (Bio-Rad) were obtained and their efficiency 
for removing unbound radiolabel was evaluated. This was done by adding 5 pCi of L- 
[2,3,4,5-3HJ-proline to 4 rnl of culture medium. Then 100 p1 aliquots were applied to each 
of 4 Biospin-60 columns and the eluate transferred to scintillation vials. Scintillation fluid 
was added to these and to 4 x 100 fl a l i~o t s  of medium which had not been passed through 
the columns. 
Media samples harvested from the cuItures were thawed, the volume of each sample 
measured, and the unbound radioisotope removed fiom 100 pl aliquots by centrifbgal size 
exclusion chromatography using BiospindO columns. The eluate from each fkaction was 
hydrolysed in 6M HCl, scintillation cocktail added, and samples were counted in a beta 
counter. The protein in a 1 ml aIiquots of each sample of medium was precipitated in 0.15% 
Fdeoxycholic acid (DOCA) and 72% trichloracetic acid (TCA), centrifbged at 3300g for 
30 minutes, the supernatant discarded, and the pellet air-dried and fiozen for later pre- 
column derivatization with dabsyl chloride and o-phtalaldehyde (OPA), and RP-HPLC(Lin 
1984; Drnevich and Vary 1993). 
Calmlation of Imorporution Rates of Rortoucfive Isotopes 
Radioactivity for each culture was corrected for the specific activity (SPA) of proline 
in the added media and divided by the dry weight of the explant to determine the molar rates 
of proline incorporation, which are measures of proline-containing protein synthesized in 
M'iro. 35S-dfkte couuts were corrected for SPA and this value divided by the dry weight of 
the explant to reflect the molar rate of & now, synthesis of sulfated glycosaminoglycans. 
3.3.5 Pre-column DabsyI Chloride Derivatizatioo and Reverse Phase High 
Performance Liquid Chromatography. 
Amino acid standards for OH-proline, proline, glycine, norleucine and a standard 
mixture of amino acids were prepared. Initially pre-column derivatization of aliquots with 
dabsyl chloride and OPA was used, but OPA was discontinued as the protocol was 
developed. Several different published solvent gradients were evaluated and modified until 
satisfactory separation of amino acid peaks was achieved, and development time could be 
. .  . 
rmmrm7ed (Lin 1984; Jansen et a2 1991; Dmevich and Vary 1993; Ikeda et al1994). An W 
absorbance detector was used to iden* chromatographic peaks at 440 nm, but peak 
detection and resolution were poor (Moore and Stein 1948). Markedly improved peak 
iddcation was obtained with a variable wavelength W fluorescence detector at 436 nrn. 
33.6 Identification of Proliferating Ceh 
Amersham's cell proliferation kit was used for monitoring cell proliferation 
(RPN.2O)(Gratmer 1982; Matsuda 1994). The kit uses a thymidine analogue, 5-bromo- 
Z'deoxyuridine (BrdU) which is incorporated into replicating DNA and subsequently 
localized using an avidin-biotin complex, specific monoclonal antibody and a peroxidase- 
based immunological detection system. Paraffin-impregnated 5pm sections &om alcohol- 
fixed explants were used. The protocol was modified until satidkctory staining of nuclei with 
minimal non-specific staining was obtained, and qualitative evaluation was possible. - 
3.3.7 Statistical Analysis 
All results were tabulated and their distribution and variances determined. Where the 
criterion for parametric testing were met, analysis of variance (ANOVA) and means 
comparison performed between limbs and between regions (proximal, middle and distal), 
with significance level set at p < 0.05 (Statistix 4.1, Analytical Software, FLA, USA). 
3.4 Results 
3.4.1 Experimental Protocols 
The experimental protocols developed in this experiment were compiled into a 
laboratory r n d  which is detailed in appendix III. The chemicals, reagents and equipment 
used throughout the study are listed in appendix 11. 
Tissue Culture of Equine SDFT&~lants 
E x p h  of a uniform size were obtained using the modified protocol with the 4 mm 
biopsy punches. than the previously used technique, but preparation took longer @.ley et al 
1996). Total time for set up of cultures was 7 hours. Modification of the roller incubator is 
required to accommodate extra cultures. Explants were successfully cultured for 24 days 
without antibiotics or evidence of contamination. 
Both isotopes were incorporated. However, the proline incorporation was several 
orders of magnitude lower than sulfate incorporation. 
Determination of ln~orpor&~on Rates 
The microwave hydrolysis protocol, although rapid, was dangerous since some vials 
exploded and released HCl gas. Hydrolysis at 1 lo°C for 24 h in a water bath was prefmed 
which, although more time consuming, was much safer. The vacuum centrifuge took several 
days to dry the hydrolysates, whereas the water bath and N, took only 6 -12 hours. 
The ~iospin@ chromatography coIumns rapidly and efficiently removed unbound 
radioisotope ftom samples of media. Comparison of the mean count of the control (505622 
dpm) with that ofthe chromatographically separated medium (41 dpm) indicated a 99.990~ 
removal of isotope label from the medium @ < 0.0001). 
The protein precipitation protocol was effective as determined by the production of 
a firm pellet of proteinaceous material £?om the dture medium 
The protocol developed is outlined in table 3.1 and in more detail in appendix ID. 
Satisfactory peak detection and resolution was obtained, with only dabsyl chloride as the 
fluorescent agent. The latter step simplified the derivatization protocol and facilitated the 
resolution of the amino acid peaks of interest. Peaks corresponding with hydroxyproline, 
glycine, norleucine (an internal control), and proline were separated, and the firactions 
corresponding to the proline and hydroxyproline were collected for scintillation counting. 
On chromatograms the hydroxyproline eluted as two close peaks corresponding to 4-OH- 
hydroxyprohe and 3-OH-hydroxyprohe isomers. 
In order to vary temperature and decrease development time, a makeshift column 
heater was constructed from 2.5 mm diameter plastic tubing which was coiled caremy 
around the columq and the ends attached to either end of a circuit water pump and heater 
that was thennostatically controlled. The column and tubing were insulated with a layer of 
aluminum foil and foam insulation taped around the column. The thermostat of the water 
heater and pump were varied until the best compromise between peak resolution and 
separation was obtained at a constant column temperature of X°C.  The elution time for the 
hydrolysates was 26 minutes, followed by four to five minutes for re-equilibration of the 
before injection of the next sample. 
Table 3.1: I s o d c  gradient elution program for RP-NPLC separation of hydroxyproline 
and proline. 
Time Row Rate SoIvent Gradient $ 
minutes mumin Concentration % 
Initial conditions 1 100 0 
+ Solvent A = 56% 100 mM sodium acetate, 28% methanol 16% acetonitrile; Solvent B = 
100% methanol; $6 = isocratic linear conditions 
Several attempts at using the BrdU assay were made. There was marked non-specific 
staining of non-auc1ea.r materia. This problem was overcome by using an antibody blocking 
step with sheep serum the protocol (see appendix m). 
3.4.2 Tow Proline Incorporation 
Rates of proline incorporation were not significandy different among regions of the 
teasile portion of the SDET (table 3.2). Incorporation rates were sigdicantly higher for the 
SDFT of the right forelimb @ < 0.05). 
Table 3.2: Mean proline incorporation per mg d q  weight of tissue by region and limb. 
Tendon Region Proline Incorporation N 
Mean + SIB pmoVmg dry wt 
Proximal 10.16 + 5.18 24 
Middle 9.27 2 4.81 24 
Distal 10.79 + 5.51 24 
3.43 TotaJ Sdphate Incorporation 
Rates of sulfate incorporation were not significantly different among regions of the 
tensile portion of the SDFX' (table 3.3). Incorporation rates were sigmficantly higher for the 
SDFT of the right forelimb (p < 0.05). 
Table 3.3: Mean sulfate incorporation per mg dry weight of tissue by region and limb. 
Tendon Region Sulfate Incorporation N 
Mean + SD umoVmg dry wt 
Proximal 
Middle 
Distal 
Left 
Right 
All explants 18.78 5 9.98 
3.4.4 Tendon Explant Dry Weight 
There were no significant differences in tendon explant dry weight between limbs, 
nor among regions of the SDFT. 
Table 3.4: Mean dry weight of tendon explants by limb and region. 
Tendon Region Explant Dry Weight 
Mean + SD rng 
Proximal 
Middle 
Distal 
Left 
Right 
All explants 11.00 23-60 
3.5 Discussion 
The succes6ul standardization of the explant size was confirmed by the lack of 
significant differences among the dry weights of different tendon regions and the relative 
equivaence of their variances. The disadvantage of the biopsy punch technique was the long 
preparation time for the cultures compared to a previously used technique, but this was 
reduced with experience and by changing the biopsy punch more frequently (Riley ei a1 
1996). The number of explants obtained was comparable to that obtained previously and 
more explants-may easily be obtained per horse, but fhther modification of the roller 
incubator is required to accommodate the extra cultures. On histologic examination, the 
reduced volume of medium from 6 to 4 ml did not appear to affect the viability of the 
cultures; there was little evidence of cell death or apoptosis . 
The radiolabeling protocol was successfirl in attaining incorporation of each isotope.. 
However, the proline-fr-ee medium resulted in low absolute values of proline incorporation. 
Since the rate of proline incorporation is proportional to the proline concentration of the 
medium up to 
standard RPMl 
a concentration optima, it is recommended that all future experiments use 
1640 medium containing prohe, and the resulting change in SPA corrected 
for in the calculation of results (as was done for mlfhte) (Riley et a2 1996). The actual counts 
reflecting subte incorporation were very high, so it is suggested that a lesser amount of the 
isotope be used in future experiments. This will reduce costs and the risk of radiation 
exposure. 
The development of the pre-column derivatization and RP-HPLC protocols were 
developed by trial and error modifications of published protocols, particularly that of 
Dmevich and Vary (1 993) (Jansen et all99 1 ; Dmevich and Vary 1993; Ikeda et a2 1994). 
The expiant digests were highly particulate, requiring filtration. In addition, the high 
concentration of native collagen prior to culture d e d  in high peaks of hydroxyproline and 
proline, most of which are not associated with newly synthesized collagen. The protein 
precipitates fiom the cultwe medium was less particulate in nature and more representative 
of newly synthesized protein Chromatogram peaks were also better resolved with narrower 
base width, facilitating M o n  collection The derivatization and RP-HPLC protocols were 
very sensitive to acid pH, and it was essential to maintain the pH in the region of 9 + 0.2 
units for satisfactory peak separation and resolution. The temperature of the column was 
determined by trial and error. Higher temperatures decreased chromatogram development 
time but also resulted in poorer peak separation whereas lower temperatures increased 
c hromat ogram development time. 
The BrdU protocol required a blocking step with sheep serum to prevent non-specific 
staining. Generally ails that were stained were variable in their degree of staining and the 
numbers of cells that were stained was low. A large number of samples would be required 
fix statktistatisticaIly mean&@ quantitative comparisons using this assay. The technique is usem 
for determining the histologic areas in which proliferation occurs, permitting qualitative 
descriptions of cell proliferation It is suggested that an alternative assay be utilized for 
quantitative estimates of cell proliferation, such as '4C-thymidine incorporation (Baserga 
1989). Howwer, it has recently been suggested that either technique may label both 
proliferating cells and those undergoing DNA repair, thus providing a possible source of 
measurement error (John Matyas -personal communication). 
Segmental differences in protein or glycosaminoglycans synthesis were not identified, 
but the diffaences between left and right tendons were unexpected. In exercised horses 
differaces in the mechanical and structural properties of left and right long bones have been 
identified, but the reason for the differences in these cultures is unclear. The differences may 
be associated with the medical condition for which the horse was euthanised. Future 
experiments will randomly assign right and left SDFT's into treatment groups. 
3.6 Coadusions 
1) AU protocols have been satisfactorily developed but may require minor modification 
during future experiments (appendix m). 
2) Significant regional variation in incorporation rates was not identified at the timepoint 
examined, but an effect related to the limb (left or right) was identihi. Although this may 
be associated with the medical condition of the animal, random assignment to treatment 
groups in fiture experiments should take this into consideration 
3) The value of the BrdU assay appears to have limited quantitative value for this study. 
4) Future experiments should use proline-containing media- 
CHAPTER FOUR 
4.0 EXPERIMENT 2 - PILOT STUDY A: DETE-ATION OF TlB EFFECTS 
OF THE DURATION OF PRE-TREATMENT AND TREATMENT PERIODS ON 
THE METABOLIC RESPONSES OF EQUINE SDFT EXPLANTS TO 
POLYSULFATED GLYCOSAMINOGLYCANS, SODIUM HYALURONATE AND 
RECOMBINANT HUMAN IGF-I 
4.1 Introduction 
Tendon healing in vifro has many s'imilarities with healing in vim, with the except ion 
that it proceeds at a slower rate and without systemic regulation (Gelberman et a2 1984; 
Manske et a2 1984). It is necessary to identify the in vitro changes in ECM synthesis that 
occur over time in order to determine the optimal window for drug use and evaluation in the 
model (Chvapil1996). It is evident f?om previous in vitro work with the equine SDFT that 
differences in protein and glycosaminoglycan synthetic rates o m  with time, and that 
variances differ depending upon the time at which endpoints are measwed (Riley 1994). 
Neither hyahmnate (HA or Hyonate", nor polysulfated glycosaminoglycan (PSGAG 
or ~dequan? have been evaluated in cultures of the equine SDFT. Previous evaluation of 
the equine SDFT explant model identified si@cant differences in ECM synthesis among 
horses (Riley 1994). It is necessary to collect data in order to make some prelirmnary 
comparisons of treatment groups and information suitable for calculating the size of 
treatment groups in more comprehensive experiments. Studies using explant cultures of 
rabbit flexor tendons indicate that insulin-like growth factor-I (IGF-I) has a potent anabolic 
effect on protein synthesis and d proliferation in both serum-fiee and supplemented media 
(Abrahamsson et d 199 la; Abmhamsson et al 199 1 b). It is possible that cultures treated 
with IGF-I may be usefbl as a positive control in the equine SDFT model when evaluating 
the effects of HA and PSGAG. 
The following experiment was performed to identi@ the mean values and distribution 
of data for each of the proposed treatment groups, to identify stabilization periods and 
duration of treatment, and to test the hypothesis that neither HA nor PSGAG will alter rates 
of sulfated GAGS or protein synthesis by explants of the equine SDFT. 
4.2 Objectives 
1) To identify the optimal pre-treatment stabilization period for the cultures prior to 
treatment with PSGAG or rhIGF-I. 
2) To identify the duration of treatment required to obtain a measurable response to 
treatment with HA, PSGAG or rhIGF-I. 
3) To obtain data for the approximation of group sample sizes for f h r e  experiments. 
4) To determine whether Hq PSGAG or rhlGF-I affect the rates of sulfated GAG or protein 
synthesis of explants of the equine SDFT in vilro. 
4.3 Materials and Methods 
4.3.1 Experimental Animal 
One three-year-old male Quarter horse (- 1.5 m at the shoulder) untrained and f k e  
from clinical evidence of tendon injury was purchased &om the Saskatoon Auction Mart. 
4.3.2 Establishment of Equine SDFT Explant Organ Cultures 
The tensile portions of the forelimb SDFI's were! harvested and explant cultures (196 
explants) prepared as per the protocol developed in chapter three, and placed in 4 ml of 
prepared medium (RPMI 1640 containing probe, with 100/o DHS and 50 p g l d  ascorbate), 
sealed and stede gas (50% OJ4S%N JS%COJ injected for ten seconds at 15 psi. C u b e s  
were maintained on rollers at 36.5+0.5*C for the duration of the experiment (23 days) and 
the media changed (50% replacement) every 72 h unless otherwise indicated. Groups of 
cultures were treated according to table 4.1. For those cultures with a stabhtion period 
of nine days, six days of treatment was proposed. However, due to the late arrival of the 
shipment of 3sS-NaS0, reqmd for radio Iabeling, the treatment period was extended by one 
day. Doses of drugs and recombinant human (rh) IGF-I used were based on the literature, 
and the availability of the drugs (Abraharnsson 199 1; Nethery et al1992). 
Table 4.1: Treatment groups 
Duration (days) 
Treatment Number of 
Stabilization Treatment Totalculture Cultures 
Period Period Period* 
PSGAG~ 
Control 
HA: 
rhIGF-r 
-- -- -- 
PSGAG' 15 6 23 16 
PSGAG~ & ~ ~ I G F - r  15 6 23 16 
HA' 15 6 23 16 
HA' & rhlGF-I# 15 6 23 16 
~ M G F - ~  15 6 23 16 
Control 
P SGAG? 
HA' 
'Dose of PSGAG = 1000 pgld (AdequanQ, 5 ml @ 100 mg/ml); tT dose of PSGAG = 2000 
pghd ( ~ d e q u a g ,  5 ml @ 100 mgld, Luitpold, NY., USA); 'dose of HA = 500 pglml 
@yonate6, 2.5 ml @ 10 @ml, Bayer Inc., ON'., Canada ); ' dose of rhIGF-I = I00 nglml 
(MGF-I 800 @ 250 nglpl, Ciba Geigy, USA); *including incubation and chase periods. 
4.3.3 RadiolPbeling of Equine SDIT Expiant Organ Cultures 
Cdtures were radiolabeled for 24 h at the end of each treatment period as per table 
4.1. A similar protocol to experiment one was used, with the exception that the serum-free 
medium used for the isotopic incubations contained proline. Cultures were then radiolabeled 
with a reduced amount of 35S-sulfBte (25 pCi/culture; SPA 1497 Cilmmol) and L-[2,3,4,5- 
3H] proline (20 pCildture; SPA 114 Cilmmol) in order to assay sulfated GAG 
(proteoglycan) and protein (prohe containing protein only) synthesis respectively. After 24 
h o u .  the radioactive media was removed and hzen at -20°C in vials for later analysis. The 
explants were then chase incubated with 2 ml of isotope-fiee, serum-free medium for 24 
hours, and then the tissue harvested and fiozen at -20°C for later analysis. 
4.3.4 Determination of Radioactive Isotope Incorporation Rates 
Preparatratron a d ScintiIWon Counting of Tendon Erplants 
RadiolabeIed explants were freeze-dried, weighed, and hydrolyzed in experiment one 
(Appendix III). A 0.5 ml aliquot was transferred &om each tube to a scintillation vial and 
evaporated to dryness. Samples were cleared with Solvable@, biodegradable scintillation 
cocktail added, and counted to determine dpm for 3sS-sulfate and L-[2,3 ,4,5-3HJ-proline. 
The remaining -on of the hydrolysates was transferred to 1.5 ml microikge tube 
with a 0.22 pm filter, cenfnfUged for 5 minutes at 3000 rpm, and the filtrates frozen at -20°C 
for possible later analysis. 
Preparation and ScintiZZ&-on C d n g  of W e d  Media 
Aliquots of 100 pl of culture medium were applied to Biospin-6' columns and the 
eluate transfmed to scintillation vials, hydrolyzed, cocktail added, and the vials counted. 
The protein in a 1 ml aliquot of each sample of medium was precipitated in 0.15% 
DOCA and 72% TCA, CentdLged at 3300 g for 30 minutes, the supernatant discarded, and 
the pellet air dried and fiozen for possible later derivatization and RP-HPLC. 
Caimh'ion of Imoqwration Rates of Radimfive Isotopes 
Radioactivity counts for each culture were corrected for the SPA of 'H-proline and 
35S-sulflite, and molar rates of incorporation for the two molecules detennined, reflecting 
measures of prohe containing protein and glycosaminoglycans synthesized in M'tro. 
4.3.5 Statistical Analysis 
All results were tabulated and their distriiution and variances determined. Where the 
criterion for parametric testing were met, analysis of variance (ANOVA) and means 
comparisons werer performed among treatment groups. The significance level was set at p 
< 0.05, and a tread recogmd at p < 0.10 (Statistix 4.1). For data not meeting the criterion 
for parametric testing, the Kruskal-Wallis non-parametric ANOVA was used. 
4.4 Results 
4.4.1 Total Proline Incorporation 
Mean proline incorporation rates for all treatment groups are listed in table 4.2. For 
cultures that were stabitized for 9 days, proline incorporation rates were significantly greater 
in the control and rhIGF-I groups than in the HA and PSGAG groups @ < 0.05). In cuitures 
tbat were stabilized for 18 days and treated for 3 days, there were no significant dBerences 
among treatment groups, but there was a trend for greater proline incorporation in the 
rhIGF-I group than the control, HA and PSGAG groups. In cultures that were stabilized for 
15 days and treated for 6 days, proline incorporation rates were greater in the HA&rhIGF-I 
@ <0.05), PSGAG @ COO. 05) and PSGAG&rhIGF-I @ < 0.1 0) than the control group. 
Means of the two control groups were similar. The mean prohe incorporation rate 
was significantly lower in the PSGAG group with a 9 day stabilization period than the other 
PSGAG groups @ < 0.001). There was a trend for lower mean proline incorporation rate 
in the HA group with a 9 day stabilization period than the other two HA groups @ < 0.10). 
Table 4.2: Protein synthesis - Mean proline incorporation per mg dry weight of SDFT 
tendon by treatment group, stabilization period and duration of treatment. 
Duration (days) Profine 
Treatment Incorporation 
Stabilization Treatment Total Culture Mean + SD 
Period Period f eriod* pmoVmg dry wt 
PSGAG~? 
Control 
HAS 
rhIGF-I# 
Control - - 23 95.49 5 14.82 
rhIGF-l! 18 3 23 114.52 17.89 
Qose ofPSGAG = 100 pglml; dose of PSGAG = 2000 pg/ml; 'dose of HA = 500 pg/ml; 
# dose of rHGF-I = 100 @d, *total culture paid = isotope incubation + chase incubation. 
4.4.2 Total Sulfate Incorporation 
Mean sllffte incorporation rates for all treatment groups are listed in table 4.3. For 
dtures that were s t a b k d  for nine days, mean sulffte incorporation rates were si@cantIy 
greater in the conbol and rbIGF-I groups than in the HA and PSGAG groups @ < 0.0 1). In 
cultures that were stabilized for 18 days and treated for three, there were no significant 
differences among treatment groups. In cultures that were stabilized for 15 days and treated 
for six, mean d a t e  incorporation rates were greater in the HA&rhIGF-I @ < 0.05), 
PSGAG @ < 0.10) and PSGAG&rhIGF-I (p < 0.10) than the control group. 
Table 4.3: Glycosaminoglycans synthesis - Mean sulfate incorporation per mg dry weight 
of SDFT tendon by treatment group, stabilization period and duration of treatment. 
Duration (days) Sulfate 
Treatment Incorporation 
Stabilization Treatment TOM Culture Mean 2 SD 
Period Period Period* ~ o V m g  dry 
PSGAG~ 
Control 
HAS 
~HGF-r# 
. - - - - - - . 
Controf - - 23 144.00 5 21 -03 
PSGAG~ 18 3 23 158.66 2 35.13 
HAt 18 3 23 166.29 + 57.24 
rh1G~-In 18 3 23 169.16 + 35.73 
?Dose of'PSGAG = 1000 @I& * dose of PSGAG = 2000 pg/ml;'dose of HA = 500 pg/ml; 
' dose of rhIGF-I = 100 nglml; *total cdtme period = isotope incubation + chase incubation. 
Differences between the two control groups were not significant, nor was there a 
trend. The mean sulffte incorporation rate was significantly lower in the PSGAG group with 
a nine day stabilization period than the other two PSGAG groups @ < 0.00 1). The mean 
sulfate incorporation rate was significantly lower in the HA group with a nine day 
stabilization period than the other two HA groups @ < 0.05). 
4.4.3 Tendon Explant Dry Weight 
There were no significant differences in tendon explant dry weight among treatment 
groups at Mkrent culture stabilization periods (9, 15 and 18 days) or following different 
treatment periods (three and six days in dtures maintained for 23 days) (table 4.4). 
Table 4.4: Mean dry weight of SDFT tendon by treatment group, stabilization period and 
duration of treatment. 
- - - -- 
Duration (days) Expiant Dry 
Treatment Weight 
Stabilization Treatment Total Culture M-,, + SD mg 
Period Period Period* 
PSGAG~ 
Control 
HA# 
rhIGF-IX 
Control 
PSGAG+ 
H A S  
MGF-r# 18 3 23 20.11 5 2.76 
'Dose of PSGAG = 1000 pB/ml; tt dose of PSGAG = 2000 pglml; 'dose of HA = 500 pglml; 
' dose of rhIGF-I = 100 ng/ml; *total culture period including isotope incubation. 
4.4.4 Sample Size Calcnlations 
Sample size calculations were performed using results of cultures that were 
maintained for 22 days using standard statistical formulae, first using the variance of the 
control and then each treatment group to produce a range (table 4.5). 
Table 4.5: Sample size calculations based on variances of control and treatment groups. 
Treatment Stabilization Treatment Proline Sulfate 
Period (days) Period (days) Sample Size Sample Size 
'Dose of PSGAG = 1000 pg/ml; 'dose of HA = 500 pg/ml; ' dose of rhIGF-I = 100 ng/d 
4.5 Discussion 
The choice of the culture periods chosen were based on a compromise between 
sampling over a four-week period (based on previous published experimental work and the 
lag between in vino and in vivo healing), and maintaining adequate sample size for each 
group (Riley et al19%). More frequent sampling of the control group may be of assistance 
in future for defining the growth, plateau and decline phases of cell pro l i fdon  and 
maaomoledar synthess for the qlants. However, the system used is antibiotic fke. W~th 
longer culture periods (> 4 weeks) maintaining contamination free cultures becomes 
increasingly difEcuIt. In addition, with increased duration of cells in culture there is an 
increased risk of selecting cell line(s) associafed with culture conditions to which the explants 
are exposed, which are morphologically or fuactionally different and less representative of 
the original cell types present in the explant at the time of the initiation of the cultures 
(Freshney 1987). 
The treatment times selected for comparisons were based on the practicalities of 
changing the medium every 3 days, and the manufac~ues recommendations for drug 
. . 
-OIL PSGAG is licensed for admum&& . . 'on every 4 days and HA every 7 days, and 
a course of repeated administration is recommended for both drugs. Treatment times were 
chosen to approximate these recommendations while not increasing the number of times 
cultures required medium exchange. If the medium is exchanged too frequently, the lag in 
cell proliferation and synthesis that occurs, may mask any responses to the drugs (Freshney 
1987). 
The extra treatment day for dtures  with a 9 days stabilization period resulted in 
ficulties in making direct and relevant comparisons with the dtures  stabilized for 18 days 
and treated for 6 days. It is possible that the apparent inhibitory effect observed in the 9 day 
group was associated with this difference. The dose of PSGAG used in this group also 
differed £?om the latter groups, and the effect seen may have been a toxic or inhibitory 
response to this concentration which was further substantiated in experiment 5 (chapter 6). 
The dose was reduced in the 15 and 18 day stabilization groups because of concerns about 
possible toxicity at such a high PSGAG concentration. 
Those cultures stabilized for 15 and 18 days had the same total time in culture. 
However, it was only in the 15 day pre-treatment s tab i t ion  period group that sigruficant 
differences were identified, suggesting that a 6 day treatment period is preferable over the 
3 day treatment period or that there are sigaficant difference between the 15 and 18 day pre- 
treatment culture periods. The 6 day treatment period may be preferable because there may 
a lag period in the response to drugs associated with a slower in vitro repair response than 
the in vivo response (Gelbennan et d 1984; Manske ei a2 1984). 
Although there were differences in protein and glycosarnhoglycans synthesis between 
cultures stabilized for 9 days and those stabilized for longer periods, this did not hold true 
for the control groups. This latter result contrasts with previous work with the equine SDFT 
in which synthetic rates for both protein and glycosaminoglycans were markedly increased 
after 4 weeks compared to 2 weeks of culture (Riley et aZ 1996). It is possible that the 
sample size in this experiment was not large enough to be representative of the control 
popWon, and sample size calculations do indicate a need for a larger number of explants 
per group than was used in this pilot study to determine if there is a difference. 
The calculated large number of HA samples required for between the day I5 and 18 
stabilization groups is high. An alternative HA dose may allow for fewer samples if there is 
a response to Hq indicating the need for a dose response trial. 
The poor response to rhIGF-I may be due to poor bioavailabilty (either due to the 
IGF itself or due to the lack of suitable binding proteins in the cultures), an inappropriate 
concentration of the agent, or species differences in the response to IGF. An alternative 
source of rhIGF-I will be used in fitme studies. 
The narrower distribution of explant dry weights for the study was indicative of 
improved explant standardization and homogeneity in size compared to the unmodified 
model (Riley 1994). This represents an improvement in the model, and enhances its 
suitability for the study of equine SDFT explants to different drugs and biological agents. 
4.6 Conclusions 
1) Rates of proline and sulfate incorporation were stable in the cultures over the 18 to 23 
days total culture period. 
2) An apparently inhibitory effects on proline and sulfate incorporation rates due to PSGAG 
at 2000 pghl (double the dose used for later cultures) were observed &mpared to controls 
in explants cultured for 9 days and treated for 7 days. 
3) Rates of proline and sulfate incorporation were increased in the presence of PSGAG at 
1000 pg/ml compared to controls in explants cultured for 15 days and treated for 6 days. 
4) The results for rhlGF-I at 100 nglml did not support its use as a positive control. 
5) The narrower distn3ution of dry weights for the explants indicates improved 
standardization of explant size than the previously used technique (Riley 1994). 
5.0 EXPEXIMENT 3 - PILOT STUDY B: DETERMINATLON ClF THE EFFECTS 
OF TEIE DURATION OF PRE-TREATMENT AND TREATMENT PERIODS ON 
METABOLIC RESPONSES OF EQUINE SDFT EXPLANTS TO 
POLYSULFATED GLYCOSAMINOGLYCANS AND RECOMBINANT HUMAN 
IGF-I 
5.1 Introduction 
In the previous experiment (pilot study A) it was determined that the response to 
treatment differed depending upon the duration of pre-treatment and/or treatment periods. 
Experimental design was sub-optimal, resulting in diffculties in making meanin@ and 
drawing conclusions. 
Sample size calcuiations indicated that PSGAG (at 1000 pg/ml) and rhIGF-I, but not 
Hq are suitable for evaluation at the concentrations tested. A dose response study was 
necessary before proceeding further with other HA studies. Therefore in this experiment HA 
was not evaiuated. Dose response studies for both HA and PSGAG were performed later. 
The results for rhlGFJ (Ciba-Geigy) did not support its use as a positive control. 
The source used had not been tested for its suitability for in vitro studies. Therefore an 
alternative source that had tested for its suitability for in vibo studies was used (Upstate 
Biotechnology hc., NY., USA). 
This experiment will test the hypothesis that differences in the pre-treatment 
stabilization culture period will not sigdicantly affect rates of sulfated GAG and protein 
synthesis in either the control or treatment groups. 
5.2 Objectives 
1) To compare the effkcts of different pre-treatment culture stabilization periods on the 
protein and sulfated GAG synthetic rates of equine SDFT explant cultures. 
2) To determine the effects of PSGAG and rhIGF-I and on the protein and sulfated GAG 
synthetic rates of equine SDFT explant cultures at each Merent dture period (stabilization 
period plus treatment period)). 
3) To obtain firrther data for the approximation of group sample sizes for future experiments. 
5.3 Materials and Methods 
5.3.1 Experimental Animal 
One two-year-old male Quarter horse cross (- 1.5 m at the shoulder), untrained and 
6ee fkom clinical evidence of tendon iniury, was obtained from the Saskatoon Auction Mart. 
5.3.2 Establishment of Equine SDFI' Explant Organ Cultures 
The tensile porn on^ of the forelimb SDWs were harvested and explant cultures 
prepared as per the protocol (appendix m). Cultures were maintained on rollers at 
36.5+o.SoC for the duration of the experiment (29 days) and the media changed (50% 
replacement) every 72 h unless otherwise indicated. A total of 221 cultures were obtained. 
The pre-treatment culture period for different groups of cultures are outlined in table 5.1. 
All cultures were treated (or not treated in the control group) for six days before 
radiolabeling. The concentration of PSGAG used was 1000 pgM. The concentration of 
rhIGF-I used was based on the manufacturers recommendations (100 ng/ml). 
Table 5.1: Number of explants in each treatment group. 
Treatment 
Pre-treatment Stabilization Period (days) 
Corrtrol 18 18 20 
YRadiolabeled on day 15; +%adiolabeled on day 21; %diolabeied on day 27; 'Dose of 
PSGAG = 1000 pg/d (~dequarf', 5 ml @ 100 mg/ml, Luitpold Pharmaceuticals, NY., 
USA); 'dose of rhIGF-I = 100 nghl (Upstate Biotechnology, 25 0 n g / d  NY., USA); *one 
explant lost during fieeze drying. 
5.33 Radiolabeling of Equine SDm Explant Organ Cultares 
Cultures were radiolabeled for 24 h at the end of each treatment period as per table 
5.1 @re-treatment stabilization period plus treatment period)). Cultures were radiolabeled and 
chase incubated as per the previously outlined protocol [35S-sulfate (25 pcifculture; SPA 
1497 Ci/mmol) and L-[~,3,4,5-~H] proline (20 pCi/culture; 1 14 Ci/rnmol)](appendix II). 
5.3.4 Determination of Radioactive Isotope Incorporation Rates 
Prepation and Scintillaon Cmting of Tendon Es,Iants 
Explants were fieeze dried, weighed, hydrolyzed and radioactivity determined as per 
the protocol developed in experiment one (Appendix m). 
Preparation and Scintiiiation Counting of Labeled Media 
Aliquots of 100 p1 of culture medium were applied to ~iospin-6@ columns and the 
eluate transferred to scintillation vials, hydrolyzed, cocktaiI added, and the vials counted. 
Calmlation of l~~~orpora-i?on Rates of Raalimctive Isotopes 
Radioactivity counts for each culture were comected for the s p d c  activity of 3H- 
prohe and 35S-suifate, and molar rates of incorporation for the two molecules determined, 
reflecting measures of probe containing protein and dfkted GAGS synthesized in vifico. 
5.3.5 Statistical Analysis 
All results were tabulated and their distn'bution and variances determined. Where the 
criterion for parametric testing were met, analysis of variance (ANOVA) and a means 
comparison performed among treatment groups. The si@cance level was set at p < 0.05, 
with a trend recognized at p < 0.10 (Statistix 4.1). For data not meeting the criteria for 
parametric testing, the Kruskal-Wallis non-parametric ANOVA was used. 
5.4 Results 
5.4.1 Total Proline Incorporation 
Mean proline incorporation rates for all  groups are listed m table 5.2 (figure 5.1). For 
cultures that were stabilized for either nine days or 1 5 days prior to treatment, mean proline 
incorporation rates were not signiscanfly different among drug treatment groups @ > 0.10). 
In cultures that were stabilized for 21 days, mean proline incorporation rates were not 
sigoificanfly different among groups (p > 0.10). Differences among the three control groups 
@re-treatment &twe periods 9, 15 and 21) were significant between the 9 and 21 day 
controls only @ < 0.05). The day 15 control group did not differ significantly fiom either of 
the two other groups, nor was there a trend. 
The mean proline incorporation rate was significantly lower in the PSGAG group 
wirh a 9 day stabilization period than the 21 day group @ < 0.02). The 15 day stabilization 
PSGAG group did not differ significantly from the two other PSGAG groups. 
Table 5.2: Protein synthesis - Mean proline incorporation per mg dry weight of equine 
SDFT by treatment group and pre-treatment stabilization period. 
Treatment 
Proline Incorporation Rates 
Mean + SD p o V m g  dry wt 
Pretreatment Stabilization Period (Days) 
-- - 
PSGAG' 97.70 + 16.87 106.47 + 34.99 177.91 + 13 1 .09 
PSGAG? & rhIG~-p 106.52 5 21 -89 106.53 + 33.59 147.27 + 57.62 
~~IGF- I '  103.88 5 27.18 117.37 & 38.33 141.76 5 35.68 
Control 90-90 + 21.00 107.67 + 33.77 128.03 1f: 45.90 
ttRadiolabeled on day 15; rradiolabeled on day 21; hdiolabeled on day 27; 'Dose of 
PSGAG = 1000 pg/ml; 'dose of rhIGF-I = 100 ng/ml. 
The mean proline incorporation mte was significantly higher in the PSGAG & rhIGF-I group 
with a 21 day stabjibation period than the other two PSGAG & rhIGF-I groups @ < 0.05). 
The 15 day s t a b w o n  PSGAG& rhIGF-I group did not differ significantly fiom the 9 day 
stabilization group, nor was there a trend. 
The mean proline incorporation rate was sigdcantly higher in the rhIGF-I group 
with a 21 day stabilktion period than the other two rhIGF-I groups @ c 0.05). The 15 day 
stabiliration rfiIGF-I group did not differ significantly fiom the 9 day stabilization group, nor 
was there a trend. 
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Fwre 5.1: Protein synthesis - Mean total proline incorporation rate per rng dry weight of 
equine SDET by treatment group and duration of pre-treatment culture period (mean + sd 
pmoVmg dry weight of tendon). PSG = polysulfated glycusaminoglycans; P S W  = 
polydfkted glycosaminoglycans & IGF-I; IGF = IGF-I; CTR = control; d = days. 
5.4.2 TOM Sulfate Incorporation 
Mean &e incorporation rates for all treatment groups are listed in table 5.3 (figure 
5.2). For cultures that were stabilized for nine days prior to the six days of treatment, mean 
d.fkte incorporation rates were not significantly different among drug treatment groups @ 
> 0.10). In cultures that were stabilized for 15 days or 21 days there were no significant 
differences in mean sulfate incorporation rates among treatment groups @ > 0.10). 
Among the three control groups (pre-treatment dture periods 9, 15 and 21) the 
mean sllfate incorporation rate was significantly lower in the nine day pre-treatment culture 
group than the 15 and 21 day controls @ < 0.05). The day 15 control group did not differ 
sigdicantly fiom the day 21 group, nor was there a trend. 
The mean sulfate incorporation rate was significantly lower in the PSGAG group 
with a nine day stabilization period than the 21 day PSGAG group @ < 0.05). The 1 5 day 
stabilization PSGAG group did not differ significantly fiom either of the other PSGAG 
groups, nor was there a trend. 
Table 5.3: Glycosaminoglycans synthesis - Mean sulfate incorporation per mg dry weight 
of equine SDFT by treatment group and pre-treatment stabilization period. 
Sulfate Incorporation Rates 
Mean + SD pnoVmg dry wt 
Treatment 
Pre-treatment Stabilization Period (Days) 
PSGAG~ 102.33 & 22.61 121.29 + 48.37 194.97 & 148.3 1 
PSGAGt&rbIG~-Jt 102.12 + 22.05 122.87 + 45.98 151.81 + 76.24 
rhIG~-p 108.70 + 30.49 143.92 5 70.62 132.94 5 37.68 
Control 93.30 5 35.52 134.3 1 f: 41.83 134.63 t 63.91 . 
i+Radiolabeled on day 15; t%olabeled on day 21; %diolabeled on day 27; 'Dose of 
PSGAG = 1000 pgM; 'dose of rhIGF-I = 100 ng/ml. 
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Figure 5.2: GlywsaminogtycaOS synthesis - Mean total sulFate incorporation rate per mg dry 
weight of equine SDFT by treatment group and duration of pre-treatment culture period 
(mean 2 sd poVmg dry weight of tendon). PSG = polysulfhted glyco saminoglycans; P S GA 
= polysulfated glycosaminoglycans & IGF-I; IGF = IGF-I; CTR = control; d = days. 
The mean sulfste incorporation rate was significantly lower in the PSGAG&rhIGF-I 
group with a nine day stabiliation period than the 21 day PSGAG&rhIGF-I group (p < 
0.05). The 15 day stabilization PSGAG&rhIGF-I group did not differ significantly from 
either of the two other PSGAGBrrhIGF-I groups, nor was there a trend. There were no 
differences among the three rhIGF-I groups in mean sulfkte incorporation rates @ > 0.10). 
5.4.3 Tendon Explant Dry Weight 
There were no significant differences in mean equine SDFT explant dry weights 
among drug treatment groups for explants stabilized for nine, 15, or 21 days (table 5.4; 
figure 5.3). However, the mean dry weight of all explants stabilized for nine days was 
significantly greater than the other two stabilization periods @ < 0.05), znd the mean dry 
weight of all explants stabilized for 15 days was sigdicantly greater than the mean dry 
weight of cultures stabilized for 21 days (p < 0.05). 
Table 5.4: Mean dry weight of equine SDFT explants by treatment group and pre-treatment 
stabilization period. 
Treatment 
Explant Dry Weight 
Mean + SD mg 
Pre-treatment Stabilization Period (Days) 
-- 
PSGAG' 18.38 + 3.79 16.73 f 3.82 9.54 5 4.38 
P SGAG~&~~IGF-IS 19.3 1 t 3.97 18.04 t 7.54 1 1.52 2 4.43 
rhIGF-It 28.59 5 3.94 15.45 5.73 13.19 t 5-08 
Control 17.87 2 6.59 16.75 + 5.73 13.08 2 5.64 
-
t+ltadiolabeled on day 15; %adiolabded on day 21; %diolabeled on day 27; 'Dose of 
PSGAG = 1000 'dose of rhIGF-I = 100 ng/ml. 
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Figure 5.3: Tendon Explant Dry Weight - Mean equine SDFT explant dry weight by 
treatment group and duration of pre-treatment culture period (mean + sd mg dry weight of 
tendon). PSG = polydfkted glycosaminoglycans; PSWI = polysulfated g lyco~og lycans  
& IGF-I; IGF = IGF-I; CTR = control; d = days. 
5.4.4 Sample Size Calculations 
Sample size calculations were performed for results of the controls and PSGAG 
treatment groups to deternine how large groups were needed to detect a significant &kt.. 
Calculations were detefariaed using standard statistical formulae, using the variance of the 
control and then each treatment group to produce a range (table 5.5). 
Table 5.5: Sample size calculations based on variances of control and treatment groups. 
Treatment Stabilization Treatment Proline Sulfate 
Period (days) Period (days) Sample Size Sample Size 
PSGAG+ 
Control 
PSGAG~ 
Control 
PSGAG+ 
Control 
'Dose of PSGAG = 1000 pglml. 
5.5 Discussion 
The significance of the results eoom this experiment are questionable given the 
findings of a decline in explant mass during the experiment, and the fkt that data was 
nomalid on the basis of dry weight. Normahtion of data based on the amount of DNA 
per explant may have improved the accwacy of comparisons, but extracting DNA fiom 
equine tendon tissue is difficult, and results in low yields because of the resistance of the 
tissue to disaggregation and its low cellular density (Birch 1993). The decline in explant dry 
weights contrasts with the results of experiments one and two, and with previous work with 
this model in which significant differences among explant dry weights over time were not 
detected (Riley 1994). There are sseveral possible reasons for this decline: 1) poor 
homogeneity in expiant preparation during the establishment of cultures; 2) cumulative toxic 
effects &om the medium or serum; 3) contamination of the cuitures with mycoplasma; 4) 
progressive catabolism of the ECM over time. 
The q l a n t  preparation proceclures were identical to those used for the previous two 
experiments, and explams appeared to be of similar size. This possibility would not explain 
the reduction in explant size across all treatment groups with successive pre-treatment 
culture periods. The same batch and concentration of serum, and the same batch of RPMI 
1640 medium was used in this experiment as the previous two experiments. Since neither 
turbidity nor rnarked acidity was noted in the cultures, bacterial infection was not indicated 
in the cultures. Therefore the most likely explanation for the reduction in explant size is 
infection with qwplasma organisms (Freshney 1987). This possibility is W e r  supported 
by the high variances of data within each treatment group, particularly in the cultures 
stabilized for 21 days prior to treatment. It is therefore recommended for d future 
experiments that representative sample be submitted for my coplasma isolation. 
It appears that a pre-treatment culture stabilization period greater than 15 days is 
preferable for future studies based on the results. However the reduction in explant size 
(possibly due to mywplasma) may have artificidy increased the values obtained for those 
cultures pre-incubated for 21 days. 
Within each pre-treatment culture period, rhIGF-I failed to increase protein or 
glycosaminoglycan synthesis at the concentration tested. Although the dose used was high, 
based on previous literature, the equine SDFT explants may be less responsive than other 
tissues (Abrahamsson 1991). Therefore a dose response study for rhIGF was recommended. 
The response of explants to PSGAG observed in experiment two was not detected in this 
experiment. This may be due to an inappropriate dose, or a reflection of the possible effect 
of mycoplama infixtion of the cultures. A dose response study is necessary for PSGAG. 
5.6 Conclusions 
1) Rates of synthesis are optimized by a pre-treatment culture period greater than 15 days. 
2) Neither PSGAG nor rhIGF-I altered the rates of synthesis of  protein or sulfated GAGS 
compared to controls within each pre-treatment culture period group. 
3) Dose response studies for PSGAG and rhIGF-I are required. 
4) The interpretation of resuits &om this cent are confounded by the decline in explant 
size during the experiment, and a high probability of mycoplasma infection of the cultures. 
5) A representative sample fiom future experiments should be tested for mycoplasma 
CmwTEx SIX 
6.0 EXPERIMENT 4 : EVALUATION OF THE EFFECT OF DOSE ON TBLE 
METABOLIC RESPONSES OF EQUINE SDFT EXPUNTS TO POLYSULF'ATED 
GLYCOSAMINOGLYCANS AND RECOMBINANT HIJMAN IGF-I 
6.1 Introduction 
The results fiom the previous three experiments suggest that a pre-treatment culture 
period of 15 to 21 days and a treatment period of six days as suitable initial conditions for 
the study of the response of the equine SDFT explants to different phannacologic and 
biologic agents. 
In the previous experiments it was determined that the response to treatment with 
PSGAG differed depending upon the pre-treatment stabilization period. Although a trend 
was observed in experiment two, si@cant differences in synthesis were not observed 
following treatment with PSGAG at a dose of 1000 pg/d when compared to controls. 
Statistical power calculations using the results of experiments two and three confirmed the 
need for larger treatment groups for comparisons. Additionally, the effect of different 
concentrations may be an important determinant of the degree of response, if any, of the 
SDFT explant cultures to PSGAG. 
The addition of rhIGF-I (at doses ranging from ten to 1000 ng/ml) to explant cultures 
of the flexor tendons has resulted in the stimulation of both sulfated GAG and collagen 
synthesis in a dose dependent manner in the rabbit, with maximal stimulation at 250 ng/ml 
(Abrahamson et d 1991a&b). Recently an equine study similar to that performed in the 
rabbit reported an increase in collagen but not sulFaed GAG synthesis in response to rhlGF-I 
at 100 and 250 nglml (but not 500 ng/ml) (Murphy and Nion 1997). The results of this 
study are ditFcult to interpret because the cultures were treated with rhIGF-I in the presence 
of 5% f d  bovine serum (FBS) which has high concentrations of growth factors including 
IGF-I, is not species specific, and varies widely &om batch to batch in its composition 
(layme 1990; Riley 1994). Experiments two and three used rhIGF-I at 100 nglml in the 
presence of 100/o DHS (same batch), but in both cases rhIGF-I done did not increase 
synthetic rates compared to controls at the concentration tested. Previous studies have 
suggestel that the response to rhIGF-I is dependent upon its concentration in the medium 
It is necessary to determine if such a relationship exists when the equine SDFT explants in 
the current study are treated with rhIGF-I. 
This aims of this experiment are to test the hypotheses that 1) The addition of 
PSGAG at Merent concentrations to explant cultures of the equine SDFT will not 
sigm5cazltly affect rates of sulfated GAG and protein synthesis compared to a control group, 
and 2) The addition of rhIGF-I at different concentrations to explants of the equine SDFT 
will not siBtuficantly affect rates of sulfated GAG and protein synthesis compared to a 
control group of cultures. 
1) To determine the effects of different concentrations of PSGAG in the culture medium on 
the rates of protein and m t e d  GAG synthesis by explant cultures of the equine SDFT. 
2) To determine the & i s  of different concentrations of rhlGF-I in the culture medium on 
the rates of protein and sultated GAG synthesis by explant cultures of the equine SDFT. 
6.3 Materials and Methods 
6.3.1 Experimental Animal 
A three and one haKyear-o1d female Thoroughbred cross (- 1.5 m at the shoulder), 
untrained and free from clinical evidence of tendon injury, was purchased from the 
Saskatoon Auction Mart. 
63.2 Establishment of Equine SDFT Explant Organ Cultures 
The tensile portions of the forelimb SDFTs were harvested and explant cultures 
prepared using the previously developed protocol (appendix m). Cultures were maintained 
on rollers at 36.5_MS°C for the duration of the experiment (27 days) and the media @PMI 
1640 containing prohe, with 10% DHS and 100 p g M  ascorbate) changed every 72 h 
unless othenvise indicated (Russell and Manske 199 1). After a pre-treatment period of 1 8 
days, cultures were treated with diEerent doses of either PSGAG (~dequan@~ Luitpold 
Pharmaceuticals, NY., USA) or rhIGF-I (Upstate Biotechnology Inc., NY., USA) for seven 
days prior to radiolabeling (table 6.1)(Nethery et a2 1992). A total of 2 12 cultures were 
obtained; six were randomly selected and tested for mycoplama at day 18. 
Table 6.1: Treatment groups for PSGAG and rhIGF-I dose response trials. 
Treatment Concentration Number of i Treatment Concentration Number of 
Pdd Explants i ng/ml Explants 
PSGAG~ 100 30 i Control 0 30 
PSGAG~ SO0 30 i ~ ~ I G F - I '  SO 8 
?~dequan@ 100 mg/d  luitpold Pharmaceuticals, NY.. USA; :rhIGF-I diluted to 160 nglpl, 
Upstate Biotechnology Inc., NY., USA 
6.3.3 Radiolabding of Equine SDET Explant Organ Cultures 
cuhms were TadioWed [3%S-suhte (20 pCi,culture; SPA 1497 Ci/rnmol) and L- 
[2,3,4,5-rn p r o k  (20 pCi~cllftm; SPA 114 Cilmmol)] for 24 h at the end of the treatment 
period (day 25) and chase incubated for 12 hours using the established protocol with 2 ml 
of serum free medium. It was planned that cultures would be labeled with methyl-C1'- 
thymidine (1 pCihhm) as an index of cell proliferation, but due to failure of the shipment 
to arrive, this was not possible. 
6.3.4 Determination of Radioactive Isotope Incorporation Rates 
Detenninafinafion of lncorporatiun &es of RaaS'oactive Isotopes by Tendon @ h t s  
The preparation and scintillation counting of the tendon explants and of the labeled 
media, as well as the calculation of incorporation rates were performed as descnied in 
Appendix ID. 
Aliquots of culture medium were precipitated in 0.15% DOCA and 72%TCA, 
incubated for 10 mins at room temperature, centrifuged for 30 minutes at 3300g and the 
supanatant decanted. Each protein pellet was digested in 6M HCl for 24 hours at 1 10'C and 
then the pH adjusted to 9.0. Aliquots of 40 or 45 pl were derivatized with DABS41 and 
then Hyp and Pro separated by RP-HPLC. Fractions corresponding to the Hyp and Pro 
peaks were collected, scintillation cocktail added and the hctions counted on a beta 
counter. The ratio of the counts and a formula accounting for the relative concentrations of 
Hyp and Pro in collagen were used to determine molar rates per mg dry weight of proline 
incorporation into collagen and noncollagen protein precipitated fiom the medium (is. 
soluble collagen) . 
6.3.5 Statistical Analysis 
AU r& were tabulated and their distribution and variances determined. Variances 
were not found to be equivalent, therefore the Kruskal-Wallis non-parametric ANOVA was 
used and a mans comparison performed among treatment groups, with a significance level 
set at p < 0.05, with a trend recognized at p < 0.10. 
6.4 Results 
The results of mycoplasma cultures were negative. Explants < 6 mg dry weight 
(mean 3.1 mg; n = 13) were excluded from the analysis, on the basis that results for these 
were subject to high measurement error due to low dry weight. Their removal ensured that 
dry weights were comparable among all groups. 
6.4.1 PSGAG Treated Cultures - Total Protein Synthesis 
Mean total proline incorporation rates were significantly greater for the 5000 p g / d  
(p < 0.01), 2000 Clglml@ < 0.05), lo00 pg/d @ < 0.01) and 500 pg/ml@ < 0.05) PSGAG 
treatment groups than the control group (table 6.2). The mean total proline incorporation 
rates were significantly greater for the 5000 pg/ml and 1000 pg/d than the 100 pg/ml 
PSGAG group @ < 0.05), giving statistical support for the apparent dose-related response 
observed in figure 6.1. 
Table 6.2: Protein synthesis - Mean total prohe incorporation rate per mg dry weight of 
equine SDFI' by concentration of PSGAG in the medium. 
- -  - - 
PSGAG Concentration Proline Incorporation Statistical Groupings 
in Medium (pglrnl) Mean 2 SD (pmoVmg) @ < 0.05)' 
0 72.06 2 26.22 A 
5000 96.66 + 28.20 C 
' Common letters denote that groups were not significantly different fiom each other 
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Figure 6.1: Protein synthesis - Mean total proline incorporation rate per mg dry weight of 
equine SDFT by concentration of PSGAG in the culture medium (mean + sd prnoVmg dry 
weight of tendon). 
6.4.2 PSGAG Treated Cultures - Collagen Synthesis 
Mean prohe incorporation rates into collagen were si@cantly greater for the 5000 
pg/d (p < 0.01), 2000 pg/d @ < 0.05), 1000 pglml@ < 0.01) and 500 pg/ml@ < 0.01) 
PSGAG treatment groups than the control group (table 6.3). The rate of collagen synthesis 
was greater in the 5000 pg/ml, 2000 pg/ml, 1000 pglml than the 100 p g M  PSGAG 
treatment group @ < 0.05), lending some statistical support to the apparent dose response 
observed in figure 6.2. 
Table 6.3: Collagen synthesis - Mean proline incorporation rate into collagent per mg dry 
weight of equine SDFT by concentration of PSGAG in the medium. 
PSGAG Concentration Proline Incorporation Statistical Groupings 
in Medium (pglml) Mean + SIB (IrmoUmg) (p < 0.05)' 
hermined  by RP-HPLC of digested protein precipitate fiom culture medium; 'common 
letters denote that groups were not signrficantly different ffom each other. 
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Figure 6.2: Collagen synthesis - Mean rate of proline incorporation into coIlagen (in the 
medium) per mg dry weight of equine SDFT by concentration of PSGAG in the culture 
medium (mean + sd pnoUmg dry weight of tendon). 
6.43 PSGAG Treated Cultures - Noncollagen Protein Synthesis 
Mean proline incorpodon rates into noncullagen protein were s i@cdy  greater 
for the all PSGAG treatment groups than the control group @ < 0.05 for the 2000 pg/ml 
group; p < 0.0 1 for all other PSGAG groups) (table 6.4). An apparent dose response 
illustrated in figure 6.3 could not be supported statistically. 
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Figure 6.3: Noncollagen protein synthesis - Mean rate of proline incorporation into 
nonwllagen protein per mg dry weight of equine SDFT by concentration of PSGAG in the 
culture medium (mean + sd pmoVmg dry weight of tendon). 
Table 6.4: Noncobgen protein synthesis - Mean proline incorporation rate into noncollagen 
proted per mg dry weight of equine SDFT by concentration of PSGAG in the medium. 
PSGAG Concentration Proline Incorporation Statistical Groupings 
in Medium W m l )  Mean 2 SD (jmoVmg) @ < 0.05)' 
0 4.04 2 3.26 A 
5000 13.98 2 14.97 B 
?Determined by RP-HPLC of digested protein precipitate f?om culture medium; 'common 
letters denote that groups were not significantly different £tom each other. 
6.4.4 PSGAG Treated Cultures - Glycosaminoglycans Synthesis 
Mean total &e incorporation rates onto GAGS were sigruficantly greater for the 
SO00 pg/ml, 2000 pg/ml, 1000 p g M  and SO0 pg/d PSGAG treatment groups than the 
control group @ < 0.0 1) (table 6.5). The mean total sulfate incorporation rates were greater 
for the 2000 pg/ml and 1000 p g h l  than the 100 pgM PSGAG group @ c 0.05), lending 
some statistical support to the apparent dose related response observed in figure 6.4. 
Table 6.5 G l y c o ~ o g l y c a n s  ynthesis - Mean total sulfate incorporation rate per mg dry 
weight of equine SDFT by concentration of PSGAG in the medium. 
PSGAG Concentration Sulfate Incorporation Statistical Groupings 
in Medium W m l )  Mean 2 SD QunoVmg) @ < 0.05)' 
0 44.13 2 21 -37 A 
100 63.49 2 13.63 A B 
500 86.53 4 47.62 B C 
1000 1 17.75 5 60.65 C 
2000 1 15.47 + 70.77 C 
5000 89.17 5 34.44 B C 
' Common letters denote that groups were not significantly different &om each other 
1 
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Figure 6.4: Giycosaminoglycans synthesis - Mean total sulfate incorporation rate per mg dry 
weight of equine SDFT by concentration of PSGAG in the culture medium (mean + sd 
pmoVmg dry weight of tendon). 
6.4.5 PSGAG Treated Cultures - Tendon Explant Dry Weight 
There were no significant differences in mean equine SDFT explant dry weights 
among PSGAG treatment and control groups (table 6.6, figure 6.5). 
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Figure 6.5: Tendon Explant Dry Weight - Mean equine SDFT explant dry weight by 
concentration of PSGAG in the culture medium (mean + sd mg dry weight of tendon). 
Table 6.6: Tendon Explant Dry Weight - Mean tendon explant dry weight by concentration 
of PSGAG in the medium, 
- -- - - - - 
PSGAG Concentration in Explant Dry Wt Statistical Grouping 
Medium W m 1 )  Mean 2 SD mg 
Common letters denote that groups were not sipXcantly different fkom each other. 
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6.4.6 rhIGF-I Treated Cuitum - Total Protein Syuthesis 
M a n  total proline incorporation rates were not si@cantiy different among rhIGF-I 
treatment and control groups (p > 0. lo), although there was a significant difference among 
the 500 ngM and 100 nglml rhIGF-I groups (p < 0.05) (table 6.7 and figure 6.6). 
Table 6.7: Protein synthesis - Mean total proline incorporation rate per mg dry weight of 
equine SDFT by concentration of rhXGF-I in the medium. 
- -  - - - - 
rhIGF-I Concentration Proline Incorporation Statistical Groupings 
in Medium (ng/rnl) Mean + SD (pmoVmg) @ c 0.05)' 
0 72.06 f: 26.22 A B 
50 70.15 + 7.48 A B 
100 69.96 + 4 1.03 B 
250 71.69 + 16.70 A B 
500 78.78 + 1 1.47 A 
Common letters denote that groups were not significantly different from each other 
I 
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F i i  6.6: Protein synthesis - Mean total proline incorporation rate per mg dry weight of 
equine SDFT by concentration of rhIGF-I in the medium (mean + sd pmoVmg dry weight 
of tendon). 
6.4.7 rhIGF-I Treated Cultures - CoIiagen Synthesis 
Mean proline incorporation rate into collagen was significantly greater for the 500 
ng/ml than the control group @ < 0.05) (figure 6.7, table 6.8). 
Table 6.8: Collagen synthesis - Mean proline incorporation rate into collagen7 per mg dry 
weight of equine SDFT by concentration of rhIGF-1 in the medium. 
- - 
rhIGF-I Concentration in Proline Incorporation Statistical Groupings 
Medium (ng/ml) Mean + SD (pmoVmg) (p < 0.05)' 
'Determined by RP-HPLC of digested protein precipitate fkorn culture medium; 'common 
letters denote that groups were not significantly different fiom each other. 
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Figure 6.7: Collagen synthesis - Mean rate of proline incorporation into collagen (ii the 
medium) per mg dry weight of equine SDFT by concentration of rhIGF-I in the medium 
(mean + sd pmoVmg dry weight of tendon). 
6.4.8 rhIGF-I Treated Cultures - NoncoUagen Protein Synthesis 
Mean prohe  incorporation rates into noncollagen protein were not significantly 
different among rhIGF-I treatment and control groups @ > 0.10) (table 6.9, figure 6.8). 
Table 6.9: NoncoIIagen protein synthesis - Mean prohe incorporation rate into noncoUagen 
protein' per mg dry weight of equine SDFT by concentration of rhIGF-I in the medium. 
MGF-I Concentration in Prohe Incorporrtion Statistical Groupings 
Medium (nglml) Mean + SD (poVmg) @ < 0.05)' 
'Determined by RP-HPLC of digested protein precipitate fiom culture medium; 'common 
letters denote that groups were not sigmficantly different f?om each other. 
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Figure 6.8: Noncollagen protein synthesis - Mean rate of proline incorporation into 
nonwllagen protein per mg dry weight of equine SDFT by concentration of rh?GF-I in the 
medium (mean + sd pmol/mg dry weight of tendon). 
6.4.9 rhlGF-I Treated Cultures - Glycosaminoglycan Synthesis 
Mean total sulfste incorporation rates onto glywsaminoglycans were not significantly 
Werent among rhIGF-I treatment and control groups @ > 0.1 O)(table 6-10, figure 6.9). 
Table 6.10: Glycoicslminoglycans synthesis - Mean total sulfate incorporation rate per mg 
dry weight of equine SDFT by concentration of rhIGF-I in the medium 
-- -- - 
rhIGF-I Concentration Sulfate Incorpodon Statistical Groupings 
in Medium (nglml) Mean 2 SD (poVmg) (p < 0.05)' 
0 44.13 + 21.37 A 
50 36.50 2 5.81 A 
100 40.29 + 17.86 A 
250 46.31 f 15.28 A 
500 43.53 5 9.57 -4 
Common letters denote that groups were not sigmficantly different fiorn each other. 
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Figure 6.9: Glycosamho&cans synthesis - Mean total d k t e  incorporation rate per mg dry 
weight of  equine SDFT by concentration of rhIGF-I in the culture medium (mean + sd 
pmoVmg dry weight of tendon). 
6.4.10 rhIGF-I Treated Cdtures - Tendon EsplPnt Dry Weight 
There were no significant differences in mean equine SDFT explant dry weights 
among rhXGF-I treatment and control groups (table 6.11, figure 6.10). 
Table 6.11: Tendon Explant Dry Weight - Mean tendon explant dry weight by 
concentration of rhIGF-I in the medium. 
MGF-I Concentration in Expiant Dry Wt 
Medium n g / d  Mean + SD mg 
Statistical Grouping 
250 23.49 + 7.99 A 
500 24.80 + 7.09 A 
' Common letters denote that groups were not signiticantly different fkorn each other. 
Tendon Explant Dry Weight 
Figure 6.10: Tendon Explant Dry Weight - Mean equine SDFT explant dry weight by 
concentration of rhIGF-I in the culture medium (mean + sd mg dry weight of tendon). 
6.5 Discussion 
Although a small number of explants were excluded fkom statistical analysis, 
genedy explant dry weight was distn'buted homogeneously among groups and cultures 
submitted for evaluation were mycoplasna f ie .  
Significant increases in protein (both collagen and nonwllagen protein) and 
gIycosaminoglycan synthetic rates occurred for concentrations of PSGAG greater than 100 
pp/nJ confirming the validity of performing a dose-response trial and increasing sample size 
(and thus power) for obtaining conclusive results and disproving the initial null hypothesis. 
A dose response was noted in the results, with stimulation of synthetic rates up to 1000 to 
2000 &rnl and an apparent decrease in response at higher doses (demonstrated with 
significance in glycosaminoglycans synthesis). Other studies have also demonstrated 
d i f f i c e s  in response based on the concentration of PSGAG over a similar concentration 
range (Nethery et d 1992). The results from the current experiment validate this 
experimental approach, and resulted in a similar experiment being performed for the 
evaluation of NaHA. 
There were three major limitations in the evaluation of synthetic responses to the 
PSGAG. Firstly, cell proliferation as determined by thymidine incorporation was not 
measured. It was initially planned to measure this variable, however failure of the isotope 
shipment to arrive prevented this determinatioq and delayed the treatment period fiom six 
to seven days. Cell proliferation was measured in experiment six. The second limitation is 
that nonsuifated GAGS (HA) were not measured. Since HA is an essential component in 
wound healing, it was also measured in experiment six. The third limitation of this 
expeximent is that the mechanism of stimulation of synthetic rates was not elucidated. This 
limitation is beyond the scope of the experiments in this dissertation, but the potential 
mechanisms of stimulation will be mentioned in the general discussion section. 
Although the doses of rWF-I used in this experiment were comparable to those 
of other studies only the rate of collagen synthesis was increased significantly at the 500 
nglml concentration (Abrahamsson 1991; Murphy and Nmon 1997). As mentioned in 
experiment three, equine SDFT exphts may be less responsive than other tissues 
(Abrahamsson 1991). To c o h  these results a W e r  study was suggested, and cell 
proliferation and ECM synthesis were evaluated in experiment six. 
6.6 Conciusions 
1) Protein (collagen and noncollagen protein) and glycosaminogiycans synthetic rates were 
significady increased in the presence of PSGAG at concentrations higher than 100 pg/ml. 
2) The degree of response to PSGAG appeared to be dose related, with optimal 
concentration for increased synthesis at 1000 to 2000 pg/d in the cuIture medium. 
3) An increased rate of collagen synthesis but not total proline incorporation occurred in 
response to rhlGF-I at 500 ngld  in the culture medium, but no other significant effects were 
obsetved and the response was not demonstrably lineariy dose related over the mncentration 
range tested. 
~HAPTER SEVEN 
7.0 EXPERIMENT 5 : EVALUATION OF THE EFFECT OF DOSE ON THE 
METABOLIC AND PROLIFERATIVE RESPONSES OF EQUINE SDFT 
EXPLANTS TO SODIUM EYALURONATE AND RECOMBINANT HUMAN IGF-I 
7.1 Introduction 
The protocol followed in experiment four produced r d t s  which clearly 
demonstrated the anabolic effects of exogenous PSGAG on explants of  the equine SDFT, 
and validated the pre-treatment culture period of 18 days. In experiments two and b e e  it 
appeared that the response to treatment with HA differed depending upon the pre-treatment 
stabilization period (as reported for PSGAG), with an apparently inhibitory response in 
shorter term cultures, and no demonstrable response in longer term cultures. Statistical 
power calculations using the results of experiments two and three co-ed the need for 
larger treatment groups for compar;.:son of control and treated explants. As demonstrated in 
for PSGAG, the e f f i  of different concentrations may be an important determinant of the 
degree of response, if any, of the SDFT explant cultures to NaHA. 
In experiment four, the addition of rhIGF-I (at doses ranging f?om 50 to 500 ngM) 
to explant cultures of the equine SDFT resulted in the stimulation of only sulfated GAG 
synthesis at 500 @ml. The lack of response in protein synthesis (collagen and nonwllagen 
protein) and the low magnitude of the response to 500 n g h l  rhIGF-I contrast with the large 
dose dependent responses reported in the rabbit ad the horse (Abrahamsson et all99 1 akb; 
mhy and Nion 1997). However, as previously stated, the equine cultures were treated 
with rhIGF-I in the presence of 5% FBS which has high concentrations of growth fictors 
including IGF-I (Jayme 1990; Riley 1994). Unlike these previous studies in which the 
response to rhlGF-I was dependent upon the concentration of the factor in the medium, a 
dose effect was not demonstrated in experiment four. It is possible that the doses of rhIGF-I 
used were too high or too low, or that the equine SDFT is noa-responsive to the rhIGF-I. 
This aim of this experiment is to test the hypotheses that 1) The addition of 
exogenous NaHA at d i f f i  c o n d o m  to arpIant cultures of the equine SDFT will not 
significantly dkzt rates of ceil prolifdon or sulFaed GAG and protein synthesis compared 
to a control group, and 2) The addition of rhIGF-I at different concentrations to explant 
cdtmes of the equine SDFT will not significantly affect rates of cell proliferation or sulfated 
GAG and protein synthesis compared to a control group of cultures. 
7.2 Objectives 
1) To determine the effkcts of NaHA on the rates of cell proliferation and the synthesis of 
protein and suEated GAG in equine SDFT explant cultures at different concentrations. 
2) To determine the effects of rhIGF-I on the rates of cell proliferation and the synthesis of 
protein and sulfated GAG in equine SDFT explant cultures at Werent concentrations. 
7.3 Materials and Methods 
7.3.1 Experimental Animal 
A two-year-old male Quarter horse cross (- 1.5 m at the shoulder), untrained and 
fke ffom clinical evidence of tendon injury, was purchased fiom the Saskatoon Auction Mart 
7.3.2 Establishment of Equine SDFT Explant Organ Cultures 
The tensile portions of the forelimb SDFT's were harvested and expIant cultures 
prepared as per the previously developed protocol. Cultures were maintained on rollers at 
3 6 . ~ 5 . 5 ~ ~  for the duration of the experiment (26 days) and the media (RPMX 1640 
containing proline, 1W DHS, 100 p g l d  ascorbate) was changed every 72 b After an 18 
day pre-treatment period, cultures were treated with diBFerent doses of either NaHA 
(Hyonate*, Bayer Incorporated, Om., Canada) or rhIGF-I (Upstate Biotechnology Inc., 
NY., USA) for six days prior to radio labeling (table 7.1). A total of 246 cultures were 
obtained; six were randomly selected and tested for mycoplarma at day 18. 
Table 7.1: Treatment groups for NaHA and rhIGF-I dose response trials. 
Treatment Concentration Number of i Treatment Concentration Number of 
MW Explants ng/ml Ex plants 
Control* 0 40 i Control' 0 40 
NaHA' 50 40 rh1GF-fl 5 10 
NaHA' 500 40 10 10 
'HyonateQ 20 m g / d  Bayer Incorporated, ONT., Canada, 'rhIGF-I, Upstate Biotechnology 
Inc., NY., USA, 'common control group for rhIGF-I and NaHA 
7.33 Radiolabeling of Equine SDFT Explant Organ Cultures 
Cubes were radiolabeled ["S-sulfate (20 pCi~culture) and ~- [2 ,3 ,4 ,5-~~]  proline 
(20 pCi~culture)] for 24 h at the end of the treatment period (day 24) and chase incubated 
for 12 hours with 2 ml of saum fke medium. Cultures were also labeled with 1 pCilCUIture 
of methyl-C14-thymidine ( SPA 55.0 mCVrnmo1) for 24 h as an index of cell proliferation. 
7.3.4 Determination of Radioactive Isotope Incorporation Rates 
Detennznatrbn of I11coprafron Rates of Radimctive Isotopes by Tendon E r p h t s  
The preparation and scintillation counting of the tendon explants and of the labeled 
media, as well as  the calculation of incorporation rates were performed as described in 
Appendix m. 
Pre-column Derivatizan'on and RP-HPLC 
Aliquots of culture medium were precipitated in 0.15% DOCA and 72%TC& 
incubated for 10 10s at room tempenrture, centrifuged for 30 minutes at 3300 g and the 
supernataat decanted- Each protein pellet was digested in 6M HCI for 24 hours at 1 lo0C and 
then the pH adjusted to 9.0. Aliquots of 40 or 45 pl were derivatized with DABS-CI and 
then Hyp and Pro separated by RE+-HPLC. Fractions corresponding to the Hyp and Pro 
peaks were collected, scintillation cocktail added and the hctions counted on a beta 
counter. The ratio of the counts and a formula accounting for the relative concentrations of 
Hyp and Pro in collagen was used to determine molar rates per mg dry weight of prohe 
incorporation into collagen and nonwllagen protein precipitated Eom the medium. 
7.3.5 Statistical Analysis 
All results were tabulated and their distriiution and variances determined. Extreme 
outliers and negative values were excluded f?om analyses (5 explants). Protein and sulfated 
GAG synthesis and Cen proliferation were compared by parametric one way ANOVA except 
where the requirements of parametric testing were not met. In these cases the Kruskal-Wallis 
non-parametric ANOVA was used and a means comparison performed among treatment 
groups. Significance level was set at p < 0.05, with a trend recognized at p < 0.10. 
7.4 Results 
Cultures submitted were fiee of mycoplasma and bacterial contarnination. 
7.4.1 NaaA Treated Cultures - Total Protein Synthesis 
Mean total proline incorporation rates were greater for the 2000 pg/ml@ < 0.001) 
and 1000 pg/ml@ < 0.10) NaHA treatment groups than the control group (table 7.2). All 
other NaHA groups had incorporation rates significantly greater than that of the 50 pghl  
group @ < 0.02), and the 2000 pglml group had a higher rate than the 1000 pg/ml group @ 
c 0.02), supporting the apparent dose related response obsewed in figure 7.1. 
Table 7.2: Protein synthesis - Mean total prohe incorporation rate per mg dry weight of 
equine SDFT by concentration of NaHA in the medium. 
NnHA Concentration in Proline Incorporation Statistical Groupings 
Medium Wml) Mean + SI) (poVmg) @ < 0.02)' 
o 57.45 5 28.73 A B 
50 42.53 + 23.37 A 
500 62.84 + 26.14 B 
1000 68.44 + 22.88 B 
2000 83.00 2 36.38 C 
Common letters denote that groups were not significantly different fiom each other. 
Protein Synthesis 
NaaA Concentration &mi 
Figure 7.1: Protein synthesis - Mean total proline incorporation rate per mg dry weight of 
equine SDFI' by concenttation of NaHA in the medium (mean + sd pmoVmg dry weight of 
tendon). 
7.4.2 NaHA Treated Cultures - Collagen Synthesis 
Mean proline incorporation rates into collagen were greater for the 2000 pglml@ 
< 0.10) and 1 000 &ml@ < 0.02) NaHA treatment groups than the control (table 7.3). The 
rate of cohgen synhsis was greater in the 2000 pg/ml and 1000 pglml than the 500 pg/ml 
and 50 pdml NaHA treatment groups @ < 0.02) (figure 7.2). 
Cohgen Synthesis 
0 50 500 loo0 2000 
NaHA Concentration llglml 
Figure 7.2: Collagen synthesis - Mean rate of proline incorporation into collagen (in the 
medium) per mg dry weight of equine SDFT by concentration of NaHA in the medium 
(mean + sd pmoVmg dry weight of tendon). 
Table 73: Collagen synthesis - Mean proline incorporation rate into collagent per mg dry 
weight of equine SDFT by concentration of NaHA in the medium 
NaHA Concentration in Proline Incorporation S t a t i s t i d  Groupings 
Medium (Wml) Mean + SD (pmoVmg) (p < 0.05)' 
0 13.09 2 8.51 B C 
2000 21.62 5 15.00 A B 
'Determined by RP-HPLC of digested protein precipitate f?om culture medium; 'common 
letters denote that groups were not significantly different from each other. 
7.43 NaHA Treated Cultures - Noncokgen Protein Synthesis 
Mean proline incorporation rates into noncollagen protein were not significantly 
different among NaHA treatment and the control groups @ > O.OS)(table 7.4). The mean 
nonwllagen protein incorporation rate for the 2000 pglml group was greater than those of 
the 1000 pglml and 50 pghl  NaHA groups @ < O.OS)(figure 7.3). 
Table 7.4: Noncollagen protein synthesis - Mean prohe incorporation rate into noncollagen 
proteint per mg dry weight of equine SDFT by concentration of NaHA in the medium. 
NaHA Concentration Proline Incorporation Statistical Groupings 
in Medium W m l )  Mean + SD @oVmg) @ < 0.02)' 
2000 32.74 + 16.33 A 
betermined by RP-HPLC of digested protein precipitate &om culture medium; 'common 
letters denote that groups were not significantly different fiom each other. 
Noncollagen Protein Synthesis 
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Figure 7.3: Noncollagen protein synthesis - Mean rate of proline incorporation into 
noncoflagen protein per mg dry weight of equine SDFT by concentration of NaHA in the 
medium (mean + sd prnol/mg dry weight of tendon). 
7.4.4 NaHA Treated Cultures - Glycosaminoglycans Synthesis 
Mean total sulFate incorporation rates onto GAGS were significantly greater for the 
2000 pglml than the 5 0 0  pgld, 50 pg/rnl NaHA treatment groups and the control group @ 
< 0.05) (table 7.5). The mean total sulfate incorporation rates were greater for the 1000 
p&I and than the 50 p g M  NaHA group @ < 0.05), lending some statistical support to the 
apparent dose-related response observed in figure 7.4. 
Table 7.5: Giycosamhoglycaus synthesis - Mean total sulfate incorporation rate per mg dry 
weight of equine SDFT by concentration o f  NaHA in the medium. 
NaHA Concentration in Sulfate Incorporation Statistical Groupings 
Medium Wml) Mean + SD (pmoYmg) @ < 0.05)' 
0 162.65 + 80.50 A I3 
50 120.64 + 65.75 A 
500 167.43 + 71.27 B 
1000 176.17 + 60.14 B C 
2000 213.30 + 79.88 C 
' Common letters denote that groups were not s i @ d y  different from each other 
Glycosaminoglycaos Synthesis 
NaHA Concentration &ml 
F i r e  7.4: Giycosaminoglycans synthesis - Mean total sulfate incorporation rate per mg dry 
weight of  equine SDFT by concentration of NaHA in the medium (mean + sd pmoYmg dry 
weight of tendon). 
7.4.5 NaHA Treated Cultures - Cell Proliferation 
The rate of Cen proliferation was lower in the 50 pg/d  NaHA group than the control 
and 2000 pglml NaHA groups @ < 0.05) (table 7.6, figure 7.5). 
Table 7.6: Cell proliferation - Mean thymidhe incorporation rate per mg dry weight of 
equine SDFT by concentration of NaHA in the medium. 
NaHA Concentration Thymidine Incorporation Statistical Groupings 
in Medium (pg/ml) Mean + SD (ClmoVmg) @ < 0.05)' 
2000 13.16 + 3.42 A 
' Common letters denote that groups were not significantly different ftom each other 
Cell Prolifecation 
NaHA Concentration pgfml 
Figure 7.5: Cell Proliferafi01.1- Mean thymidine incorporation rate per mg dry weight equine 
SDFT by concentration of NaHA in the medium (mean + sd pmoVrng dry weight of tendon). 
7.4.6 NaHA Treated Cultures - Tendon Explant Dry Weight 
There were no significant differences in mean equine SDFT explant dry weights 
among NaHA treatment and control groups (table 7.7, figure 7.6). 
Table 7.7: Tendon Explaot hy Weight - Mean tendon explant dry weight by concentdon 
of NaHA in the medium, 
NaHA Concentration in Explant Dry Wt Statistid Grouping 
Medium W m l )  Mean + SD mg 
0 11.37 2 3.79 A 
2000 11.53 2 3.46 A n 
Common letters denote that groups were not significantly Werent from each other. 
Tendon Explant Dry Weight 
NaaA Concentration &ml 
Figure 7.6: Tendon Explant Dry Weight - Mean equine SDFT explant dry weight by 
concentration of NaHA in the medium (mean + sd mg dry weight of tendon). 
7.4.7 rhIGF-I Treated Cultures - Total Protein Synthesis 
Mean total proline incorporation rates were sigdicantly greater for all rhIGF-I 
treatment groups than the control group @ < 0.0 1) (table 7.8, figure 7.7). 
Table 7.8: Protein synthesis - Mean total proline incorporation rate per mg dry weight of 
equine SDFT by concentration of rhIGF-I in the medium. 
rhIGF-I Concentration Proline Incorporation Statistical Groupings 
in Medium (ng/ml) Mean + SD (pmollmg) (p < 0.01)' 
0 57.45 2 28.73 A 
100 123.78 + 57.21 B 
' Common letters denote that groups were not sigdicandy dierent f?om each other. 
Protein Synthesis 
5 
rhlGF Concentration nglml 
Figun 7.7: Protein synthesis - Mean total proline incorporation rate per mg dry weight of 
equine SDFT by concentration of rhIGF-I in the medium (mean + sd pmoVmg dry weight 
of tendon). 
7.4.8 rhIGF-I Treated Coltares - Collagen Synthesis 
Mean prohe incorporation rates into collagen were significantly greater in al l  except 
the 5 ng/ml rhIGF-I groups than the control group@ < O.Ol)(figure 7.8, table 7.9) 
Table 7.9: Collagen synthesis - Mean prohe incorporation rate into collagen? per mg dry 
weight of equine SDFT by concentration of MGF-I in the medium. 
MGF-I Concentration in Proline Incorporation Statistid Groupings 
Medium (ng/ml) Mean + SD (pmoVmg) @ < 0.05)' 
0 18.04 + 15-20 A 
100 36.27 4 28.44 B 
'Determined by RP-HPLC of digested protein precipitate fiom culture medium; 'common 
letters denote that groups were not sigruticantly different Corn each other. 
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Figure 7.8: Collagen synthesis - Mean rate of proline incorporation into collagen (in the 
medium) per mg dry weight of equine SDFT by concentration of rhIGF-I in the medium 
(mean + sd jmohg dry weight of tendon). 
7.4.9 rhIGF-I Treated CuItures - Noncollagen Protein Synthesis 
Mean proline incorporation rates into noncollagen protein were significantly greater 
in aIl rhIGF-I groups than the control group @ < 0.0 1) (figure 7.9, table 7.10). 
Table 7.10:Nonmllagen protein syntbesistt~ean proline incorporation rate into noncollagen 
protein per mg dry weight of equine SDFT by concentration of rhIGF-I in the medium 
rhIGF-I Concentration in Proline Incorporation Statistical Groupings 
Medium (n%ml) Mean 2 SD (pmomg) @ < 0.05)' 
0 24.52 4 15.63 A 
5 52.72 5 25.64 B 
'Determined by RP-HPLC of digested protein precipitate fiom culture medium; 'common 
letters denote that groups were not sigmficantly different fiom each other. 
Noncollagen Protein Synthesis 
0 5 10 25 100 
dGF-I Concentration nglml 
Figure 7.9: Nonwllagen protein synthesis - Mean rate of proline incorporation into 
nondlagen protein per rng dry weight of equine SDFT by concentration of rhIGF-I in the 
medium (mean + sd pmolhg dry weight of tendon). 
7.4.10 rhIGF-I Treated Cdtures - Gtycosaminoglycan Synthesis 
Mean total sulffte incorporaiion rates onto glycosaminoglycans were not significantly 
different among rhIGF-I treatment and control groups @ > 0. I O)(table 7.1 1, figure 7.1 0). 
Table 7.11: Glycosaminoglycans synthesis - Mean total sdkte incorporation rate per rng 
dry weight of equine SDFT by concentration of rhIGF-I in the medium. 
rhIGF-I Concentration Sulfate Incorporation Statistical Groupings 
in Medium (nglml) Mean + SD (pollmg) @ < 0.01)' 
0 162.65 i 80.50 A 
5 289.74 & 118.36 B 
10 359.55 + 115.02 B 
25 370.25 + 121.28 B 
100 352.69 160.3 1 I3 
' Common letters denote that groups were not significantly different &om each other 
Glycos arninogtycans Synthes h 
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Fire 7.10: Glycosaminoglycans synthesis - Mean total sulfate incorporation rate per mg 
dry weight of equine SDFI' by concentration of dGF-I  in the medium (mean + sd pmoVmg 
dry weight of tendon). 
7.4.11 rhIGF-I Treated Cuitures - Cell Proliferation 
Mean rates of cell proLiferation as determined by thymidine incorporation were 
significantly greater in all except the 5 n g M  rhIGF-I treatment groups than the control 
group@ < 0 .OS)(figure 7.1 1, table 7.12) 
Table 7.12: Cell Proliferation - Mean thymidine incorporation rate per mg dry weight of 
equine SDFT by concentration of rhIGF-I in the medium. 
rhIGF-I: Concentration Thymidine Incorporation Statistical Groupings 
in Medium (ng/ml) Mean + SD (IrmoVmg) (p < 0.05)' 
0 13.62 5 3.80 A 
5 16.21 + 3.48 A B 
10 19.12 5 3.58 B 
25 19-25 5 4.39 B 
100 18.50 2 4.51 B 
Common letters denote that groups were not significantly different f?om each other.. 
Cell Proliferation 
Figure 7.11: Cell Proliferation - Mean thymidine incorporation rate per mg dry weight of 
equine SDFT by concentration of rhIGF-I in the medium (mean + sd d m g  dry weight 
of tendon). 
7.4.12 rhIGF-I Treated Cultures - Tendon Explant Dry Weight 
There were no significant differences in mean equine SDFT explant dry weights 
among rhIGF-I treatment and control groups (table 7.13, figure 7.12). 
Table 7.13: Tendon Explant Dry Weight - Mean tendon explant dry weight by 
concentration of MGF-I in the medium, 
---- - 
rhIGF-I Concentration in Explant Dry Wt Statistical Grouping 
Medium ng/ml Mean + SD mg 
0 11.37 + 3.79 A 
100 12-79 2 6.09 A 
' Common letters denote that groups were not sipficantly different fiom each other. 
Tendon Explant Dry Weight 
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Figure 7.12: Tendon Explant Dry Weight - Mean equine SDFT explant dry weight by 
concentration of rhIGF-I in the medium (mean + sd rng dry weight of tendon). 
7.5 Discussion 
Explant dry weights were distniuted homogeneously among groups and cultures 
submitted for evaluation were mycoplasma eee. 
Increases in rates of total proline incorporation into protein, collagen synthesis and 
sulfated GAG synthesis were obmed for the higher doses ofWaHA There were differences 
in protein and GAG synthesis between high, intermediate and low concentrations o f N m  
indicative of a dose dependent response. However, the latter two groups were not 
significantly different h m  the control group. The response of the 50 pghl  group appeared 
to indicate inhi'bition of synthetic responses at low concentrations. The upper concentration 
of NaHA used (2000 pg/rnl) was determined by the commercial preparation itself which at 
20 mg/ml, represented 20% of the volume of the medium (which was corrected to ensure 
equal nutrient and serum concentrations among groups). Higher doses could be evaluated 
ifmore concentrated forms of the product became available, with caution given to the effect 
such preparations may have on medium osmolality. Cell proliferation did not appear to be 
affected by NaHA in this experiment. The anabolic responses demonstrated for NaHA 
require experimental confirmation (experiment six). 
All synthetic rates were increased in the presence of rhIGF-I. This occurred in 
contrast to the previous experiments, all of which examined the response to rhIGF-I to 
doses greater than 100 ng/rnl. The hone used in this experiment was slightly younger than 
that used in experiment four, and may have contributed to the response observed. However, 
although the increase fiom 25 ng/ml to 100 ng/ml was four-fold, a concomitant four-fold 
increase in synthesis did not occur. This latter faa suggests that &n higher doses are 
unlikely to increase the response obsewed, or may even be inhibitory. 
7.6 Conciusions 
1) Protein (collagen but not noncollagen protein) and gIycosaminoglycans synthetic rates, 
but not cell proliferation, were significantly increased in the presence of NaHA at 
concentrations of 1000 pg/d or 2000 pgM. 
2) The degree of response to NaHA appeared to be dose related, however values for 
concentrations lower than 1000 pghd were not sigrtificantly different from the controls. 
3) The responses to NaHA at 50 pg/d  may be &'bition of protein and GAG synthesis. 
4) An increase in rates of protein synthesis (coUagen and noncollagen protein), sulfated GAG 
synthesis, and cell proliferation occuned in response to rhIGF-I at doses greater than or 
greater than and equal to 5 ng/ml in the culture medium. 
5) The response to aGF-I  was not demonstrably dose related over the concentration range 
tested. 
CHAPTER EIGHT 
8.0 EXPERIMENT 6 : COMPARISON OF THE METABOLIC AND CELL 
PROLIFERATION RESPONSES OF EQUINE SDFI' EXPLANTS TO 
POLYSQLF'ATED GLYCOSAMINOGLYCANS AND SODIUM EYALURONATE 
8.1 Introduction 
The protowl followed in experiment four and five produced red ts  which 
demonstrated anabolic effects in response to exogenous PSGAG and NaHA respectively on 
explants of the equine SDFT. However, previous work in the horse has demonstrated 
variation in biochemical composition and in the biological response to tissue culture (Riley 
1994; Bailey ei d unpublished data). Therefore reproduction of the results were considered 
necessary to confirm the observations made in the chapters six and seven. 
In the rabbit PSGAG, chondroitin bsulffte, chondroitin C d f k t e  and other individual 
&ted GAGS have been shown to increase HA synthesis of the h e e  synovid membrane 
( N i i  et aZ 1985). In experiment four it was indicated that cell proliferation and synthesis 
of HA should be measured in order to obtain fUrther information on the effect of PSGAG. 
The latter parameter can be readily measured by radioimetric assay of HA in the culture 
medium (Tengblad 1980). However for NaHA treated cultures it would be necessary to use 
radiolabeled NaHA or glucosamine to distinguish the exogenous HA fiom the newly 
synthesized HA, followed by dialysis and chromatographic separation (Nishika et al1985). 
The development of such a protowl is beyond the scope of this study so HA measurement 
be limited to radiometric assay of the medium fkom PSGAG treatment and control groups. 
The response of the explants to PSGAG appeared to be more marked than that of 
the explants exposed to N m  as was the apparent dose - response relationship over the 
comparable portions of the dose ranges. Critical evaluation of these obsenations requires 
comparisor~ of the two drugs at similar levels. Determining molarity of the formulations was 
beyond the scope of the current study. Therefbre NaHA and PSGAG were compared on the 
basis of weight per unit volume at a high end dose. The suspected inhibitory effect of low 
concentrations of HA (50 pg/ml) also required further investigation with an increase in 
samples size per group to ensure adequate statistical power. 
This aim of this experiment is to test the hypotheses that 1) There are no differences 
in the rates of protein and GAG synthesis, or cell prolifition between equine SDFT explant 
adtures exposed to exogenous NaHA or PSGAG at equivalent concentrations, and 2) The 
addition of NaHA at high and low concenfradons to explant cultures of the equine SDFT will 
not si@cantly afkct rates of cell proliferation, sulfated GAG and protein synthesis 
compared to a control group of cultures. 
8.2 Objectives 
1) To compare the effects of NaHA (1000 pg/ml) and PSGAG (1 000 pg/ml) to each other 
and to a control group (0 pglml) on the rates of cell proliferation, protein (collagen and 
noncollagen protein) and GAG (sulfated and nonsulEated HA) synthesis of equine SDFT 
explant cultures at different NaHA concentrations. 
2) To determine the e E i  of NaHA on the rates of cell proliferation, protein (collagen and 
nonwllagen protein) and sulfated GAG synthesis of equine SDFT explant cultures at 50 
pglml and 1000 pg/ml. 
8.3 Materials and Methods 
8.3.1 Experimental Animal 
A two-year-old f d e  Thoroughbred (- 1.5 m at the shoulder), untrained and fie 
from clinical evidence of tendon injury, was purchased Itom a local farm. 
8.3.2 Establishment of Equine SDFT Explant Organ Cultures 
The tensile portions of the forelimb SDFT's were harvested and explant dtures 
prepared as per the previously developed protocol. Cultures were maintained on rollers at 
36.59S°C for the duration of the experiment (26 days) and the media @PMi 1640 
containing proline, with 10% DIIS and 100 p g h l  ascorbate) changed wery ?2 h unless 
0th- indicated. AAer a pre-treatment period of 18 days, cultures were exposed to either 
NaHA or PSGAG for six days prior to radio labeling (table 8.1). A total o f  246 cultures were 
obtained; six were randomly selected and tested for mycoplasma at day 18. 
Table 8.1: Treatment groups for comparison of NaHA and PSGAG. 
Treatment Concentration pg/ml Number of Explants 
Control 0 70 
PSGAGS 1000 70 
'Hyonatea 20 mg/ml, Bayer Incorporated, OW., Canada. '~dequan" 100 mg/ml, 
Shirley, NY., USA 
8.3.3 Radiolabeling of Equine SDl?T Explant Organ Cultures 
Cultures were radiolabeled with 3sS-dfkte (20 pcidculture, SPA 1497 Ci/mmol) and 
L-[2,3,4,5-3Hl proline (20 pCilculture, SPA 114.0 Ci/mmol) for 24 h at the end of the 
treatment period (day 24) and chase incubated for 12 hours as per the established protocol 
with 2 ml of serum free medium. Cultures were also labeled with 1 pCi/dture of methyl- 
C1-thymidine (SPA 55.0 mCilmmol) as an index of cell proliferation for 24 h. Twenty 
control and 20 PSGAG explants were not radiolabeled but were harvested and stored for 
possible later analyses. 
83.4 Determination of Radioactive Isotope Incorporation Rates 
Detenninarion of I11~01poration m e s  of Radioactive Isotoopes by T d n  Erplants 
The preparation and scintillation counting of the tendon explants and of the labeled 
media, as well as the calculation of incorporation rates were performed as described in 
Appendix III. 
Pre-column Derivutization and RP-HPLC 
Aliquots of culture medium were precipitated in 0.15% DOCA and 72%TCA, 
incubated for 10 minutes at room temperature, centrifuged for 30 minutes at 3300 g and the 
supernatant decanted. Each protein pekt was digested in 6M HCl for 24 h o w  at 1 1 o°C and 
then the pH adjusted to 9.0. Aliquots of 40 or 45 pl were derivatized with DABS-Cl and 
then Hyp and Pro separated by RP-HPLC. Fractions corresponding to the Hyp and Pro 
peaks were collected, scintillation cocktail added and the fkdons  counted on a beta 
counter. The ratio of the counts and a formula accounting for the relative concentrations of 
Hyp and Pro in collagen was used to determine molar rates per mg dry weight of prohe 
incorporation into collagen and noncollagen protein precipitated from the medium. 
8.3.5 Determination of Rates of Hyduronate Synthesis 
A commercial radiometric assay kit was used for determination of concentrations of 
HA in the serum fiee medium (Phannacia HA Test, Phannacia AB, Sweden). Briefly, 100 
jd aliquots of PSGAG, control and standard HA solutions were added to 200 pl of 
hyaluronic acid binding protein (HABP-'tSI) in duplicate. Following an hour at 4*C, the 
mixture was incubated with 100 pl of HA-Sepharose at 4OC for an hour. The liquid was 
decanted and the remaining radioactivity measured in a gamma counter. The response is 
inversely proportional to the concentration of the HA A standard a w e  was constructed, 
and the HA concentration of PSGAG and control samples determined fiom this a w e .  
8.3.6 Statistical Analysis 
All resuks were tabulated and their and variances determined. Extreme 
outliers and negative values were exchded from d y s e s  (3 explants). Data were compared 
by parametric one-way ANOVA unless one of the conditions for parametric testing were not 
met. In this instance, the Kruskal-Wallis non-parametric ANOVA was used a d  a means 
comparison performed among treatment groups. Significance level was set at p < 0.05, with 
a trend recognized at p < 0.10. 
8.4 Results 
Cultures were fiee of mycoplasma, and bacterial contamination did not occur. 
8.4.1 Total Protein Synthesis 
Mean total prohe incorporation rates were greater for the PSGAG group than all 
other groups (p < 0.01). The mean total proline incorporation rate for 1000 pg/d NaHA @ 
c 0.0 1) and 50 pgh l  NaHA (p < 0.02) treatment groups were greater than that of the 
control group but not significantly different fiom each other (table 8.2, figure 8.1). 
Table 8.2: Protein synthesis - Mean total proline incorporation rate per mg dry weight of 
equine SDF'I' by treatment group. 
Treatment Group Proline Incorporation Statistical Groupings 
Mean + SD pmoVmg @ < 0.02)' 
Control (0 P&/W 32.84 5 7.90 A 
NaHA (50 pdml) 36.75 + 8.71 B 
NaHA (1000 pg/d) 38.44 + 6.23 B 
PSGAG (1000 pglml) 43 -26 2 6.94 C 
Common letters denote that groups were not significantly different fiom each other. 
Rotein Synthesis 
I 
Control NaHA NaHA ISGAG 
0 SO loo0 loo0 
Treatment & Concentrationpghnl 
F i r e  8.1: Protein synthesis - Mean total proline incorporation rate per mg dry weight of 
equine SDFT by treatment group (mean + sd pmoVmg dry weight of tendon). 
8.4.2 Collagen Synthesis 
Mean proline incorporation rates into collagen were sigolficantly greater for the 
PSGAG and 50 pg/ml NaHA groups (p < 0.0 I), and tended to be greater in the 1000 pglml 
NaHA group (p < 0.10) than the control group (table 8.3). The rate of collagen synthesis 
was greater in the PSGAG group than the 1000 pg/ml NaHA group @ < 0.05) (figure 8.2). 
Table 8.3: Collagen synthesis - Mean proline incorporation rate into collagent per mg dry 
weight of equine SDFT by treatment group. 
Treatment Group Proline Incorporation S t a t i s t i d  Groupings 
Mean + SD p o V m g  @ < 0.05)' 
Control (0 P ~ M )  3.34 + 1.98 A 
NaHA (1000 pg/ml) 4.12 2 1.71 A B 
NaHA (50 P @ )  4.90 5 3.22 B C 
PSGAG (1000 &ml) 5.47 5 2.3 1 C 
'Determined by RP-HPLC of digested protein precipitate &om culture medium; 'common 
letters denote that groups were not significantly different fiom each other. 
CoIlagen Synthesis 
Control NaEA NaHA PSGAG 
0 50 loo0 lo00 
Treatment & Concentration d m 1  
Figure 8.2: Collagen synthesis - Mean rate of proline incorporation into coUagen (im the 
medium) per mg dry weight of equine SDFT by treatment group (mean + sd jmoVmg dry 
weight of tendon). 
8.43 Noncollagen Protein Synthesis 
Mean proline incorporation rates into noncollagen protein were significantly greater 
for the PSGAG group than the control group @ < 0.05), but there were no other sigdicant 
differences among groups (table 8.4, figure 8.3). 
Table 8.4: Noncollagen protein synthesis - Mean proline incorporation rate into noncollagen 
proteinT per mg dry weight of equine SDFT by treatment group. 
- 
Treatment Group Proline Incorporation Statistical Groupings 
Mean + SD p o V m g  @ < 0.05)' 
Control (0 ~ g f m  6.22 2 2.60 A 
NaKA (50 ~g/ml) 7.15 5 3.56 A B 
NaHA (1000 pg/d) 7.19 + 2.92 A B 
PSGAG (1000 pdd)  7.96 If: 3.99 B 
betermined by RP-HPLC of digested protein precipitate fiom d t u r e  medium; 'common 
letters denote that groups were not significantly different fkom each other. 
Noncollagen Protein Synthesis 
Control 
0 
Treatment & Concentration d m 1  
PSGAG 
1000 
Figure 8.3: Noncollagen protein synthesis - Mean rate of proline incorporation into 
noncollagen protein per mg dry weight of equine SDFT by treatment group (mean + sd 
pmovmg dry weight of tendon). 
8.4.4 Sulfated Giycosaminoglycans Synthesis 
Mean total sulfate incorporation rates onto sulfated GAGS were significantly greater 
fw PSGAG than all other groups @ < 0-Ol), and for the 1000 pghl NaHA group than the 
SO pglml NaHA and wntroI groups @ < 0.0 1) (table 8.5, figure 8.4). 
Table 85: GQmsaminogh/cans synthesis - Mean total sulfate incorporation rate per mg dry 
weight of equine SDFT by treatment group. 
Treatment Group Sulfate Incorporation Statistical Groupings 
Mean + SD pmoVmg @ < 0.01)' 
Control (0 cldml) 71.17 + 18.76 A 
NaHA (50 ~ g / m l )  76.60 + 22.02 A 
NaHA (1000 pg/ml) 91.22 2 15.88 B 
PSGAG (1000 @ml) 102.15 + 19.89 C 
Common letters denote that groups were not signrficantly different fiom each other 
Glycosaminoglycans Synthesis 
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Figure 8.4: GlycosaminoBtycans synthesis - Mean total sulfate incorporation rate per mg dry 
weight of equine SDFT by treatment group (mean + sd pmoVmg dry weight of tendon). 
The rate of HA synthesis was significantly reduced for the PSGAG group compared 
to the control group @ < O.O01)(table 8.6, figure 8.5). 
Table 8.6: Hyaluronate synthesis - Mean rate of hyaluronate synthesis rate per mg dry 
weight of equine SDFT by treatment group. 
Treatment Group Hyaluronate Synthesis Statistical Groupings 
Mean + SD nmoVmg @ < 0.001)' 
control (0 km) 6.46 + 2.46 A 
PSGAG (1000 pglml) 3 -49 5 1.94 B 
' Letters denote that groups were significantly Merent from each other 
Eyalumnate Synthesis 
Control 0 PSGAG 1000 
Treatment & Concentration pg/ml 
Figure 8.5: Hyaluroaate Synthesis - Mean rate of HA synthesis rate per mg dry weight of 
equine SDFT by treatment group (mean + sd pmoUmg dry weight of tendon) 
8.4.6 Cell Proliferation 
The rates of cell proIiferation were significantly greater for the PSGAG group than 
an other groups @ < 0.0 I), and for the 1 OW pg/d NaHA group than the 50 pg/ml NaHA 
group but not the control group when differences in dry weight were controlled for (table 
8.7, figure 8.6). 
Table 8.7: Cell proliferation - Mean thymidine incorporation rate per mg dry weight of 
equine SDFT by treatment group. 
Treatment Group Thymidine Incorporation Statistical Groupings 
Mean + SD nmoYmg (p < 0.01)' 
PSGAG (1000 pg/ml) 5.00 + 0.78 C 
Common letters denote that groups were not si@cantly different from each other 
Cell hliferation 
E 
Control NaEA NaaA 
0 50 lo00 
Treatment & Concentration &ml 
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1000 
Figure 8.6: Cell ProWeration - Mean thymidine incorporation rate per mg dry weight of 
w e  SDFI' by treatment in the a h r e  medium (mean + sd nmoVmg dry weight of tendon) 
152 
8.4.7 Tendon Explant Dry Weight 
There were significant differences in mean equine SDFI' explant dry weights among 
the control, PSGAG and 1000 pdml NaHA treatment groups (table 8.8, figure 8.7). The 
differences were controlled for in the statistical comparisons above, and did not alter the 
results of statistical comparisons except for cell prolifefafion 
Table 8.8: Tendon Explant Dry Weight - Mean explant dry weight by treatment group. 
Treatment Group Explant Dry Wt Statistical Grouping 
Mean + SD mg @ < 0.05)' 
Control (0 P&W) 2 1.06 2 4.80 A 
NaHA (50 ~g/ml) 19.3 1 + 4.79 A B 
NaHA (1000 P~M) 18.29 + 4.13 B 
PSGAG (lOOOpg/ml) 18.51 k4.41 B 
'Common letters denote that groups were not signifkantly different &om each other. 
Tendon Explant Dry Weight 
Control NaaA 
Treatment & Concentration j@d 
PSGAG 
loo0 
Figure 8.7: Tendon Explant Dry Weight - Mean equine SDFT explant dry weight by 
treatment group (mean + sd mg dry weight of tendon). 
8.5 Discussion 
In contrast to Scperiments £bur and five, explant dry weights mered among groups 
by - 1%. The power of this experiment was greater than the former two, and therefore may 
have permitted detection of this difference. The reduction in dry weight may be indicative 
of general metabolic stimulation - both anabolic and catabolic but this remains to be 
confirmed However when this &kt was controlled for, the outcome of comparisons of the 
other variables, except cell proliferation (NaHA group) was not affkcted. Cultures submined 
for mycoplasma evaluation were mycoplasma fiee. 
Increases in rates of total proline incorporation into protein for all treatment groups 
confirmed the results obtained in experiments four and five but the response to PSGAG was 
more marked. Although cuIlagen synthesis was increased for the PSGAG and NaHA groups, 
only P S GAG treatment resulted in greater nonwllagen protein synthesis. Therefore it 
appears that PSGAG is more potent in stimulating protein synthesis than NaHA when 
compared on a weight basis. 
Sulfated GAG synthesis was most marked in response to PSGAG followed by 1000 
p g h l  NaHA However HA synthesis (nonsulfated GAG) was significantly decreased in the 
PSGAG group. This laner result suggests that the effect of PSGAG is selective with respect 
to the its effects on GAG metabofism. 
8.6 Conclusions 
1) Protein, dfhted GAG synthetic rates and cell proliferation in explant culNes of the 
equine SDFT were significantly increased by exogenous PSGAG or NaHA 
2) The degree of responses to 1000 pdml PSGAG was more marked than that of cultures 
exposed to 1000 pg/ml NaHA 
3) In contrast to sulfated GAG synthesis, HA synthesis was markedly decreased in the 
presence of PSGAG. 
4) A significant decrease in explant dry weight occurred in response to exogenous PSGAG 
and NaHq suggesting a possible catabolic effect of these drugs. 
5) NaHA at 50 pglml does not result in inhibition of protein, sulfated GAG synthesis or cell 
proliferation. 
CHAPTER NINE 
9.0 GJ3lWM.L DISCUSSION 
9.1 General Consideration of the Model 
The basic tool utilized for determination of the metabolic responses of the equine 
SDFT to pharmacologic agents was a modification of a previously developed explant tissue 
culture system (Riley 1994; Riley el d 1996). Representative in virro tis~de culture models 
have been highly valued as devices for studying the biological or biochemical responses of 
tendon at the cellular and molecular level to cytokines and drugs during the repair phase of 
tendon healing (Graham et d 198 1; Gelberman et al1984; Manske et al 1984; Mass and 
Tuel 199 1; Russell and Mmke 1991; Dahlgren et a2 1997; Murphy and N ~ o n  1997). 
ExpIant models have been fhvoured by many workers because they preserve and permit the 
study of cell-matrix interactions which are considered an essential part of the homeostatic 
mechanism and repair process in comeaive tissues (Parry et a2 1982; Vogel et a2 1984; 
Scott 1988; Scott 1990; Abrahamsson 1991; Mass and Tuel 1991; Russell and Manske 
1991). This approach has been supported in recent literature as a suitable technique for 
investigating the effects of pharmaceutical agents and growth factors on the equine SDFT, 
whereas other workers have employed simple cell cultures for such studies (Riley et d 1996; 
Dahlgren et uZ19%; Dahlgren et al1997; Mbqhy and Nucon 1997). The use of RPMl1640 
and 10% DHS in this study was based on extensive comparisons of different sera and media 
which found this combination to permit satisfactory detection of newly synhesized ECM 
molecules with reduced variance of results compared to fetal sera or other media @ley et 
d1996). It was also felt that this model that was more representative of the in vivo repair 
phase of tendon healing than models employing fetal senun (Riley et a2 1996; Dahlgren et 
al19%; Dahlgren et al1997; Murphy and Nmon 1997). The major limitations of the SDFT 
explant model used in this study are that, although tendon 'healing' in vitro has many 
similarities with healing in vivo, it proceeds at a slower rate, does not permit study of the 
effect of systemic homeostatic mechanisns on tendon repair, and limits the study of cell-cell 
interactions, other than those between the tenocytes themselves (Gelberman et al 1984; 
Manske et aZ 1984). To overcome the slower rate of progression the cultures were 
mahtained long-term, reqgizhg that the effects observed may differ f?om those observed 
in short-term witures (Abrahamsson et a2 1991qb). Despite these limitations, it was possible 
to determine changes in the rates of protein synthesis (collagen and noncollagen protein), 
polysulfated GAG synthesis, HA synthesis and cell proliferation of tissue f?om the equine 
SIlFT in responses to exogenous PSGAG, NaHA and rhIGF-I. 
9.2 Experimental Animals 
Ideally animals should be single sourced and of the same sex, breed, age and strain 
to eliminate inter-animal variation as a confounding variable. In the chick, rat, cow and to 
a lesser degree the horse, differences in the histologic and biochemical composition of 
tendons with age have been demonstrated (Scott 1980; Vogel and Evanko 1987; Scott and 
Hughes 1986; Vogel and Heinegard 1985; Scott 1988; McCallion and Ferguson 1996; 
Smith and Webbon 1996). Although it is possible to study identically aged litter mates in the 
rat, mouse and rabbit studies, it is dEa& to attain such rigorous standards in canine studies, 
and not currently possible in equine studies (Abraharnsson et a2 lggla, b; Abrabamsson el 
al 1994; Riley et al 1996). The age of the animal has also been demonstrated to be an 
important determinant of in uitro responses, with greater rates of biosynthesis and cell 
prolifdon generally attained using fetal or immature tissues (Freshney 1987). An attempt 
was made in the current study to obtain tendons fkom young horses approaching skeletal 
maturity so that the biosynthetic potential of younger animals could be used and the 
b e n t  for in v iw approximate represensation of tendons in which disease occun could 
be maintained. The six horses used for the entire study ranged fkom 14 months to 3.5 years 
in age (mean 2.3 years; median 2 years). There were three of each sex, and two Quarter 
horses, two Quarter horse crosses, a Thoroughbred cross and a purebred Thoroughbred 
horse. When the horse that was used for development of protocols in experiment one is 
excluded, the range of ages for comparisons of responses to different ppharmacologic agents 
was from 2 years to 3.5 years (mean 2.5 years; median 2 years). Previous studies by Riley 
et aZ and Bailey et aZ have demonstrated significant variation between horses with respect 
to biochemical composition and biologic responses in M'tro, even when horses were closely 
matched for breed and age (Riley ef al1995; Bailey ef all996; Riley et a! 1996). Despite 
these liO;litations, an effort was made to obtain young untrained, and SDFT injury f i e  horses 
of similar type and size. However, as observed in the previous studies, siguficant differences 
occurred in control values for proline, sulfate and thymidine incorporation between horses. 
This made confirmation of metabolic changes in response to PSGAG or NaHA necessary by 
examining dtures &om more than one horse. Experiment six confirmed most of the 
observations made in experiments four and five. 
9.3 Discussion of Culture and Analytical Techniques 
93.1 Equine SDFT Explant Cultures 
Some of the variation in the current model was thought to be due to variation in 
explant size. This problem which was reduced by the use of a standard-sized biopsy punch 
and the complete exclusion of the epitendon or peri-tendinous tissue in these experiments. 
There was some variation in explant dry weight between horses. However, within horses at 
a given time period there were no significant differences detected between groups, except 
in experiment six (which had 50 explants per group). Standard deviations for explant dry 
weights were smaller than those attained in previous work and variances equivalent in the 
definitive experiments (Riley 1994). The decline in weight over time in experiment three 
suggested accelerated catabolism either by enzymes of tendinous origin, or exogenous origin. 
Since this &kt  had not been obsened in the earlier experiments in the present or previous 
study and there was no evidence of fungal or bacterial infection, infection with mywplasma 
was coosidered the most likely cause (Freshney 1987; Riley 1994; k Richardson - personal 
communication). Mycoplasma testing was incorporated as part of the protocol of 
Bcperiments fbur, five and six. The small but significant differences observed in explant dry 
weight in experiment six may have been a response to treatment with either PSGAG or 
NaHq suggesting that these drugs may exert both anabolic and catabolic e f f i s .  Changes 
in dry weight were not obsmed in experiments four and five. However, sample sizes of at 
least 50 and 500 respectively, (based on sample size calculations), would have been required 
to identify the presence any differences that may have been present. In fimue experiments 
where there is sutficient tissue, a number of representative explants may be collected 
following harvest from the horse for dry weight determination and compared to those 
explams weighed at the end of the cuhure period. Unfortunately there were too few explants 
available for this purpose due to the desire to m a x h k  the number of cultures per horse and 
minimize the number of animals used for the study. 
. 
The size of the explants was smaller than those prepared for the previous study so 
the volume of medium was reduced accordingly to reduce the costs of each experiment 
(Riley 1994). There was no evidence of necrosis or cellular death as a consequence of these 
changes based on haematoxylin and eosin or BrdU stained sections of explants (experiment 
one), and cells were proliferating in these sections at the time of harvest. Later experiments 
confirmed that cells were synthesizing DNA proliferating, determined by incorporation of 
radiolabeled thymidine. Although antimicrobial agents were not used after the preparation 
of the cultures, rates of bacterial or fungal contamination were minimal (1 to 2 expiants) to 
nil when cultures were maintained for up to four weeks. 
93.2 Radiolabeling and Determination of Radioactive Isotope Incorporation Rates 
It has been established that the equine SDFT is metabolically active, but the rates of 
synthesis of ECM components are low in the mature hone (Birch 1993; Riley 1994). 
Therefore, assays which are parti&y sensitive and have a reasonable degree of specificity 
are necessary for e m h i o n  of synthetic responses in this tissue. In previous work using this 
equine SDFT model, colorimetric methods for the measurement of protein in the culture 
medium were not sensitive enough, and did not differentiate between newly synthesized 
protein and protein bemg lost or d i f l b i q  from the explants (Watanabe et d1986; Freshney 
1987; Boyer 1991; Riley 1994). Radio labelling of explants and cell cultures with "S-sulfate, 
'H- or *%-proline and ?H- or "C-thymidine have been widely accepted as tools for the 
measurement of PGs (GAGS) synthesis, collagen synthesis and cell proliferation respectively 
in tendon explant culture studies (Manske et a2 1978a; Manske and Lesker 1982; Qrunones 
et al1986; Abrahamsson et al1989qb; Abrahamsson et al1994; Dahlgren et a2 1996; Riley 
et d 1996; Murphy and Nmon 1997). After incubation with the isotopes, chase incubation 
with isotope-fke medium is recommended to ensure movement of incorporated 35S-suIfate 
and %-proline fbm the h t m c e h h  pool to the extracelIular pool and was performed in the 
current study (Vogel and Peterson 1981; Abrahamsson et d 1989b). Radio isotopes which 
were not incorporated were removed fiom the medium by size exclusion chromatography 
(m cut-off of 6000). Therefore unbound isotopes and those incorporated into short peptide 
sequences or short GAG chains not bound to a protein core were excluded from the 
measurement of incorporation rates. 
Several workers have reported using 35S-sulfate incorporation in order to determine 
rates of PG synthesis (Abrahamsson 1991; Abrahamsson 1994; Dahlgren et a2 1996 
Dahlgren et al1997). There are several possible sources of error in this assumption, and little 
attention has been devoted to these limitations in the literature. The first is that the number 
of sulfded GAG chains per PG molecule varies fiom one or two per protein core for decorin 
and biptycan respedvely and up to 100 for aggrecan (Jackson et u2 199 1 ; Kresse et a2 1993; 
Gallo and Bernfield 1996). Therefore, there may be a poor correlation between 3sS-sulfate 
incorporation and PG concentraton d e s s  synthesis of one PG species predominates. Ideally 
the PGs should be isolated, the types of PG present identified, and the number of GAG side 
chains per molecule determined. However, due to the difficulties associated with isolating 
these highly anionic molecules relatively few have been characterized (Jackson et a2 199 1). 
Therefore, the level of "S-dfkte incorporation most accurately reflects rates of sulfated 
GAG synthesis rather than PG per se. In the SDFT the predominant GAGs are the 
galactosaminoglycans CS and DS, with lesser amounts of KS (Birch 1993; Bailey et al 
unpublished data). Because CS and DS have three d a t e d  esters per disaccharide, and KS 
has one to two sulfated esters per disaccharide, 35S-suEate incorporation is better correlated 
with sulfated GAG synthesis than PG synthesis (Gallo and Berniield 1996). The types of 
GAGs produced h vim in this study were not determined and although likely to be similar 
in type to those isolated ex vivo, this cannot be assumed to be so (Bailey et al 1996). 
Protocols for the isolation and identification have been developed for evaluation of GAGS 
in equine digital flexor tendons and would assist in better defining the relationship between 
3sS-sulfate incorporation and sulfated GAG synthesis in future experiments (Bailey et a2 
1996). Finally, it should be remembered that type JII collagen may be cross-linked by 
&sulfide bridges, and it is possible that a small proportion of the 3SS-sulfate may be 
incorporated into such links (Birch 1993). 
Proline incorporation and the subsequent separation by RP-HPLC of Hyp and Pro 
pemined determination of rates of collagen synthesis using a formula based on the ratio of 
hydroxyprohe to proline (Diegelmann and Peterkofsky 1972; Bailey and Light 1989; 
Abrahamsson et al 1994; Murphy and Nucon 1997). Although many authors use this 
technique, few have typed the collagen to determine the correct ratio of Hyp to Pro for the 
c a I d o m  (table 2.2). In vivo studies of equine SDFT healing found that type III collagen 
predominates during the early repair phase, whereas in a recent in virro study, type I 
collagen was found to predominate (Willliams et a2 1984; Watkins et al1985a,b; Murphy 
and Nixon 1997). Collagen was not typed in the present study and the calculations and 
reported figures for collagen and noncolIagen protein were based on thi assumption that the 
collagen produced was predominantly type EI (Watkios et al 19854b). The calculations 
were also performed based on 30% type III and 70% type I collagen and although absolute 
values for collagen and noncdagen protein were greater, there were no significant 
differences in the outcome of Statistical comparisons (Wiams et a1 1984). Although prohe 
incorporation was r e p m e  of collagen synthetic rates, only those noncollagen proteins 
containing proline were measured in these experiments. Labeling with radioactive leucine 
may be a more acwate measure of total protein synthesis. However, salt precipitation or 
alternative chromatographic techniques would be required to separate collagen fiom the 
nonwlIagen proteins (Bailey and Light 1989). Given the low rates of synthesis previously 
identified in this model, this approach may not have been &ciently sensitive for 
determination ofrates of collagen synthesis (Riley 1994). It is possible that other noncollagen 
proteins were a f f ' ed  in this study which did not contain significant numbers of proline 
residues. Proline may also be incorporated into elastin but its synthesis by equine tendon in 
vitro has not been confirmed and less than 1.5% of residues are Hyp. 
Thymidine incorporation was used as a measure of cell proliferation and therefore 
tissue growth. Tissue growth in vitm may be due to an increase in cell number, an increase 
in cell size or increasing the amount of EChl; the latter is usually a variation of the former 
two parameters (Baserga 1989). Increase in cell number is the most important component 
of growth in cultures and may be measured directly by counting the number of cells in the 
cultures, or indirectly by measuring the amount of DNA, RNA, protein or mitosis. Cell 
counting in the SDFT explants is hampered by the low celIularity of the tissue and the low 
yield and cell survival f?om tendon digests (Birch 1993; Bailey er al unpublished data). 
Histomorphometric analysis of 5 p m  sections of SDFT explants is a difficult and time 
consuming technique (Riley et al1996). The amount of DNA per cell is usually constant and 
its measurement is the method of choice for evaluating growth and cell survival in solid 
tissue cultures and its measurement may be easier than counting cells in the SDFT explants 
(Baserga 1989; Riley 1994). This technique was not used in the equine SDFT cultures due 
to the problem of low cell density mentioned. Counting of mitotic figures either directly or 
with the assistance of a stain such as BrdU is an indication of cell proliferation but not 
growth (Baserga 1989). Thymidine incorporation is  also limited to estimating the amount 
of cell proliferation and does not permit the study of the quiescent cell population. However 
it is a sensitive and powem assay which is widely used to quantitat cell prolifmtion 
(Baserga 1989). Additionally, it may be employed in autoradiographic procedures in a 
qualitative manner (as can the BrdU assay) in order to determine which cell types are 
undergoing mitosis @wqp 1989; Matsuda 1994). In the merit study, "C-thymidine was 
fbund to be an &&e tool for quantitative comparisons of the & a s  of N u  PSGAG 
and rhIGF-I. 
9 3 3  Pre-c.duxnn D a m  Chloride Derivitization and Revem Phase High Performance 
Liquid Chromatography 
Dabsyl amino acids are highly chromophoric compounds produced by the reaction 
of DABS-CI with amino acids in alkaline conditions (Lin 1984). The technique developed 
and used in this study enabled separation of Hyp and Pro in nanomolar amounts and the 
subsequent measurement of radioactivity of hctions corresponding to each peak is 
permitted the calculation of rates of incorporation into collagen and non-collagen protein 
(Lin 1984; Dmevich and Vary 1993; Ikeda et a2 1993). Dabsyl chloride was used as a 
derivatitation agent because the dabsyl amino acids are stable for several months at -20°C, 
the derivatization time with DABS-CI is short compared to other agents, and it reacts with 
both primary and secondary amino groups (Ikeda ei al1993). 0-phtalaldehyde reacts with 
only primary amino groups and did not improve detection of Hyp and Pro in this study 
(Ikeda et al 1993). Initially digests of the explants were derivatized using a published 
protocol, separated by RP-HPLC and absorbencies measured at 425 nrn (Lin 1984; Drnevich 
and Vary 1993). However the relatively particulate nature of the tendon digest after filtering 
resulted in rapid clogging of the pre-column filter and most of  the Hyp and Pro separated 
was associated with collagen that was present in the explant at the time of harvest fiom the 
horse. The high background concentrations resulted in markedly reduced SPA and the peak 
resohrtion and separation were poor. Therefore newly synthesized protein was precipitated 
f?om the medium, dried, digested, derivatized and separated. The absorbance detector was 
exchanged for a fluorescence detector set at 436 nm. Detection in the visible range at 436 
mn deaeases the interfiefence caused by W absorbing material in biological samples (Ikeda 
et al1993). The sensitivity of the dabsylation RP-HPLC technique is enhanced by 5 to 10 
times when a fluorescence detector is used d e a d  of a photometer based absorbence 
detector (Lii 1984; Hancock and Harding 1984). This resulted in chromatographs with 
peaks that were smaller with excellent resolution and separation that was sensitive enough 
to discriminate between the 3-OH and 4-OH isomers of Hyp (Bailey and Light 1989). f i e  
derivatization procedure was particulady pH sensitive and great care had to be taken to 
maintain conditions at pH = 9.0 for successfid dabsylation and separation (Dmevich and 
Vary 1993). 
The formulation of the two ehhon solvents arid the program used was initially based 
on the work of Dmevich and Vary (1993). Success using this protocol was limited with the 
available equipment, so an alternative protocol was developed based on two fbrther 
publications (Negro et aZ1987; Ikeda et (11 1993). Flow rate was decreased to consenre 
solvents and the column tempaature and percentage mix of solvents were art,itra.dy adjusted 
until satidkctory resolution and minimum development time were obtained. Maintaining 
stable conditions was difEcuIt because much of the equipment required maintenance and 
repair. However once these problems were resolved 20 p1 samples wuld be separated every 
30 minutes and fkactioos collected for scintillation counting. Ideally an in-line radioactivity 
counter would permit more rapid collection of data and disposal of radioactive wastes 
(Macek et al1989). 
9.4 Pilot Studies 
Following the establishment of the equine SDFT explant tissue culture system and 
the suitable analytical procedures, two pilot studies were conducted. In previous tendon 
explant culture studies it was found that rates of cell proliferation and synthesis of 
macromolecules differed depending upon the duration of the culture period (Abrahamsson 
el al 198%; Abrahamssoa et al 1991 b; Riley 1994). When equine SDFT explants were 
cultured for up to four weeks in RPMI 1640 the variances of isotope incorporation rates 
were bigher at week two than at week four (Riley 1994). Because the mechanism of action 
of PSGAG and NaHA as pharmacologic agents on tendons has not been elucidated it was 
not hown what dose or duration of treatment was required in order to Stiate a response, 
if any. The recommendation for treatment of articular disease in the horse with PSGAG is 
to administer a dose every four days for eight injections @ow et al 1996; Luitpo1d 
Pharmaceuticals, Animal Health Division, Shirley, NY, USA), whereas NaHA is given 
weekly for three treatments (Swanstrom 1978). The pilot studies were designed to give some 
indication of the optimal pre-treatment stabilization period which would minimize variability 
during the testing of the drugs and of the duration of treatment required for a measurable 
response. In experiment two, three of the groups that were dtured for a total of 21 days 
prior to radiolabeling were exposed to treatment for three days and four were exposed to six 
days of treatment. This approach differs from that of other long-term in vitro tendon explant 
studies in which the explants were continuously exposed to the agent of interest throughout 
the d tu re  period (Abrabamsson et al1991b; Murphy and Nmon 1997). It is more likely that 
m vivo administration with either PSGAG or NaHA would occur at intervals of four days 
or one week respectively according to current recommendations for these drugs (Man et a2 
1993). For this reason, and the apparent greater reproducibility of the 6-day treatment 
protocol, we elected to conduct all subsequent experiments with a 6-day treatment period. 
In horses affected with tendinitis, subclinical injury is usually present before the onset 
of a more severe acute episode of tendinitis (Stromberg and Tufiesson 1969; Silver et al 
1 983; Genovese et al1985; Dow et af 1 99 1 ; Marr et a2 1 993). Therefore the treatment of 
most injured horses occurs at some time after injury during the phase of healing 
predominated by reparative responses @ow et a2 199 1 ; Marr et al 1993). After injury, in 
vivo inflammation predominates in the first few days, mediated by neutrophils and 
macrophages which stimulate both cell death and activation of previously quiescent 
mesenchymal cells (Chvapil19%). SimJarly, in q1ant cultures some cells die, some remain 
quiescent and some proliferate, differentiate and migrate (Freshney 1987). However this 
process is neither initiated nor controUed systemically or locally by mediators produced by 
inflananatory cells. Rather, its course is detecmined by the degree of tissue damage caused 
during establishment of the cuitures and by the environmental and nutrient media conditions 
of the arlture system Although tendon healing in vibo has many similarities with healing in 
W, it proceeds at a slower rate without systemic regulation (Gekrman et al1984; Manske 
et al 1984). In vivo the maximal rate of cell proliferation occun by day seven, and of 
collagen synthesis by day ten (Chvapil 1996; Davis 1996). From the results of experiments 
two and three it is evident that protein and GAG synthesis were still increasing between 15 
and 21 days of cuIturq and possibly after day 21. More data points are necessary to descnie 
the relationship between time and synthetic rates in vitro and determine the time of peak 
synthesis but it is apparent that it is delayed compared to that reported for in vivo healing 
(Geiberman etal1984; Maoske e t d  1984; Abrahamsson 1991). It is evident f?om previous 
work with the equine SDFT in vitro that differences in synthetic rates occur with time and 
interest@& the response to some of the treatments in the present study differed according 
to the duration of the pre-treatment culture period (Riley 1994). In experiment two after a 
nine-day pre-treatment culture period NaHA and PSGAG appeared to inhibit protein and 
GAG synthesis but after a 15&y pre-treatment culture period there was no significant 
difference for the NaHA group and increased synthesis in the PSGAG group. These 
differences will be discussed further in the sections addressing the responses to each drug. 
Following experiments used a compromise pre-treatment culture period of 18 days and 
concentrated on increasing sample size to improve the statistical power of each trial. 
A treatment group containing rhIGF-I was included as a positive control group in 
both pilot studies. Studies using explant cultures of rabbit flexor tendons indicate that IGF-I 
has a potent anabolic effect on protein synthesis and cell proliferation in serum-fiee and 
supplemented media (Abrahamsson et a2 1991a,b). It was thought that rhIGF-I would be 
useful as a positive control in the equine SDFT model when evaluating the effects of NaHA 
and PSGAG. Groups combining each dmg and rhIGF-I were also included to determine 
whether interactive effects were possible. The doses of drugs used in the pilots were based 
on other publications which had investigated them in other species or other connective 
tissues (Abrahamsson 1 99 1 ; Nethery ei a l l  992; Salti et a2 1 993). The response to rhIGF-I 
was poor in both experiments (even though rhIGF-I f?om two ditferent sources was used) 
so it was considered unsuitable as a positive control group at the dose tested. Therefore, 
dose response studies were conducted in experiments four and five to M e r  evaluate the 
response of the equine SDFT explants to rhIGF-I. 
The positive anabolic & i  of exogenous PSGAG on cartilage have been reported 
previously but this study is the first to codinn comparable effixts on the equine SDFT 
(Adam 1982; von der Mark 1982; Glade 1990; Ghosh et d 1992; Steinmeyer et all992). 
These effects were first observed in experiment two and examined more critically and 
confinned in arpaiments four and s i x  Interpretation of the results of experiment three were 
confounded by a decline in explant size suspected to be due to contamhation with 
mycoplasma. After experiment tbree all subsequent experiments were tested and found to 
be negative for mycoplasma. Prior to the initiation of this study, the effects of PSGAG on 
the equine SDFT had only been investigated under c h i d  conditions following 
administration of either intra-Iesional, pen-lesional or systemic ~ d e q u d  for tendinitis 
(Redding et a2 1992; Goodship et a2 1992; Marr et ul 1993; Barr et al 1995; Dow et a2 
1996). Howwer, in the only one of these studies with a control group, there were no 
significant differences between the percentage of Thoroughbred horses returning to work 
following a course of intratendinous or intramusculx PSGAG and those returning to work 
following conservative management alone (Mm et a2 1993). 
In the horse only one in virro study investigating the effect of PSGAG on isolated 
tenocytes has been published (Dahlgren et a2 1996). This study utilized a model based on 
equine tendon fibroblasts in monolayer culture and examined the responses to doses of 
PSGAG ranging fiom 25 to 200 pg/ml (Dahlgren et ul1996; Dahlgren et d 1997). It was 
concluded fiom this study that neither proteoglycan synthesis nor cell viability were affected 
compared to controls. The equine SDFT explant model was chosen in the current study in 
order to maintain cell-matrix interactions. The effects of PSGAG were examined over the 
dose range 100 to 5000 pg/d and a dose dependent increase in the rate of sulfated GAG 
synthesis was found. This compares to an approximate CS concentration of 2.5 pghg wet 
weight in normal equine SDFT of horses of similar age estimated on the basis of data 
obtained in biochemical d y s e s  (Birch 1993). The results concur with those of Dahlgren 
et al in that neither protein (collagen and noncollagen) nor sulfated GAG synthesis were 
significantly d i f f m  h m  the control group at concentmtons less than 500 @ml (Dahlgren 
et ai 1996). However, at concentrations greater than or equal to 500 pg/d there were 
significant increases m the rates of protein synthesis (collagen and noncollagen protein) and 
dfkted GAG synthesis, and it appeared that the degree of response was dependent upon the 
concentration of PSGAG in the culture medium, In short term studies of equine explant 
cultures of articular cartilage, exogenous PSGAG at concentrations of 12500,25000 and 
50000 pg/ml on collagen and &ted GAG synthesis were examined and the latter two 
concentrations were found to increase 35S incorporation by 120 and 3 16% respectively 
(Glade 1990). The latter two concentrations are similar to those present in synovid fluid 
after intra-articular injection of 250 mg PSGAG but the reported concentration after intra- 
muscular injection of 500 mg is only 0.25 &ml in normal horses (Glade 1990; Burba et al 
1993). In a later study, six days of exposure to PSGAG at 200 pg/d was found to inhibit 
PG (GAG) synthesis and had no effect on PC breakdown in short term equine explant 
cultures of articular cartilage (Caron et a[ 1991). When a similar study was performed with 
cartilage h m  osteoarthdic middle carpal joints at a concentrations of 25 pghl and 25000 
p Jd similar findings were made (Caron et al 1993). The reasons for the contrary finding 
in the studies by Caron and workers is unknown, but 35S-NaS~, was added at the same t h e  
as PSGAG and there is no mention in the experimental materials and methods of the SPA 
o f  the 3SS or whether or not this was corrected for the concentration of sulfate due to 
PSGAG in the medium. In the current study, all rates of synthesis were based on the 
comected SPA for each isotope which was determined by considering the concentrations of 
radioactive and non-radioactive of proline and sodium sulfate in the culture medium @ley 
et al1996). Culture medium RPMI 1640 is thymidine free. 
The significant increase in &ted GAG and nonwllagen protein strongly suggests 
that PG synthesis was increased. However, confinnation of this awaits polyacrylamide gel 
electrophoresis ofprotein precipitated h m  the medium and staining with dimethyhethylene 
blue (DMMB) or specific antibodies. Chromatographic separation and digestion of GAG 
sidechains would be required to codinn this supposition (Caron et al 1993; Bailey et al 
19%). Increased amounts and molecular weights of PG are synthesized in a dose dependent 
manner by cultured human and rabbit articular chondrocytes in response to exogenous 
PSGAG, but not in chick embryo or rabbit meniscus fibroblast cultures (Burkhardt and 
Ghosh 1987; Ghosh et al 1992). In cultured osteoarthritic human and chick cartilage 
PSGAG induced si- increases in PG (the core protein hction and GAGs) synthesis, 
partiahly in PG W o n s  associated with link protein (Adam 1982). Investigations into the 
distriiution and binding of PSGAG have concluded that the drug has a greater affinity for 
PG and nonwUagen proteins than for collagen (Ghosh et al1992). The present study did not 
specifically investigate the binding affinities of PSGAG for different macromolecules in the 
SDFT-ECM, but there were no great differences among the relative degree or rates of 
collagen, noncollagen protein or GAG synthesis. It is possible that the type of PG produced 
in the treatment groups differed fiom that produced by the control group. In normal tensile 
SDFI' the predominant PGs are decorin, biglycan and fibromodulin and in the 
metacarpophaiangeal regions levels of CS compatible with the presence of aggrecan in the 
metacarpophalangeaI regions have been detected (Smith and Webbon 1996). However, these 
results conflict with studies that have determined that CS (the major GAG in versican and 
apgrecaa) is the predominaat GAG followed by DS (the major GAG in decorin and bidycan) 
in the tensile SDFT (Birch 1993; Bailey et uZ 1996; Gallo and Bernfield 1996). Because the 
SDFT explants were not under tension or compression it is possible that the types PG 
synthesized in v i ~ o  may differ fiom those norndy synthesized in vim in response to motion 
and tension (Koob and Vogel 1987b; Okuda e! al1987; Kubota et al 1996; Nabeshima et 
a2 1996). Since the present study has established a significant response to PSGAG it would 
be of interest in future studies to quanm the different types of GAGs and PGs 
produced-Very few of the core proteins of PGs have been isolated and their structure 
characterized and attempts to do so have had limited success because their high charge 
density makes separation and purification difEcuIt (Jackson et aZ 199 1; Caron et d 199 1; 
Caron et a2 1993). In a recent investigation, PSGAG at 10 and 100 pghl increased K S  
synthesis (the predominant GAG of fibromodulin) in cultured canine articular chondrocytes 
(Steinmeyer et a2 1992). In the previously mentioned study investigating the effect of 
PSGAG on equine cartilage from osteoartbritic middle carpal joints, the only significant 
anabolic effect identified was an increased concentration of KS substitution on the core 
protein of an unidentified large PG (Caron et QZ 1993). 
Protein synthesis was stimulated in a dose-dependent manner in this study. The 
results concur with those of the study quoted above which investigated the response of 
canine articular cadlage chondrocytes to PSGAG and concluded that the response was not 
specific beause both collagen and noncullagen protein synthesis were increased (Steinmeyer 
el al 1992). Collagen synthesis by equine articular cartilage explants also increases in 
response to PSGAG m a dose dependent manner (Glade 1990). The objectives of the study 
included determination of the e f f i  of PSGAG on collagen and noncollagen protein. As 
discussed above, now that an anabolic effect has been observed, the pudication, isolation, 
identification and quantifLing individual proteins would be u&bl in future experiments to 
more accurately document qualitative changes in the distribution of ECM macromolecules. 
Ofparticular interest would be collagen typing since the production of larger fibril diameter 
type I collagen is considered desirable to optimize scar strength in vivo (Wiiams el d 1984; 
Watkins ef a2 198%). The present study reports on the metabolic responses of the tissue, 
particularly the cells, to exogenous PSGAG. In rat tendon, the GAG moieties of the PGs 
hkmct electrostaticdly in a reversible manner with type I collagen with an affinity which is 
dependent upon m o l d  shape and linear charge density. This provides up to 25% of the 
stabilization forces in tendon collagen (Nimni and Harkness 1988; Scott 1990). Naturally 
d g  CS accelerates fibre formation during the nucleation phase, but when CS or PGs 
are added after the nucleation phase the growth phase of fibdogenesis is delayed, limiting 
fibril diameter ( N i i  and Harkness 1988; Parry and Craig 1988). Further in vitro and in 
vivo investigation into the interactive effects between collagen and PSGAG would be of 
value in elucidating the complex responses to CS. 
Hyaluronic acid was markedly decreased (46%) in the culture medium of SDFT 
explants treated with PSGAG at 1000 pgld compared to the control group. This result 
contrasts with reports in which HA synthesis by chondrocytes and synovial cells was 
markedly increased by PSGAG (up to 25Ph at 100 Wmi) and the average molecular 
weight of HA synthesized was increased (Greiling 1982; Nshikawa et a2 1985; Smith and 
Ghosh 1986; Burkhfttdt and Ghosh 1987). In s y n o d  membrane ex vivo explant cultures, 
HA synthesis was increased in rabbits after systemic injection of c h o n d r o i t i n 4 ~ t e  aid 
chondroitin-6-dfbe ~~ et al1985). An explanation of the cause of decreased HA 
in the medium in experiment eight is speculative. In synovial cells the action of PSGAG 
appears to result from binding to receptors on the cell surfkce and it likely that this occurs 
on the su.rfkce of the SDFT tenocytes (Ghosh et d 1992). Hyaluronate differs fiom other 
GAGS because it is synthesized in the plasma membrane. Although hyaluronidase has been 
isolated fiom lung fibroblasts, most HA is not degraded locally but by reticuloendothelid 
cells in the liver (Sampson et al 1992; Gallo and Bernfield 1996). Therefore, the decrease 
in HA in the medium may have resulted from inhibition of HA synthetase by binding of 
PSGAG to the plasma membrane andlor by binding and sequestering cytokines that are 
essential for the stimuJation of HA synthesis (Sampson et al1992). Although this effect has 
not beea demonstrated for HMW-Hq a recent study found that a very low molecuiar weight 
form of NaHA consisting of hyaluronate hemsaccharide (HAJ inhibited HA synthesis by 
blocking receptors and displacing endogenous HA &om chondrocytes in culture (Knudsen 
1993). Alternatively, PSGAG may up regulate CD44 receptors and enhance binding of 
synthesized HA to these membranes or HA may become bound in aggregates associated with 
the increased levels of synthesis of PG and LP, resulting in decreased levels of HA liberated 
into the medium In future experiments an isotopic assay for HA may give more information 
on newly synthesized HA levels associated with the explants themselves (Nshikawa et a2 
1985). 
In addition to stimulating the synthesis of macromolecules, exogenous PSGAG at 
1000 p Jml also stimulated cell proliferation in experiment six. In virro studies of synovial 
cells exposed to exogenous PSGAG have shown anhitotic effects (Trotter 1996). However 
studies of cartilage have demonstrated stimdated proliferation in response to lower doses 
of PSGAG (Vacha et a2 1984; Glade 1990). Thymidine incorporation into equine articular 
cartilage cultures doubles at 12500 pg/ml PSGAG, is not affected by 25000 pg/d, and is 
inhibited by 50000 p d d  of PSGAG. A dose response study planned to examine the 
relationship between PSGAG commtmtion and thymidine incorporation was not complaed 
due to logistical problems in experiment four but based on the effects upon cartilage should 
be considered for fuhlre investigation. 
In experherxt, two after a nine-day stabilization period PSGAG appeared to inhibit 
protein and GAG synthesis, but after a 15-day pre-treatment culture period there was 
increased synthesis in the PSGAG group. However a dose of 2000 pg/ml PSGAG was used 
in the nine-day pretreatment period group. The inhtiitory response may be due to an 
interaction of the time of treatment and dose. In experiment four (effect of concentration of 
PSGAG on arplams) it appeared that optimal synthetic response at 1000 p g M  PSGAG with 
an apparent dedine in response to c o n d o m  >lo00 pglrnl PSGAG. Although statistical 
support for this apparent declining or inhl'bitory response was lacking, the apparent trend 
warrants fbther investigation of the possible toxic eE&s of PSGAG at concentrations 
higher than 1000 pgM PSGAG. Other studies have shown inhibition of GAG synthesis by 
synovial cells exposed to 300 mg/ml (Kleesiek and Greiling 1982). Thus, it would be of value 
to more closely examine the effect of PSGAG on different phases of the healing process in 
vivo and in vitro. 
Many of the effects of PSGAG have been identified in vivo and in vifro, but the 
precise mechanism of its action upon cells is unknown (Trotter 1996). Presumably the 
response to PSGAG is mediated by interactions with cell surface associated proteoglycans 
andlor integrins. There is evidence that such interactions are dependent upon the degree of 
sulfation of the &saccharides. For example, when HA is synthetically polysulfated its 
biological activity is markedly enhanced (Chang et d1994). The principal GAG present in 
PSGAG is CS which is highly anionic due to an average of three to four sulfate esters per 
disaccharide thus endowkg PSGAG with the capacity to covalently bind many molecules 
(Ghosh et a2 1992). Because its afEnity for PG and noncollagen protein is reportedly greater 
than that for collagen it is possible that PSGAG binds to the cell surface associated 
proteoglyrans to exert its effect (Andrews et aZ1985). There is little specific information 
on the interactions between PSGAG or other sulfated GAGS and cell surface receptors or 
on the tnnmhion of signals to the intracelldar space (Labat-Robert et ai 1990; CiareIli ef 
a2 1996). 
Although the PSGAG appeared to increase rates of synthesis of collagen, 
noncohga protein and GAGS, it is possible that this effect was in part or totally the result 
of decreased catabolism (Ghosh et aZ 1992). The reported effects on catabolism are the most 
widely kwwn of PSGAG properties. It is a competitive inhibitor of neutrophil elastase and 
an inhibitor of d e p s i n  a, and a strong inhibitor of B-glucuronidase, Bgdactosidase, D-N- 
acetylglucosaminidase, a-glucosidase, a-mannosidase, KS glycanohydrolase, chondroitin 
sulfotransferase, neutral protease, O-glucuronidase, myeloperolddase, cathepsin G, and 
human granulocyte elastase (Baici and Fehr 1982; Trnavsky 1982; Ghosh et ai 1992). In an 
in vivo lapine cartilage model, significant suppression of MMPs and serine proteinase activity 
occurred after ha-articular administration of PSGAG (Howell et ui 1986). In enzyme 
assays, its effect upon MMP synthesis appears to be dose and species dependent (Netfiery 
et d 1992). Rat colhgenase activity is increased by PSGAG concentrations > 0.5 pg/ml up 
to a dose of SO pg/ml, and human coIlagenase activity increases at concentrations > 5 pg/ml 
(Nethery 1992). In the same study, stromeolysin &om both species was inhibited in a dose 
dependent manner over the concentration range 0.5 to 5000 p g M  PSGAG. Samples were 
collected during the present study for detection and quantifying collagenase, stromeolysin 
and TIMPs in order to determine if these molecules played a role in the observed synthetic 
responses. Stromeolysin and collagenase activity were identified in these samples, but data 
for comparative analysis are not yet available. 
9.6 Sodium Hyaluronate @yonate@) 
The results of this study indicated that exogenous NaHA exerts positive anabolic 
effects on equine SDFT explants in a dose related manner. There is little comparative 
idtonnation on the effects of NaHA on soft wnnecfive tissues. It inhibits granulation tissue 
f o d o n  in vivo, possibly by inhliiting the chemoattraction of fibroblasts by macrophages 
(Rydell 1970; Rydell and Balazs 1971; Balazs 1985). However in the current study 
macrophages were excluded from the equine SDFT explant model. Studies in rabbits with 
traumatized digital tendon sheaths treated with NaHA showed less connective tissue reaction 
and scarring, or no significant improvement in wound healing (Rydell and B a l m  1971; 
Thomas et al1986). Little is known of its mechanism of action in joints or tendons because 
studies reported in the horse have been clinical trials in which few or no biochemical 
parameters have been measured (Chwchill 1985; N m  and Gaughan 1989; Spurlock et al 
1989b; Gaughan et aZ 199 1; Giff ef a2 1992). The current study is the first to determine the 
metabolic responses of the equine SDFT to NaHA 
The effects of NaHA were examined over the dose range 50 to 2000 pg/d. The 
upper concentration was Iimited by the relatively low concentration of the available 
commercial preparation. In experiment five an apparent dose dependent increase in the rate 
of sdfkted GAG synthesis, total protein synthesis and collagen synthesis was found. These 
were significant only at the 1000 and 2000 &ml. In vibo studies of NaHA at concentrations 
< 1.0 @ml found inhibition of PG synthesis by chondrocytes but no inhibition occurred in 
musde, mature human skin or buman synovial fibroblasts at concentrations up to in 10 pg/ml 
(Ghosh et d 1992). In one of the few studies investigating the effects of the drug at a higher 
concentration, NaHA at 100 Mml increased glucosamine incorporation into HA by primate 
fibroblasts (Balzacs 1985). The cunCentrZEtions of NaHA examined in the current model were 
much higher than those examined in other in vitro studies and the anabolic effects on 
macromolecular synthesis occxlrred only at the upper end of the dose range. This may explain 
the diflicultly that has been experienced establishing its effect on tendon healing in vivo 
because very high concentrations seem to be required at the site of injury in order to observe 
an effect, and the commercial preparation tested comes only in 20 mg/ml concentration 
(Gaughan et al1991; Gift et al1992; Gaughan 1995). 
In addition to stimulating the synthesis of macromolecules, NaHA at 1000 pg/d 
also stimulated cell proliferation in experiment six. In experiment five, cell proliferation 
appeared to be inlv'bited by 50 pdml NaHA but in experiment six there was no difference 
among the 50 @ml NaHA and control groups. In experiment six there were more explants 
per treatment group and imreased cell proliferation was identified in the 1000 pghl NaHA 
There was a concurrent decrease in dry weight in experiment six. However, statistical 
analysis yielded the same results whether of not this was controlled in comparisons. 
Although there is a M e d  understanding of some of the chondroprotective and anti- 
idammatory &'eas o m  the m e c m  of action which resulted in increased synthesis 
and cell proliferation is h o w n  and previously unreported in the horse (Trotter 1996). 
Recent work with canine hcular cadage in vivo determined that HMW-HA (Hydovet'@) 
is capable of down-regulating stromeolysin andlor its regulatory pathway through TNEa 
(Comer et ~21996). Furthennore, when HA is artificially sulfated its effkct is increased 5000 
fold (Chang ef a2 1994). In studies of synovial cells HA receptors are preferentially 
stimuhed by HMW-HA or inhibited by LMW-HA (Ghosh et al1992). It is possible that the 
synthetic effects of NaHA are mediated through the same or related HA receptors and that 
a high concentration of NaHA is required to saturate these receptors and promote a more 
generalized synthetic response (Gallo and Bernfield 1996). 
9.7 Comparison of PolysuUated Glycosaminoglyc~n and Sodium Hyaluronate 
Many of the specific responses observed in experiment six have been discussed 
above. The degree of response at comparable weight based concentrations (1 000 pg/ml) was 
less marked for cultures treated with NaHA than those treated with PSGAG. This 
concentmtion was chosen for comparison based on the apparent optima identified in the dose 
response studies for PSGAG and NaHA The molecular weight of the drugs used in the 
study were not measured for this experiment but have been estimated in other studies to be 
10,000 and 3 2 1,600 for PSGAG (Adquan9 and NaHA(HyonateQ) respectively (Steinmeyer 
et aZ 1992; Uden and Lavoie 1997). Although the molar concentration of NaHA was lower 
than that of the PSGAG, the number of disaccharides was several orders of magnitude 
greater. These findings agree with those of others that ligand binding with the sulfate groups 
on PSGAG results in stronger interactions and more pronounced metabolic effects than the 
much weaker reversible binding that occurs with the carboxyfate moieties of the NaHA 
molecules (Njtmni and Harkness 1 988; Chang et a1 1 994). 
In addition to the significant effects on protein, d t e d  GAG synthesis and cell 
proliferation, there were small but significant decreases in explant dry weight of the 1000 
pg/ml NaHA and PSGAG groups. This response was not observed in experiments four and 
five and explant dry weights differed among groups by - IP!. The size of treatment groups 
in experiment six was greater than the former two studies and therefore may have assisted 
the detection of this difference. This difference may be associated with an inter-horse effect 
as identified in previous studies, but it is also possible that the reduction in dry weight may 
be indicative of general metabolic stimulation - both anabolic and catabolic (Riley 1994; 
Bailey ei a2 unpublished data). Such a dichotomous response has been reported previously 
when PSGAG was found to stimulate collagenase activity while at the same time inhibiting 
stromeolysin activity in viiro (Nethery et QZ 1992). The present study was designed to 
investigate the possible anabolic effects of NaHA and PSGAG. Further investigation of the 
catabolism of the macromoldes of the ECM is recommended in future studies. Despite the 
reduction in dry weight of the treated cultures, when this effect was controlled for in 
statistical an@& the outcome of comparisons of the variables (other than cell proliferation 
for the 1 0 0  pg/ml NaHA group) was not slffected. Cultures submitted for evaluation were 
mycoplasma, bacteria and fitngus f ie .  
9.8 Insulin-like Growth Factor I 
Insulin-like growth factor I is a basic peptide consisting of 70 amino acids which is 
synthesized predominantly by the liver and occurs in high concentrations in serum but low 
concentrations in the tissues (Froesch et d 1 98 5; Daughday and Rotwein 1 989). Recently 
the role of rhIGF-1-1 in tendon metabolism has been investigated in virro (Abrahamsson et 
aZ 1991a,b; Lin et al 1991). Based on the potent effect of rhIGF-I on rates of matrix 
synthesis by rabbit tendon flexor tendon, rhIGF-I was selected as  a positive control against 
which the responses of equine SDFT explants could be compared. A concentration of 100 
ng/ml was chosen for the pilot studies (experiments two and three) based on previous works 
and budgetary coIlStfainfS (Abrahamsson ei a l l99  la,b; Li et a l l99  1). In experiment two 
rhIG3;-1 in combination with PSGAG or N- but not singly, resulted in increased protein 
and dfkted GAG synthesis in the groups which were treated for six days after a pre- 
treatment culture period of 15 days. The magnitude of the response compared to the control 
group was small. The MGF-I product used had not been previously culture tested, and 
following the poorer than expected response, an alternative source 3rhIGF-I was used in 
@ent three. However, significant anabolic responses with rhIGF-I were not observed 
in experiment three, possibly due to mycoplasma contamination 
These results led to two rhIGF-I dose response studies in experiments four and five. 
When the effects of wxmntmtiofls of rhlGF-I between 50 and 500 ng/ml on SDFI' explants 
h m  a 3 -5 years old horse were cornpared to a control group, the only significant difference 
was an increase in collagen synthesis of only 15.6% at 500 nglrnl rhIGF-I. However, when 
concentrations of rhIGF-I between 5 and 100 ng/ml were evaluated in SDFT explants &om 
a younger horse, mean rates of protein (collagen and noncollagen protein), sulfated GAG 
synthesis and cell proliferation were significantly elevated by up to 126% (1 14% and 176%), 
128% and 41%, respeaiveIy. As we1 there was a clear dose-response relationship between 
the concentration of the rhIGF-I in the range of 5 and 10 to 25 ng/m2 depending upon the 
parameter being measured. The interaction and synergistic effects of rhIGF-I with other 
cytokines has been well documented (Lin et al 199 1). 
When short term cultures of embryonic chicken tenocytes were cultured in rhlGF-I 
at 1, 5, 10, 100 and 1000 ng/ml in the presence of 0.5% FBS, DNA synthesis was 
sigdicantly increased at 5 to 10 ng /d  (Lin el al 199 1). Short term rabbit flexor tendon 
explant dtures exposed to 10,25,50, 100,250, 500 and 1000 ng/ml of rhIGF- I in s e w  
fke medium increased PG synthesis in a dose dependent manner between 10 and 1000 nghl  
(Abrahamsson e t all  99 1 a). Collagen and noncollagen protein synthesis increases between 
10 and 500 nglml, and 10 and 250 ngh l  rbIGF-I occurred in a dose dependent manner and 
there was decline in rates of synthesis at higher doses. Stimulation of cell proliferation by 
rhIGF-I was dose responsive between 10 and 100 ng/ml. In similar long term cultures 
exposed to rhlGF-I at 50 ng/ml, PG, collagen and noncoIlagen protein were significantly 
increased compared to controls (Abrahmson et a2 1991b). It is possible that the higher 
doses of rhIGF-I used in the experiment two were too high and prevented the agent from 
exerting an effect on synthetic responses. The reason for the lack of effect of rhIGF-I at 
higher concentrations is not known and M e  attention has been given to this observation 
(Froescheid1985; Abrahamsson eta2 MUa; Lin et d 1991). In all of these studies young 
animals were used for the cultures. It is possible that the lack of response to rhIGF-I in 
experiment two was an animal &kt because the horse was h o s t  two times older than that 
used in experiment three. Thus, even though some of the concentrations of rhIGF-I were 
similar to those evaluated in experiment five, there were no significant differences in rates 
of synthesis. 
Recently, other workers have evaluated the effkcts of rhIGF-I at concentrations of 
100,250 and 500 n g / d  on long term explant cultures of the equine SDFT in the presence 
of 5% FBS (Murphy and N i o n  1996). There were some similar findings to those of 
experiment four. Only in the 500 nghl rhIGF-I treated explant was GAG synthesis 
i n a d .  Howevery this was not significantly different from the control group (Murphy aid 
Nxon 1996). Likewise, cell proliferation was not sigmficantly affected by rhIGF-I over the 
dose range tested. Collagen synthesis, on the other hand, was s ign i f idy  elevated at all 
concensafions with an apparent dose dependent relationship. The data fiom the rbIGF-I trial 
in experiment four supports this finding, and in addition, confirms the stimulation of sulfated 
GAGS and cell proliferation observed in rabbit tendon experiments. 
The equine cultures of why and Nmon were treated with rhIGF-I in the presence 
of 5% FBS which has high concentrations of other growth factors including IGF-I (Jayme 
1990; Riley 1994; Murphy and Nmon 1996). The present study used homologous species 
specific serum which is more unifom in composition &om batch to batch because the 
d e n t  medium and the responses of the SDFT in vilzo are more likely to be representative 
of the in vivo response to IGF-I and other drugs (Manske e al 1984; Jayme 1990; Riley 
1994). 
9.8 Conclusions 
1) Mean rates of protein synthesis by cultured equine SDFT explants as determined by 
proline incorporation were significantly increased in the presence of exogenous PSGAG at 
concentrations between 500 to 5000 pg/ml in a dosedependent manner. 
2) Mean rates of collagen synthesis by cuItured equine SDFT explants were significantly 
increased in the presence of exogenous PSGAG at concentrations between 500 to 5000 
pg/d in a dosedependent manner. 
3) Mean rates of nonwllagen protein synthesis by cultured equine SDFT explants were 
significantfy increased in the presence of exogenous PSGAG at concentrations between 100 
to 5000 pg/d in a dosedependent manner. 
4) Mean rates of sulfated glycu~oglycaus  ynthesis by cultured equine SDFT explants 
as determined by sulfate incorporation were significantly increased in the presence of 
exogenous PSGAG at concentrations &om 500 to 5000 pg/ml in a dose-dependent manner. 
5) The mean rate of hyahxonate synthesis by cultured equine SDFT explants as determined 
by radioimmunoassay of the culture medium was sigmficantly decreased in the presence of 
exogenous PSGAG at a concentration of 1000 pg/ml. 
6) The mean rate of cell proliferation by cultured equine SDFT explants as determined by 
thymidine incorporation was significantly increased in the presence of exogenous PSGAG 
at a concentration of 1000 &ml. 
9.83 Sodium Hynluronate @yonate@) 
1) Mean rates of protein synthesis by cultured equine SDFT explants as determined by 
prohe incorporation were sipficamly increased in the presence of exogenous NaHA at 
concentrations between 500 to 2000 pg/d in a dodependent manner. 
2) Mean rates of collagen synthesis by cultured equine SDFT explants were sipficantly 
increased in the presence of exogenous NaHA at concentrations between 1000 to 2000 
pg/d in a dose-dependent manner. 
3) Mean rates of noncollagen protein synthesis by cultured equine SDFT explants were not 
significantly affected by the presence of exogenous NaHA at concentrations between 50 to 
2000 pg/rnl. 
4) Mean rates of sulfated glycosaminoglycans synthesis by cultured equine SDFT explants 
as determined by sulfate incorporation were significantly increased in the presence of 
exogenous NaHA at concentrations between 500 to 2000 pg/d in a dose-dependent 
manner. 
5) The mean rate of cell proliferation by cultured equine SDFT explants as determined by 
thyrmdine incorporation was not sigaificaotly increased in the presence of exogenous NaHA. 
9.8.3 Insulin-like Growth Factor I 
1) Mean rates of protein synthesis by cultured equine SDFT explants f?om a two-year-old 
horse as determined by proline incorporation were significantIy increased in the presence of 
exogenous rhIGF-I at concentrations between 5 and 100 nghl in a dose dependent manner, 
but mean rates of protein synthesis by equine SDFT explants f?om a three and one half-year- 
old horse were not significantly increased in the presence of exogenous rhIGF-I at 
concentrations between 50 and 500 ng/ml. 
2) Mean rates of collagen synthesis by cultured equine SDF7' explants from a two-year-old 
hone were significantly increased in the presence of exogenous rhIGF-I at concentrations 
between 5 and 100 r#d in a dose-dependent manner, but mean rates of collagen synthesis 
by equine SDFT explants from a three and one haE-year-old horse were significantly 
increased in the presence of exogenous rHGF-I at 500 n g / d  only. 
3) Mean rates of noncollagen protein synthesis by cultured equine SDFT explants from a 
two-year-old horse were significantly increased in the presence of exogenous rhIGF-I at 
concentrations between 5 and 100 ng /d  in a dose-dependent manner, but mean rates of 
noncollagen protein synthesis by equine SDFT explants f'iom a three and one half-year-old 
horse were not sigmficantly increased in the presence of exogenous rhIGF-I at 
concentrations between 50 and 500 nglml. 
4) Mean rates of sulfated glycosaminoglycans synthesis by cultured equine SDFT explants 
£?om a two-year-old hone as determined by sulfate incorporation were significantly 
increased in the presence of exogenous rhIGF-I at concentrations between 5 and 100 ng/d 
in a dose-dependent manner, but mean rates of dfhted glycosaminoglycan synthesis by 
equine SDFT explants f?om a three and one haKyear-old horse were not significantly 
increased in the presence of exogenous rhIGF-I at conceatrations between 50 and 500 nglrnl. 
5 )  The mean rates of cell proliferation by cultured equine SDFT explants f?om a two-year- 
old horse as determined by thymidine incorporation were significantly increased in the 
presence of exogenous rhIGF-I at concentrations between 5 and 100 ngM in a dose- 
dependent manner. 
CHAPTER TEN 
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CHAPTER ET,'EVEN 
11.0 APPENDICES 
11.1 Appendix I 
Table A1 : Signalment and source of experimental animals 
Experiment Animal Source 
Experiment 1 : 14 mo female Quarter horse Donation 
Experiment 2: 3 yo male Quarter horse Saskatoon Auction Mart 
Experiment 3: 2 yo male Quarter horse cross-bred Saskatoon Auction Mart 
Experiment 4: 3.5 yo female Thoroughbred cross-bred Saskatoon Auction Uart 
Experiment 5: 2 yo male Quarter horse cross-bred Saskatoon Auction M k t  
Experiment 6: 2 yo female Thoroughbred Privately owned farm 
11.2 Appendix II - Materials and Equipment 
Table A2: Source of essential materials and equipment 
Tissue Culture 
Lactated Ringers 1 liter 
Gentocin, Gentamicin sulGite 50 m g h l  
Fungizone, amphotericin 33 200 pg/d 
Penicillin G sodium 100, 000 IU 
Acu-Puncha biopsy punch 4mm 
20 mm Wheaton AIuminum seals 
30 d Wheaton culture bottles 
20 mm rubber flange stopper 
Donor Horse Serum 100 ml 
RPMI Medium 1640 powder 
L-Ascorbic acid 
CorningQ Disposable Sterile Bode Top 
FiIt ers 
Hyouate@hyaluronate sodium injection 
20mglml 
Adeqm@IM polysulfated 
g l y c o ~ o g l y  can 
Abbott Laboratories, QC, Canada. 
Schering Plough Aoimal Health, Shering Canada 
Inc., Poime Claire, QC, Canada 
Giibco BRL, Grand Island, NY, USA 
Novophann Ltd, Toronto, ONT, Canada. 
Acudexm Inc., Fort Lauderdde, IT, USA 
VWR Canlab, Edmonton, AB., Canada 
VWR Canlab, Edmonton, AB., Canada 
VWR Canlab, Edmonton, AB, Canada 
Giico BRL, Grand Island, NY, USA 
Gibco BRL, Grand Island, NY, USA 
Sigma Chemical Company, StLouis, MO, USA 
Corning Laboratory Sciences, ONT, Canada 
Bayer - Canada, Agricultural Products Division, 
Guelph, ONT, Canada 
Luitpold Pharmaceuticals, Animal Health 
Division, Shirley, NY, USA 
Human recornbinant IGF-I (CGP 3 5 1 26) Ciba Geigy, Animal Health Division, 
Mississauga, ONT, Canada 
Human recombinant IGF-I (W1- 14 1) Upstate Biotechnology Incorporated, Lake 
Placid, NY, USA 
Table A2: Continued 
- - - - -  
ProduetlEquipment Manufacturer/Sopplier 
RadiochemicaLr mad Equrpment 
Proline G[2,3,4,s3W- 1 14.0 CVmmol, 5 Mandel Scientific, Geulph, Om, Canada. 
mCi 
Sulfur-35 in water, carrier fiee 5.00 Mandel Scientific, Geulph, ONT, Canada. 
mCilmI 
Methyl-"C-thymidine Amenham Life Sciences, Buckinghamshire,,UK 
Pharmacia HA Test ( 112'HABP) Pharmacia AB, Uppsala; Sweden. 
BCS biodegradeable counting scintillant Arnersham Canada Ltd, Oakville ONT, Canada 
Extran 3 00 Concentate BDH VWR Canlab, Edmonton, AB, Canada 
B e c h  LS6000IC Liquid Scintillation Beclanan Instruroents, Mississauga, ON', 
System Canada 
Minax 18 Autogamma 5000 series United Technologies, Packard Instrument 
Gamma counter Company, Meriden, CT, USA 
RP-HPLC Eqtnpment 
AUtech Absorbosphere OPA HR 5 CI, Mandel Scientific., Geulph, ONT., Canada. 
150 x 4.6 mm, C fitting, HPLC column 
Alltech Absorbsphere OPA HR 5 p, 7.5 Mandel Scientific., Gedph, Om, Canada. 
x 4.6 mm, all guard cartridge column 
guard 
Alltech A.U-guarP Guard cartridge Mandel Scientific, Geulph, ONT, Canada. 
holder 
Waters Data Module Model M7302 Millipore (Canada) Lt4 Waters Chromatography 
Waters M-45 Solvent Delivery System Division, Mississauga, ONT, Canada. 
Waters M600A Solvent Delivery System 
Table A2: Continued 
-- - 
ProduetlEquipment Manufacturer/Supplier 
Waters Model 720 System Controller Millipore (Canada) Ltd, Watas Chromatography 
Waters Mode1420 Fluorescence Detector Division, Mississauga, ONT, Canada. 
Waters Mode1 450 Absorbance Detector 
Rheodyne Syringe Loading Sample Rheodyne Inc., Cotati, CA, USA 
Injector Model 7125 
Other Materials 
SolvableQ tissue solubilizer 
Pro-X-Micro-Spinm 
DuPont/NEN, Nbillerica, MA, USA 
Lida Manufacturing Corp., WI, USA 
Bio-SpinQ 6 Chromatography Columns Bio-Rad Laboratories, Hercules, C 4  USA 
VWR clear graduated pipette tips 200 fl 11 Canlab, Edmonton, AB, Canada 
VWR serological pipettes 5 ml VWR Canlab, Edmonton, AB, Canada 
Eppindorf ultra-micro tips 10 pl VWR C d a b ,  Edmonton, AB, Canada 
CeIl Proliferation Kit RPN.20 Amersharn Canada Ltd, ONT, Canada. 
11.3 Appendix III 
Laboratory Procedures Manual 
Kopyright Christopher Bruce Rilqr, 1997. AU rights reserved. 
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1.0 Preparation Of Equine SDFT Explant Organ Cultures 
1.1 SteriIe removal of tendons &om the donor horse 
Materials 
Sterile stainless steel tray and lid (20 cm x I6 crn) 
- 1 litre Ringer's lactate 
- high concentration sucrose solution 
- 2 u g / d  Fungizone (2 mg) 
- I00 ug/ml Gentamicin (100 mg) 
- 100 IU/rnl Crystalline penicillin (100,000 ILT) 
Euthanasia solution - pentobarbitone 
Clippers 
Chlorhexidine scrub 
70% Alcuhol 
Sterile s w a b d m b  brush 
2 x pair sterile surgical gloves 
4 x 2 sterile draping towels 
2 x 4 Bachaus towel clamps 
Sterile laceration pack with 3-4 number 22 scalpel blades 
Protocol for removal of tendons from donor horse 
1. Assemble all equipment required in the preparation area adjacent to the yellow 
recovery stall. 
2. Euthanisdanaesthetize the horse in the yellow recovery room. 
3. Suspend the forelimbs using the hoist and 1" white tape so that they are at a reasonable 
working height and ofkt relative to each other. 
4. Clip each forelimb &om the accessory carpal bone to the bulbs of the heels over the 
palmar aspect for 270~~360~. 
5. Surgically scrub the upper limb with chlorharidine followed by an alcohol rinse. Repeat 
this procedure 3 times over the space of 5 minutes. 
6. Place the saline and antimicrobials into the sterile stainless steel tray. 
7. Open the laceration pack towel clamps, scalpel blades and dressing towels in a sterile 
manner. 
8. Put on sterile surgical gloves and '+way' drape the leg leaving the prepared palmar 
aspect over the SDFT exposed. 
9. Incise the skin in the midline over the SDFT fiom the accessory carpal bone to the 
ergot of the fetlock 
10. Sharply dissect away any peritendinow time and bluntly dissect between the SDFT 
and DDFT medidy and laterally as far p r o d  as possible and distally to the tendon - 
sheath.. 
11. Transect the tendon at the junction of the digitd tendon sheath and as far p r o d  as 
possible, and place into the sterile saline containing antimicrobials. 
12. Place the lid on top of the tray. 
13. Repeat steps 5 to 12 for the other forelimb. 
14. Place the tendons in their sterile tray into a tissue culture incubator at 37C until 
ready to dissect into segments. 
1.2 Preparation of explant tissue segments from SDFT of donor horse 
Materials 
2 x pair sterile surgical gloves 
Sterile laceration pack with 6 number 22 &pel blades 
10-20 x 4 mm biopsy punches 
Gas sterilized plastic cutting board 
Gas sterilized clamp apparatus (jig) 
Sterile b e  hood 
RPMI f 640 culture medium 
1-2 x 6-well cuiture plates 
Protocol for dissection of tendons from donor horse 
1. Open all equipment, including the tray containing the tendons, in a sterile manner in the 
h e  hood and put on gloves. 
2. Gently clamp the tendon perpendicularly in the jig on the cutting board and make 
transverse incisions in the tendon at 5 rnm intends using the plexiglass guide. 
3. Remove the tendon slices and place into labeled culture wells according to their segmental 
location. 
4. Using the biopsy punch and forceps, punch 3 to 4 explants fiom each slice. 
5. Place the tray containing tendon segments in the incubator at 37°C until the culture bottles 
containing media have been prepared. 
13 Preparation of tissue culture media 
Materials 
Equipment & materials Chemicals 
1000 or 2000 rnI beaker Appropriate powdered media (RPMJ 1640) 
1000 ml measuring cylinder 1.5M sterile sodium bicarbonate solution 100mg/d 
Magnetic stirrer & bar Sterile double distilled de-ionized water 
pH meter & standards 1OM NaOH 
Electronic scale 1N HC1 
Weigh trays 700A ethanol 
Stainless steel spatula 20 mg/d ascorbate solution 
Sterile tissue culture washed 1000 d Pyrex bottle(s) & orange cap(s) 
500 ml h e 1  Corning disposable sterile bottle top filter (0.22 urn pore size) 
Water vacuum system 
Laminar flow hood 
Gas sterilizing flame 
C 4  bottle 
Electric pipette vacuum pump 
Sterile 2ml Pasteur pipettes 
Sterile 10 ml pipettes 
hgdadditives of interest to  be tested 
Protocol for preparation of powdered culture media. 
1. Calibrate the pH meter with the ph = 7 and pH = 10 standards. 
2. Place a magnetic stirrer bar in a 1000 ml beaker on the stirrer base. 
3. Measure 1000 ml of sterile double distilled de-ionized water into a measuring cylinder 
4. Pour approktely 80 % of the water into the beaker and turn on the stirrer. 
5. Shake the powdered medium down into the bottom of the packet and cut the top off. 
6. Empty the packet of medium into the swirling water and wash the packet out into the 
beaker with the remaining water. 
7. When the medium has dissolved into the water, add 20 mVlitre of medium of 1 .S M of 
sodium bicarbonate solution to the medium. 
8. Measure the pH of the solution and adjust the pH of the media to 7.10+0.1 with 1 OM 
NaOH if it is too acidic, of 1N HCl if it is too basic. 
9. Lift the h e  hood to activate the laminar flow and wipe out the &aces with 70% 
ethanol. 
10. Place the media, a sterile tissue culture washed 1000 ml Pyrex bottle and sterile 
orange cap, a packaged 500 ml -el Corning disposable sterile bottle top filter and 
suction h e  on the work d a c e  within the laminar flow hood. 
11. Caremy remove the foil fiorn the top of the sterile Pyrex bottle maintaining sterility . 
12. C a r m y  remove the filter unit &om its packaging and without touching the threaded 
portion of the fiIter, screw the filter onto the sterile bottle. 
13. Remove the dust cover from the filter and carefblly pour the medium into the funnel. 
14. Apply vacuum line to the filter (5-10 psi) and tum on the water vacuum 
15. Upon completion of filtration, disconnect the vacuum line prior to turning off the 
water to prevent water being sucked back into the filter unit. 
16. C a r m y  remove the filter unit and flame the neck of the Pyrex bottle.. 
17. Remove the orange cap fkom its sterile packagmg without touching the inside 
threaded portion and screw it onto the Pyrex bottle containing media. 
18. Immediately label the medium with its type, the date, and your initials. 
19. Cover the bottle with aluminium foil and refkigerate. 
Protocol for preparation of serum containing media. 
1. Into a sterile tissue culture washed Pyrex bottle of appropriate size, pipette the required 
volume of sterile serum fiee media with a sterile 10 rnl pipette. 
2. For each lOOml of medium, pipette the 10 ml of sterile filtered s e w  into the Pyrex 
bottle. 
3. Pipette the required volume of ascorbate (to make a concentration of 50 pg/rnl) into the 
medium eg. For 100 mls RPMI 1640 media containing 10% DHS add 250 ul of 20 m g / d  
ascorbate 
4. Flame sterilize the neck of the Pyrex bottle and place a sterile orange cap on without 
touching the neck of the bottle, and mix the contents of the bottle by using a gentle swirling 
action 
5. Immediately label the media with its type, the date, and the initials of the person who 
prepared it. 
NB. If at any time a sterile piece of equipment comes into contact with a non-sterile surface 
(eg-hand), discard the equipment and get a new piece of sterile glassware. Change pipettes 
between different media. 
1.4 Preparation of explant tissue cultures 
Materials 
Laminar flow hood 
Sterile prepared media with serum and ascorbate 
Sterile culture washed 30 ml Wheaton bottles (1 per tissue segment) 
Tendon segments 
Sterile thumb forceps 
Sterile 10 ml pipettes 
Electric pipette vacuum pump 
Sterile plugs for Wheaton bottles 
Aluminium seals for Wheaton bottles 
Manual press for seals 
Sterile 20 G needles 
Gas cylinder containing 50% 0,45% N, 5% C 4  
Millepore filter (0.22 urn) 
70% ethanol 
RoUer modified incubator set at 3 6.5OC 
Protocol for preparation of cultures. 
1. Lift the fume hood glass to activate the laminar flow and wipe al l  surfaces with 70% 
ethanol. 
2. Place the cylinder of pipettes, the desired number of labeled sterile Wheaton bottles, the 
sterile plugs, sterile forceps and pipette vacuum handle, and media onto the work Surface 
within the laminar flow hood. 
3. Caremy remove the foil fiom the top of the sterile Wheaton bottles enswing that the 
necks of the bottles are not touched. 
4. Caremy remove the cap ftom the top of the sterile Pyrex bottle containing the media, 
ensuring that the neck of the bottie is not touched. 
5. Using the tips of the sterile thumb forceps, c a r W y  H e r  one tendon segment per 
Wheaton bottle i?om the sterile tray containing the dissected tendon 
6. Wah a sterile 10 ml pipette, aansfer 4 mi of appropriate media into each Wheaton bottle. 
7. Candidly place the sterile plugs on top of the bottles using sterile forceps, then gently seat 
the plugs into the neck of the Wheaton bottles using gently thumb pressure, taking care not 
to touch the rim or the neck of the bottles. 
8. Place the aluminium caps over the plugs and seal them using the manual press. 
9. Remove the centres of the seals by gentle pressure on the centres or using the wall 
mounted opener. 
10. Sterilize the top of the bottles with alcohol. 
11. Place the d e p o r e  filter on the outflow tubing from the gas cylinder. 
12. Place a sterile 20G needle on the millepore filter. 
13. Insert the needle into the exposed sterile portion of the plug, and insert another sterile 
20 G needle for an outflow, taking care not to touch either the needle shafts or the exposed 
rubber plug. 
14. Turn on the gas at 15 psi for 15-20 seconds. 
15. Remove the needles without touching the shafts, and continue gassing the other bottles. 
16. When all the cultures have been gassed, place them on the rollers, 5 per row, with the 
caps facing towards the incubator door. 
17. Repeat the gassing procedures every 24 hours for all cultures. 
18. Change the media every 72 hours. 
N.B. Ifat any time a sterile piece of equipment comes into contact with a non-sterile s d c e  
(eg-hand), disczd the equipment and get a new piece of sterile glassware. Change pipettes 
between different media. 
1.5 Changing the medium of explant tissue cultures 
Materials 
Laminar flow hood 
Sterile prepared medium with senun and ascorbate 
Wheaton bottles containing tendon segments 
Multigrips or vial opener for cap removal 
Sterile 10 d pipettes 
Electric pipette vacuum pump 
Sterile thumb forceps 
Sterile plugs for Wheaton bodes 
Aluminium seals for Wheaton bottles 
Manual press for seals 
Sterile 20 G needles 
Gas cylinder containing 50% 0,45% N, 5% CO, 
Millepore filter (0.22 urn) 
70% ethanol 
Betadine scrub 
Roller mof led  incubator set at 3 7S°C 
Preparation of cultures. 
1. Lifl the &me hood glass to activate the lamioar flow and wipe out the hood surfaces with 
70% ethanol. 
2. Place the cylinder of pipettes, the labeled Wheaton bottles containing the dtures, the 
sterile plugs, sterile forceps and pipette vacuum handle, and media onto the work h c e  
within thc laminar flow hood. 
3. Carefidly remove the caps and plugs Wheaton bottles ensuring that the necks of the 
bottles are not touched. 
4. Using a fiesh sterile pipette every 3-4 cultures (1 per culture if problems with 
contamhation have been experienced), remove and discard 50% (2nd) of the used media. 
5. Carefully remove the cap from the top of the sterile Pyrex bottle containing the media, 
ensuring that the neck of the bottle is not touched. 
6. W~ a sterile 10 ml pipette, &er 2 ml of appropriate fresh medium into each Wheaton 
bottle. 
7. C a r e  place the sterile plugs on top of the bottles using sterile forceps, then gently seat 
the plugs into the neck of the Wheaton bottles using gently thumb pressure, taking care not 
to touch the rim or the neck of the bottles. 
8. Place the dllminium caps over the plugs and seal them using the msnual press. 
9. Remove the centres of the seals by gentle pressure on the centres or using the wall 
mounted opener. 
10. Sterilize the top of the bottles first with betadine scrub, then with alcohol. 
11. Place the d e p o r e  filter on the outflow tubing fiom the gas cylinder. 
12. Place a sterile 20G needle on the millepore filter. 
13. Insert the needle into the exposed sterile portion of the plug, and insert another sterile 
20 G needle for an outflow, taking care not to touch either the needle shafts or the exposed 
rubber plug. 
14. Turn on the gas at 1 5 psi for 1 5-20 seconds. 
15. Remove the needles without touching the shafts, and continue gassing the other bottles. 
16. When all the cultures have been gassed, place them on the rollers, 5 per row, with the 
caps facing towards the incubator door. 
17. Change the.media every 72 hours. 
N.B. If at any time a sterile piece of equipment comes into contact with a non-sterile d a c e  
(eghand), discard the equipment and get a new piece of sterile glassware. Change pipettes 
between different media. 
1.6 Gassing of culturn 
Sterile 20 G needles 
Gas cyhder containing 50%OJ45%N J5% C4 
Millepore filter (0.22 urn) 
70% ethanol 
Betadine scrub 
Roller modified incubator set at 37S°C 
Procedure for gassing cultures. 
1. Sterilize the top of the bottles first with betadine scrub, then with alcohol. 
2. Place the millepore filter on the outflow tubing fiom the gas cylinder. 
3. Place a sterile 20G needle on the milepore filter. 
4. W the needle into the exposed sterile portion ofthe plug, and insert another sterile 20 
G needle for an outflow, taking w e  not to touch either the needle shafts or the exposed 
rubber plug. 
5. Turn on the gas at 15 psi for 15-20 seconds. 
6. Remove the needle without touching the shafts, and continue gassing the other bottles. 
7. When a l l  the cultures have been gassed, place them on the rolers, 5 per row, with the caps 
facing towards, the incubator door. 
8. Repeat the gassing procedures every 24 - 72 hours as required for all cultures. 
N.B. Ifat any time a sterile piece of equipment comes into contact with a non-sterile surf%= 
(eg-hand), discard the equipment and get a new piece of sterile equipment. 
2.0 Radiohbeling Procedures 
2.1 Radiolabeling of equine superficial digitd flexor tendon explant organ cultures 
Materials 
Laminar flow hood 
Sterile prepared media without serum 
Ascorbate 20 mglml 
Probe 20 m g h l  
Wheaton bottles containing tendon segments 
Multigrips for cap removal 
Sterile 10 ml pipettes 
Sterile disposable 5 rnl pipettes 
Plastic 10 ml capped vials 
Glass 3 ml vials 
Electric pipette vacuum pump 
10 ul Pipette and sterile tips 
Tritiated proline (1 000 pCi/ml) and labeled sulphate (1 050- 1600 pCi/ml) 
Radioactive waste disposal containers 
Disposable plastic backed bench protector 
Gloves 
Sterile thumb forceps 
Sterile plugs and aluminum seals for Wheaton bodes 
Manual press for seals 
Sterile 20 G needles 
Gas cylinder containing 50% 0,45% N, 5% C02 
mepore filter (0.22 um) 
NB. Wear gloves and protective clothing f5r all procedures associated with the handling and 
disposal of radioactive materials. 
Protocol for radiolabeling of SDFT cultures. 
1. Lift the h e  hood glass to acthate the laminar flow and wipe out the hood sudkces with 
70% ethanol. 
2 Place &cient bench protector on the work Surface within the laminar flow hood for all 
the Wheaton bottles and the isotope container. 
3. Place the cylinder of pipettes, the sterile plugs, sterile forceps and pipette vacuum handle, 
the micropipettor and sterile tips onto the work surface within the laminar flow hood. 
4. Place the Wheaton bottles containing the cultures on the bench protector. 
5. Car- remove the caps and plugs Wheaton bottles with the multigrips ensuring that the 
necks of the bottles are not touched. 
6. Using a fkesh sterile Pasteur pipette every 3-4 cultures (1 per culture if problems with 
contamination have been experienced), aspirate the used media with the water vacuum into 
a volumetric flask and discard or keep for later use. 
7. Caremy remove the cap &om the top of the sterile Pyrex bottle containing the media, 
ensuring that the neck of the bottle is not touched. 
8. Wah a sterile 10 ml pipette, transfer 4 ml of and serum free RPMI 1640 media into each 
Wheaton bottle and aerate with 5%Co2. 
9. Wearing gloves and glasses, remove the isotope containers fiom the refigerator, place it 
in the b e  hood on the bench protector, and carefidy remove the caps from the containers. 
10. Using a new sterile tip each time, transfer 20p1(20pCi/dture) of radiolabeled proline 
and (25 pCi~culture) radiolabeled sulphate to each culture, ensuring the tip of the pipette 
touches the inside of the neck of the Wheaton bottle to ensure accurate transfer. 
11. Discard each tip into a radioactive waste container. 
12. CareUy place the sterile plugs on top of the bottles using sterile forceps, then gently 
seat the phgs into the neck ofthe Wheaton bottles using gently thumb pressure, taking care 
not to touch the rim or the neck of the bottles. 
13. Place the alluninium caps over the plugs and seal them using the manual press. 
14. Remove the centres of the seals by gentle pressure on the centres. 
15. Place cutaues on the rollers, 5 per row, with the caps ficing towards the incubator door. 
Protocol for chase incubation of radiolabeled of SDFT cultures, 
1. Lift the h e  hood glass to activate the laminar flow and wipe out the hood surfkces with 
7W ethanol. 
2. Place the sufEcient bench protector on the work M a c e  within the laminar flow hood for 
all the Wheaton bottles and the isotope container. 
3. Place the cylinder of pipettes, the sterile plugs, sterile forceps and pipette vacuum handle, 
the micropipettor and sterile tips onto the work d a c e  witbin the laminar flow hood. 
4. Wearing gloves, place the Wheaton bottles containing the radiolabeled cultures on the 
bench protector. 
5. CarefUy remove the caps and plugs fiom the Wheaton bottles with the rnultigrips 
ensuing that the nedcs of the bottles are not touched, and discard the caps into a radioactive 
waste container. 
6. Using a fresh sterile pipette for every culture, remove the radioactive media from each 
bottle and place into individually labeled plastic 10 ml capped vials. 
7. Carefirlly remove the cap fkom the top of the sterile Pyrex bottle containing the serum free 
media, ensuring that the neck of the bottle is not touched. 
8. W& a sterile 10 ml pipette, transfer 2 or 4 ml of appropriate serum fiee media with added 
proline into each Wheaton bottle and aerate with 5%Co2. 
9. Cardidly place the sterile plugs on top of the bottles using sterile forceps, then gently seat 
the plugs into the neck of the Wheaton bottles using gently thumb pressure, taking w e  not 
to touch the rim or the neck of the bottles. 
10, Place the alluninium caps over the plugs and seal them using the manual press. 
11. Place the cultures on the rollers, 5 per row, with the caps facing towards the incubator 
door for 24 hours. 
12. Harvest al l  chase media and tendon segments 24 hours after placement in incubator, 
placing media samples into labeled plastic 10 ml tubes and tissues into plastic 7 ml 
scintillation vials. 
13. Store all samples in the -70°C fieaer for later analysis. 
3.0 Preparative Procedures and Analysis of Radiolabeled Tissue Samples 
3.1 Hydroiysis and Scintirlation Counting of Radiolabeled Tissue Samples 
Materials 
Radiolabeled tissue 
6N HCI 
2ml glass 1yophilijr;ltion vials 
Water vacuum 
Bunsen burner 
N2 g= 
Hot water bath 
SolvabltS tissue solubilizer 
Hydrogen peroxide 
7 ml Polyethylene scintillation vials 
BCS scintillation fluid 
Protocol 
1. Freeze dry tendon radiolabeled tendon segments. 
2. Weigh fieeze dried tendon segments. 
3. Placed each freeze dried explant in a labeled 2nd lyophilization tube. 
4. Add 1 ml of warm 6 M HCl and apply the tubing connected to the water vacuum to the 
mouth of the vial. 
5. While the vacuum is applied, heat the neck of the lyopbilization tube until the glass is 
plastic, and draw out the glass until a seal is created, then using a circular motion, remove 
the glass at the open end and discard. 
6. Hydroiyse the tendon segments in 1 ml of 6M HCI at 110 OC for 24 hours. 
7. Remove the hydrolysates fiom the heat and allow to wol. before 
8. Vortex gently, then tlansfer 500 pl of aliquot of the hydrolysate to a labeled scintillation 
vial and dry sample with nitrogen 
9. Transfix the remhder of the hydrolysate to 1.5 ml mimfbge vials with 0.22 prn pore size 
microfbge fiber and centrifUge at 3000 rpm for 5 minutes. Conserve and vacuum centrifbge 
filtrate and then freeze at -20°C for later derivatization.(Vacuum centrifuge in Veterinary 
Microbiology) 
10. To the fieeze dried samples in scintillation vials add tissue solubilizer as per guideline 
below. 
11. Cocldail addition: Add 6 ml ofcocktail to each vial. (Samples > 150 mg may need up to 
1 5 ml to clear ). 
12. Count in scintillation counter on 2 channels (3H and 35S) with color quench correction, 
using the customized quench curve installed by Riley.(Counter in Dow Elanco laboratory, 
Animal Science) 
Tissue solubilization for sam~les up to 3 00me bhrQ 
I. Add solvable to the minced fiesh tissue sample in a glass scintillation vial - 
< 50mg add 0.5 ml; < 200 mg add 1.0 ml; < 300mgadd 1Sml 
NB. T i e  sample must be completely immersed. Gently agitate the sample; do not vortex 
because pieces of the tissue will adhere to the walls of the scintillation vials. 
11. Incubate at 50 O C  until clear - approximately 3 hours. 
ID. Decolorization (optional): hydrogen peroxide is the best bleaching agent, but foaming 
may be a problem. Add 0.1-0.2 mi 30°/0 H24 to each vial and incubate at room temperature 
for one hour. 
NB. If> 0.2 ml of hydrogen peroxide is needed, add in aliquots to prevent foaming. 
3.2 Pn-eolumn derivatizatioo of amino acids in tendon digest with dabsyl chloride 
Materials 
Aliquot of tendon hydrolysate 
Dabsyl chloride (Sigma) 
lOOmM carbonate-bicarbonate bufIkr solution (pH 8.30) HPLC grade 
7.5 MKOH KPLC grade 
Acetone HPLC grade 
Acetonitrile HPLC grade 
Standard amino acids mixture 
L-Proline standard (mw 1 1 5.1) 
OH-L-Proline standard (mw 13 1.1) 
Norleucine standard 
Distilled water 
Glass 10/20 ml scintillation vials 
Syringe filters 
20 ml syringe 
18G needle 
Protocol 
1. Rinse 2 scintillation vials with acetonitrile. 
2. Dissolve 13 mg of dabsyl chloride in 10 mls acetonitrile in a via. 
3. Vortex to dissolve - heat if necessary. 
4. Syringe filter into another vial (good for 2 weeks, but better to make up each day). 
1. Prepare a solutions of standard amino acids as required: 
OH-L-Proline 10 llM/ml 
L-Proline 10 pMld 
Norleucine 10 pMIm.1 
Glyciae 10 clM/ml 
Standard amino acid mix 2.5 pWml 
CombinatioL1S/dilutions of the above in buffer 
2. Adjust pH of each hydrolysate to 9.0 + 0.2 with KOH and measure total volume. 
3. Add 40 pl of 100 mM sodium bicarbonate (pH 8.3) to microfbge tube. 
4. Add 40 p1 of sample or standard to the tube (may add 5 p1 of norleucine as internal 
standard if desired). 
5. Add 80 pl of Dbs-C1 to tube, cover with paraffin fh and incubate for 12 minutes at 70°C. 
6. Vortex at time = 1 minute. 
7. Vortex at time = 4 minutes. 
8. Remove from heat at 12 minutes and allow to cool for 5 minutes. 
9. Add 440 p1 of 100 mM sodium bicarbonate, seal and gently invert. 
10. Aspirate 20 pl samples into a Hamilton syringe, expel any air and wipe the needle clean, 
and inject into the RP-HPLC column 
4.0 Preparative Procedures and Analysis of Radiolabded Media Samples 
4.1 Preparation of radiolabeled medium for scintillation counting 
Radiolabeled medium 
Bio-Spin696 chromatography columns (7324002) 
7 ml Polyethylene scintillation vials 
Solvable@ tissue solubilizer 
BCS scintillation fluid 
Protocol 
1. Invert each column several times to resuspend settled gel. 
2- Remove the top cap and then snap off the snap-off tip to allow excess buffer to drain by 
gravity (discard buffer). 
3. Place the cohunn in a collection tube and cenaifige at 1,100 x g (2300 rpm) for 2 minutes 
in a swinging bucket centrifuge. 
4. Re-spin if any buffer remains in the tip of the cohunn. Store the buffer and collection tube. 
5. CarefUUy apply 100 pl of radiolabeled medium to the centre of the column, dowing the 
liquid to drain into the gel bed between successive drops of the sample. 
NB. Avoid applying the sample to the sides of the column and avoid adding more than the 
recommended amount. 
6. Place the column containing the applied sample in a clean collection tube and centrifbge 
for 4 minutes at 1,100 x g. 
7. Discard the column into the radioactive waste or recycle using SCC buffer and transfer 
the eluent to a scintillation vial. 
8. Solubilize with 0.5 ml of solvable for 3 hours at 50°C, then add 6 ml of sintillant. 
9. Count in scintillation counter on 2 channels CH and "S) with color quench correction. 
4.2 Preparation of protein in radiolabded culture medium for pre-column 
derivatization 
Materials 
Radiolabeled medium 
Standard amino acids with norleucine 
Distilled water 
Microfbge tubes 
0.15% DOCA (7-Deoxycholic acid) 
72% TCA (Trichloracetic acid) 
6 N HCl 
Protocol 
1. Transfer 1 ml of radiolabeled medium to a 1 .S ml micro£bge tube (may make duplicates 
if required). 
2. A 100 p1 of 0.15% DOCA to culture medium, mix and d o w  to stand for 10 minutes at 
room temperature (20-25OC). 
3. Add 100 pl of 72% TCA to each tube, mix and centrifuge at 3300g for 30 minutes. 
4. Decant or aspirate supernatant and dry precipitate fkom samples in vacuum microfuge. 
5. Freeze at precipitant at -70°C for storage, or continue with protocol. 
6. Add 100 pl (or 10 x the weight of protein, whichever is the greater) of 6 N HC1 to each 
microfbge tube, displace the air with nitrogen gas, seal tube and incubate at 1 lo0C for 24 
hours. 
7. Vaamm centrifUge or dry with nitrogen gas to remove HCI and derivatize amino acids. 
4.3 Prtxolornn derivatization of protein hydrolysate from radiolabeled culture 
medium with d a b 4  chloride 
Materials 
Radiolabeled medium 
Dabsyt chloride Acetone 
1 OOmM carbonate-bicarbonate buffer solution (pH 8.3) Acetonitrile 
Glass 10/20 ml scintillation vials Standard amino acids 
Syringe filters Norleucine 
20 ml syringe Distilled water 
18G needle 
Protocol 
Dab& chloride preparation 
1. Rinse 2 scintillation vials with acetonitrile. 
2. Dissolve 13 mg of dabsyl chloride in 10 mls acetonitrile in a vial. 
3. Vortex to dissolve - heat if necessary. 
4. Syringe filter into another vial (good for 2 weeks, but better to make up each day). 
1. Prepare a solutions of standard amino acids as required: 
OH-L-Proline 10 llM/ml 
EProline 10 @ml 
Norleucine 10 @Urn1 
Glycine 10 jdWd 
Standard amino acid mix 2.5 pM7d 
Combioations/dilutions of the above in buffer 
2. Adjust pH of each hydrolysate to 9.0 2 0.2 with KOH and measure total volume. 
3. Add 40 pl of 100 mM sodium bicarbonate @H 8.3) to microfbge tube. 
4. Add 40 pl of sample or standard to the tube (may add 5 pl of norleucine as internal 
standard ). 
5. Add 80 pl of Dbs-Cl to tube, cover with parafh film and incubate for 12 minutes at 70°C. 
6. Vortex at time = 1 minute. 
7. Vortex at time = 4 minutes. 
8. Remove fiom heat at 12 minutes and allow to cool for 5 minutes. 
9. Add 440 pl of 100 mM sodium bicarbonate, seal and gently invert. 
LO. Aspirate 20 pl sampIes into a Hamilton syringe, expel any air and wipe the needle clean, 
and inject into the RP-HPLC column. 
5.0 Reverse Phase High Pressure Liquid Chromatography 
Materials 
Waters HPLC apparatus 
MilleporeGD Waters Data Module M730 
MillepordB Waters System Controller M720 
MilleporeG3 Waters Solvent Delivery System M45 (B) 
Millepord Waters Solvent Delivery System M6000A (A) 
Waters Lambda Max LC W A b s o h c e  Detector M48 1 (variable 0 set at 436 nm) 
Rheodyne Syringe Loading Sample Injector M7125 
AUtech Adsorbosphere OPA-HS 5 pm (100 x 4.6 mm) column 
Alltech Adsorbosphere guard column and cartridges 
Column heater at 30°C (custom made) 
Hamilton syringe 100 pl 
Fraction collector 
Solvent A: 
56% 100 mM Sodium acetate (5.8 rnl Glacial acetic aciatre) 1 
1 6% Acetonitrite 1 
28% Methanoi ) pH=5.8 vhh 
0 to  0.5% TetrahydrafUrans 1 
Solvent B : 
l o r n  Methanol 
Nylon filter and Millipore filter apparatus 
7 d Polyethylene scintillation vials 
BCS scintillation fluid 
M chemical used should be HPLC grade or better 
Protocol 
Solvent Preparatratron 
1. Prepare solvent A 100 mM sodium acetate by adding 5.8 d of gIacial acetic acid per 1000 
ml of double distilled water and adjust pH to 5.8. 
2. Add the remaining components to solvent A as formulated above, adjust pH to 5.8, filter 
and degass. 
3. Prepare solvent B, filter and degass. 
Operation of RP-HPLC Apparatus 
1. Turn on column heater at least 12 hours before running sampled 
2. Turn on controller, pumps, module, detector (0.1 AUFS; 43 6 nm) and fiaction collect or. 
3. Program controller with gradient. 
4. Run 1W/o ethanol through both pumps for 30 minutes each at 1 -0mVmi.n and check flow 
rates. 
5. Check W monitor for evidence of gas bubbles and bleed both pumps carefitlly. 
6. Calculate compressibility coeBcients for each solvent and calibrate the pumps using the 
controller. 
cf=( 7im - 1) x 100 x 6000 
VolumdFlm rate Pressure 
7. Check flow rates again and adjust as necessary. 
8. Check column temperature has stabilized at 32OC. 
9. Set fiaction collector to peak collection (1 0?4 threshold). 
10. Apply 20 p1 of a standard sample to w 1 m  with Hamilton syringe. 
11. Initiate preset chromatography program and check the chromatogram. 
12. F i e  tune the system as necessary before applying next sample. 
13. Run standards. 
14. Run test samples. 
15. Collect 0.5 or 1.0 ml hctions from the outflow tubing of the absorbance detector into 
7 ml scintillation vials. 
16. Add 6 rnl of BCS scintilla$ cap and mix gently. 
17. Count in scintillation counter on 2 channels and 3SS) with quench correction. 
Isocratic gradient. 
-- 
Time Flow Solvent Gradient 
(mins) (mumin) A(%) B(%) 
Initial 1 100 0 * 
5 1 100 0 6 
10 1 99 1 6 
15 1 65 35 6 
18 1 60 40 6 
6.0 Identifkation of Cell Proliferation In Vitro 
Materials 
Amershmn cellproii$ierdion kit 
1. Labeling reagent (5-bromo-2'deoXyuridine & Sfluoro-2'deoxyuridine in 10: 1 ratio) 
2. Nuclease 
3 Anti-bromo-deoxyuridine monoclonal IgG2A antibody (murine) 
4. Peroxidase anti-mouse IgG2a (concentrate) 
5. Peroxidase anti-mouse IgG2a diluent 
6. Substrate intensifier - hydrogen peroxide with cobalt chloride and nickel chloride 
7. DAB - 3,3'-diaminobenzidine tetrahydrochloride 
100h Sheep serum 
Humidified chamber 
Coplin jar 
Tissues 
RPMI 1640 medium 
Xylene 
70,95 and 100% ethanol 
Phosphate buffered saline 
Phosphate buffer 
Harris hematoxylin 
Eosin 
NB. See kit guideline for notes on preparation and storage of saline, buffer and reagents. 
Protocols 
6.1 In vitro labelling with 5-bromo-2'-deoryuridine (BrdU) 
1. Prepare labeling medium by dihmng reagent 1 : 1000 with complete tissue culture medium 
and sterilize by filtration through a 0.22 pn filter. Warm to 37% before use. 
2. Add 10 ml of warmed labeling medium to the tissues in culture vessels. 
3. Add 100 p1 of 300/o(v/v) hydrogen peroxide and seal culture vessel. Discard unused 
labeling medium, 
4. Incubate at 370C for 24 hours in incubator. 
5. Wash tissue in PBS for 15 minutes at 3%. 
6. Fix tissue in 70% ethanol and embed in parailk as required. Padfin wax temperature 
must not exceed 58OC (see kit guidelines for detailed protocol). 
7. Cut 3-5 p sections fiom the outer 100 pm o f f  e tissue exposed to the labeling medium- 
6.2 Dewwaxing and rehydration of param embedded tissue sections 
1. Immerse sections in xylene for 2-3 minutes (Do not let sections dry out between steps). 
2. Repeat with 2 changes of fiesh xylene (replace solvents regularly, ie every 40 slides). 
3. Immerse sections in 10W ethanol for 2-3 minutes. 
4. Repeat with 1 change of eesh 10W ethanol. 
5. Immerse sections in 70% etbanol for 2-3 minutes. 
6. Immerse sections in aqueous (phosphate) buffer for 2-3 minutes. 
6.3 Blocking of endogenous peroxidase 
1. Immerse sections in 0.3% H202 in methanol for 30 minutes at room temperature. 
2. Wash 3x with phosphate buffer. 
6.4 Immunocytochemistry protocol 
1. De-wax p e  sections and inactivate endogenous peroxidase. 
2. Rehydrate specimen in washing 3 x in PBS, drain and wipe away excess soIution around 
specimen. 
3. Add sdiicient 10% sheep serum to cover specimen and place in humidifying chamber for 
20 minutes. 
4. Drain sheep serum off (do not rinse). 
5. Add sufficient reconstituted nuclease/anti-BrdU to cover specimen. 
6. Incubate for 1 hour at room temperature in bumidifed chamber. 
7. Wash 3 x with PBS (3 minutes each time minimum). W~pe around specimen. 
8. Add sutfcient peroxidase anti-mouse IgG2a to cover specimen. 
9. Incubate for 30 minutes at room temperature. 
10. During this incubation period thaw out one aliquot of DAB concentrate and dilute into 
50 ml of phosphate buffer. 
11. Wash slides with 3 x PBS (3 minutes each time minimum). 
12. Add substratdmtensifier to dilute DAB solution. Use 5 drops/ DAB, stir vigorously 
during addition of drops. 
13. Immerse slides in DAB staining solution for 5-1 0 minutes. 
14. Wash slides in 3 x distilled water. 
15 Counterstain as desired - weak nuclear stain (eg.Hamis hematoxylin ) or cytoplasmic stain 
is recommended. 
6.5 Counterstaining 
1. Stain in Harris hematoxylin for 20 seconds (less for a weaker staining reaction). 
2. Wash well in 3 rinses of distilled water. 
3. Quickly dip (1 second) in 0.5% acid alcohol. 
4. Blue in sodium diphosphate. 
5. Wash well in 3 rinses of distilled water. 
6. Immerse in 70ah ethanol for 1 minute. 
7. Tmmerse in 95% ethanol for 1 minute. 
8. Stain for 20 seconds in 0.1% alcoholic eosin. 
9. Immerse in 100% ethanol for 1 minute. 
10. Repeat once in 100% ethanol for 1 minute. 
11. Clear in 2 changes of qlene each for 2 minutes. 
12. Mount in synthetic resin 
7.0 Hyaluronate Radiometric Assay 
Materials 
Phannacia HA Test Kits (I1%ABp) 
100 p1 micropipette with disposable tips 
100 p1 and 200 pl repeating pipettes 
Test tubes 
Centrifuge capable of 1500 x g 
Gamma Counter 
Protocol 
1. Pipette 100 pl of HA standards (0,5, 1 Oy 15,25, 5Q75, 100, 200, 500 and 1000 pgA) and 
unknown samples into tubes. 
2. Add 200 pl of HABPJY solution to tubes including two extra tubes to determine the 
activity of the solution. 
3. Incubate for at least 60 rniutes at 4 to 20°C. 
4. Add 100 p1 of HA-sepharose after thoroughly resuspending the beads. 
5. Incubate for 45 minutes but not more than 60 minutes at 4 to 20°C. 
6. Add 2 rnl of decanting solution after shaking it before use. 
7. Centrifbge for 10 minutes at 1500 x g, then decant tubes in one movement and allow to 
stand upside down on absorbent paper - the firmly packed precipitate should remain on the 
bottom of the tubes. 
8. Measure the radioactivity in a gamma counter. 
9. Express the counts (B) for the standards and -owns as a percentage of the mean 
counts of the 0-standard (B,) 
% activity bound = B/B, x 100 
10. Plot the percentage values of the standards against the HA concentration on linear-log 
paper and construct a standard awe (ahexnatively can use a w e  fitting software to develop 
aa equation describing the relationship) and read unknown samples fiom the curve. 
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